US20100059443A1 - Chromatography Membranes, Devices Containing Them, and Methods of Use Thereof - Google Patents
Chromatography Membranes, Devices Containing Them, and Methods of Use Thereof Download PDFInfo
- Publication number
- US20100059443A1 US20100059443A1 US12/551,762 US55176209A US2010059443A1 US 20100059443 A1 US20100059443 A1 US 20100059443A1 US 55176209 A US55176209 A US 55176209A US 2010059443 A1 US2010059443 A1 US 2010059443A1
- Authority
- US
- United States
- Prior art keywords
- fluid treatment
- certain embodiments
- composite material
- fluid
- treatment device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 117
- 239000012528 membrane Substances 0.000 title claims description 127
- 238000004587 chromatography analysis Methods 0.000 title description 5
- 239000012530 fluid Substances 0.000 claims abstract description 310
- 239000002131 composite material Substances 0.000 claims abstract description 171
- 239000000126 substance Substances 0.000 claims abstract description 69
- 239000011148 porous material Substances 0.000 claims abstract description 46
- 239000003446 ligand Substances 0.000 claims description 182
- 229910052751 metal Inorganic materials 0.000 claims description 154
- 239000002184 metal Substances 0.000 claims description 154
- 229910021645 metal ion Inorganic materials 0.000 claims description 85
- 239000000499 gel Substances 0.000 claims description 66
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 54
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- 150000002500 ions Chemical class 0.000 claims description 32
- 239000000463 material Substances 0.000 claims description 28
- 239000000835 fiber Substances 0.000 claims description 27
- 229910052759 nickel Inorganic materials 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 25
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 24
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 24
- 125000000524 functional group Chemical group 0.000 claims description 24
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 24
- 229910052726 zirconium Inorganic materials 0.000 claims description 24
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 20
- 108010000912 Egg Proteins Proteins 0.000 claims description 18
- 102000002322 Egg Proteins Human genes 0.000 claims description 18
- 102000016943 Muramidase Human genes 0.000 claims description 18
- 108010014251 Muramidase Proteins 0.000 claims description 18
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 18
- 235000014103 egg white Nutrition 0.000 claims description 18
- 210000000969 egg white Anatomy 0.000 claims description 18
- 229960000274 lysozyme Drugs 0.000 claims description 18
- 235000010335 lysozyme Nutrition 0.000 claims description 18
- 239000004325 lysozyme Substances 0.000 claims description 18
- 230000003993 interaction Effects 0.000 claims description 17
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 16
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims description 13
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 13
- 229910052753 mercury Inorganic materials 0.000 claims description 13
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 12
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 12
- 229910052802 copper Inorganic materials 0.000 claims description 12
- 239000010949 copper Substances 0.000 claims description 12
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 12
- 229910052737 gold Inorganic materials 0.000 claims description 12
- 239000010931 gold Substances 0.000 claims description 12
- 229910052763 palladium Inorganic materials 0.000 claims description 12
- 229910052697 platinum Inorganic materials 0.000 claims description 12
- 229910052709 silver Inorganic materials 0.000 claims description 12
- 239000004332 silver Substances 0.000 claims description 12
- 229910052684 Cerium Inorganic materials 0.000 claims description 10
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims description 10
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 10
- 229910052793 cadmium Inorganic materials 0.000 claims description 10
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims description 10
- 229910017052 cobalt Inorganic materials 0.000 claims description 10
- 239000010941 cobalt Substances 0.000 claims description 10
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 10
- 229910052733 gallium Inorganic materials 0.000 claims description 10
- 229910052742 iron Inorganic materials 0.000 claims description 10
- 229910052746 lanthanum Inorganic materials 0.000 claims description 10
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims description 10
- 239000011133 lead Substances 0.000 claims description 10
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 10
- 229910052719 titanium Inorganic materials 0.000 claims description 10
- 239000010936 titanium Substances 0.000 claims description 10
- 229910052725 zinc Inorganic materials 0.000 claims description 10
- 239000011701 zinc Substances 0.000 claims description 10
- BUZRUIZTMOKRPB-UHFFFAOYSA-N carboxycarbamic acid Chemical compound OC(=O)NC(O)=O BUZRUIZTMOKRPB-UHFFFAOYSA-N 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 claims description 8
- 230000002209 hydrophobic effect Effects 0.000 claims description 8
- 229910021644 lanthanide ion Inorganic materials 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 229910001428 transition metal ion Inorganic materials 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 239000000017 hydrogel Substances 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 229940072221 immunoglobulins Drugs 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 239000010935 stainless steel Substances 0.000 claims description 6
- 229910001220 stainless steel Inorganic materials 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 239000002351 wastewater Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 229940088598 enzyme Drugs 0.000 claims description 5
- 229920000867 polyelectrolyte Polymers 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 102000018832 Cytochromes Human genes 0.000 claims description 4
- 108010052832 Cytochromes Proteins 0.000 claims description 4
- 102000000588 Interleukin-2 Human genes 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 4
- 102000004142 Trypsin Human genes 0.000 claims description 4
- 108090000631 Trypsin Proteins 0.000 claims description 4
- 230000009881 electrostatic interaction Effects 0.000 claims description 4
- 230000007717 exclusion Effects 0.000 claims description 4
- 108010074605 gamma-Globulins Proteins 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 239000012588 trypsin Substances 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 102000004856 Lectins Human genes 0.000 claims description 2
- 108090001090 Lectins Proteins 0.000 claims description 2
- 101710120037 Toxin CcdB Proteins 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 102000028557 immunoglobulin binding proteins Human genes 0.000 claims description 2
- 108091009323 immunoglobulin binding proteins Proteins 0.000 claims description 2
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 2
- 150000002602 lanthanoids Chemical class 0.000 claims description 2
- 239000002523 lectin Substances 0.000 claims description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 229920000098 polyolefin Polymers 0.000 claims description 2
- 229910052723 transition metal Inorganic materials 0.000 claims description 2
- 150000003624 transition metals Chemical class 0.000 claims description 2
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 claims 2
- 238000009295 crossflow filtration Methods 0.000 abstract description 14
- -1 feed screen Substances 0.000 description 34
- 238000001914 filtration Methods 0.000 description 31
- 238000000926 separation method Methods 0.000 description 30
- 239000012466 permeate Substances 0.000 description 28
- 230000008569 process Effects 0.000 description 18
- 238000013461 design Methods 0.000 description 16
- 239000007791 liquid phase Substances 0.000 description 12
- 241000894007 species Species 0.000 description 11
- 229920001577 copolymer Polymers 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 238000010348 incorporation Methods 0.000 description 9
- 125000006850 spacer group Chemical group 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000013077 target material Substances 0.000 description 7
- 238000010828 elution Methods 0.000 description 6
- 238000003306 harvesting Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000008055 phosphate buffer solution Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 239000012465 retentate Substances 0.000 description 6
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 5
- 238000004382 potting Methods 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108091006054 His-tagged proteins Proteins 0.000 description 4
- 108010058846 Ovalbumin Proteins 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- 229910010272 inorganic material Inorganic materials 0.000 description 4
- 239000003014 ion exchange membrane Substances 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 4
- 229940092253 ovalbumin Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 239000011147 inorganic material Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000001471 micro-filtration Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- LSHROXHEILXKHM-UHFFFAOYSA-N n'-[2-[2-[2-(2-aminoethylamino)ethylamino]ethylamino]ethyl]ethane-1,2-diamine Chemical compound NCCNCCNCCNCCNCCN LSHROXHEILXKHM-UHFFFAOYSA-N 0.000 description 3
- 159000000001 potassium salts Chemical class 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000004451 qualitative analysis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VZGWAKNZBJGHAD-UHFFFAOYSA-N 3-(carboxymethyl)hex-3-enedioic acid Chemical group OC(=O)CC=C(CC(O)=O)CC(O)=O VZGWAKNZBJGHAD-UHFFFAOYSA-N 0.000 description 2
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 2
- 239000011837 N,N-methylenebisacrylamide Substances 0.000 description 2
- 108010064983 Ovomucin Proteins 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000011072 cell harvest Methods 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- OEIXGLMQZVLOQX-UHFFFAOYSA-N trimethyl-[3-(prop-2-enoylamino)propyl]azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCCNC(=O)C=C OEIXGLMQZVLOQX-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- FDEQCKRAOAKSSZ-UHFFFAOYSA-N (2-acetylsulfanyl-4-oxopentyl) 2-methylprop-2-enoate Chemical compound CC(=O)CC(SC(C)=O)COC(=O)C(C)=C FDEQCKRAOAKSSZ-UHFFFAOYSA-N 0.000 description 1
- KPEQPKRICXXXNT-UHFFFAOYSA-N (3-acetylsulfanyl-2-hydroxypropyl) 2-methylprop-2-enoate Chemical compound CC(=O)SCC(O)COC(=O)C(C)=C KPEQPKRICXXXNT-UHFFFAOYSA-N 0.000 description 1
- MEXGHTFPQKSRSH-UHFFFAOYSA-N (3-acetylsulfanyloxan-2-yl) 2-methylprop-2-enoate Chemical compound CC(=O)SC1CCCOC1OC(=O)C(C)=C MEXGHTFPQKSRSH-UHFFFAOYSA-N 0.000 description 1
- XSNINSKDIOZDOL-UHFFFAOYSA-N (3-benzoylsulfanyl-2-hydroxypropyl) 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CSC(=O)C1=CC=CC=C1 XSNINSKDIOZDOL-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- MVWQZIKQYNDOLK-UHFFFAOYSA-N 2-methyl-n-prop-2-enoylprop-2-enamide Chemical compound CC(=C)C(=O)NC(=O)C=C MVWQZIKQYNDOLK-UHFFFAOYSA-N 0.000 description 1
- RALDEEUHNXQFIN-UHFFFAOYSA-N 2-methylideneicosanamide Chemical compound CCCCCCCCCCCCCCCCCCC(=C)C(N)=O RALDEEUHNXQFIN-UHFFFAOYSA-N 0.000 description 1
- AUZRCMMVHXRSGT-UHFFFAOYSA-N 2-methylpropane-1-sulfonic acid;prop-2-enamide Chemical compound NC(=O)C=C.CC(C)CS(O)(=O)=O AUZRCMMVHXRSGT-UHFFFAOYSA-N 0.000 description 1
- AJWDVSJQPIRAKK-UHFFFAOYSA-N 4-ethenyl-1-methylpyridin-1-ium Chemical class C[N+]1=CC=C(C=C)C=C1 AJWDVSJQPIRAKK-UHFFFAOYSA-N 0.000 description 1
- JTHZUSWLNCPZLX-UHFFFAOYSA-N 6-fluoro-3-methyl-2h-indazole Chemical compound FC1=CC=C2C(C)=NNC2=C1 JTHZUSWLNCPZLX-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010026206 Conalbumin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- CNCOEDDPFOAUMB-UHFFFAOYSA-N N-Methylolacrylamide Chemical compound OCNC(=O)C=C CNCOEDDPFOAUMB-UHFFFAOYSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- NJSSICCENMLTKO-HRCBOCMUSA-N [(1r,2s,4r,5r)-3-hydroxy-4-(4-methylphenyl)sulfonyloxy-6,8-dioxabicyclo[3.2.1]octan-2-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)O[C@H]1C(O)[C@@H](OS(=O)(=O)C=2C=CC(C)=CC=2)[C@@H]2OC[C@H]1O2 NJSSICCENMLTKO-HRCBOCMUSA-N 0.000 description 1
- MMKJDICTSMRLJH-UHFFFAOYSA-N [2-(acetylsulfanylmethyl)-3,5-dioxohexyl] 2-methylprop-2-enoate Chemical compound CC(=O)CC(=O)C(CSC(C)=O)COC(=O)C(C)=C MMKJDICTSMRLJH-UHFFFAOYSA-N 0.000 description 1
- FBEQIWPDCUXPES-UHFFFAOYSA-N [2-(acetylsulfanylmethyl)-3-oxobutyl] 2-methylprop-2-enoate Chemical compound CC(=O)SCC(C(C)=O)COC(=O)C(C)=C FBEQIWPDCUXPES-UHFFFAOYSA-N 0.000 description 1
- KYCIOUVMTSNTOV-UHFFFAOYSA-N [3-(2,2-dimethylpropanoylsulfanyl)-2-hydroxypropyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CSC(=O)C(C)(C)C KYCIOUVMTSNTOV-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000011021 bench scale process Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- YIOJGTBNHQAVBO-UHFFFAOYSA-N dimethyl-bis(prop-2-enyl)azanium Chemical class C=CC[N+](C)(C)CC=C YIOJGTBNHQAVBO-UHFFFAOYSA-N 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 125000003916 ethylene diamine group Chemical group 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 230000003311 flocculating effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- PBOSTUDLECTMNL-UHFFFAOYSA-N lauryl acrylate Chemical compound CCCCCCCCCCCCOC(=O)C=C PBOSTUDLECTMNL-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 description 1
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 1
- PNLUGRYDUHRLOF-UHFFFAOYSA-N n-ethenyl-n-methylacetamide Chemical compound C=CN(C)C(C)=O PNLUGRYDUHRLOF-UHFFFAOYSA-N 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 229940065472 octyl acrylate Drugs 0.000 description 1
- ANISOHQJBAQUQP-UHFFFAOYSA-N octyl prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=C ANISOHQJBAQUQP-UHFFFAOYSA-N 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920003172 poly (isopropyl acrylamide) Polymers 0.000 description 1
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920006380 polyphenylene oxide Polymers 0.000 description 1
- 229920005749 polyurethane resin Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- PNXMTCDJUBJHQJ-UHFFFAOYSA-N propyl prop-2-enoate Chemical compound CCCOC(=O)C=C PNXMTCDJUBJHQJ-UHFFFAOYSA-N 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000002398 sedimentation field-flow fractionation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 101150065015 spa gene Proteins 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000001370 static light scattering Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 229920006337 unsaturated polyester resin Polymers 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/005—Microfluidic devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
- B01D63/024—Hollow fibre modules with a single potted end
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
- B01D63/034—Lumen open in more than two directions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/08—Flat membrane modules
- B01D63/082—Flat membrane modules comprising a stack of flat membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/08—Flat membrane modules
- B01D63/087—Single membrane modules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/10—Spiral-wound membrane modules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/14—Pleat-type membrane modules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/10—Supported membranes; Membrane supports
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/10—Supported membranes; Membrane supports
- B01D69/106—Membranes in the pores of a support, e.g. polymerized in the pores or voids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/12—Composite membranes; Ultra-thin membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502753—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/10—Cross-flow filtration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/36—Hydrophilic membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0803—Disc shape
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0887—Laminated structure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0409—Moving fluids with specific forces or mechanical means specific forces centrifugal forces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L9/00—Supporting devices; Holding devices
- B01L9/52—Supports specially adapted for flat sample carriers, e.g. for plates, slides, chips
- B01L9/527—Supports specially adapted for flat sample carriers, e.g. for plates, slides, chips for microfluidic devices, e.g. used for lab-on-a-chip
Definitions
- biomolecules such as enzymes and glycoproteins
- separation of lysozyme from crude sources, such as egg white has been achieved by salt precipitation (U.S. Pat. No. 4,504,583), or ion exchange techniques (U.S. Pat. Nos. 4,705,755; 4,966,851; 4,518,695; and 4,104,125). Due to the viscous, highly concentrated nature of egg white, and the nature of the other protein constituents, recovering high-purity lysozyme in good yield is extremely laborious and costly.
- the species of interest is that which is retained by the membrane, in which case the objective of the separation is typically to remove smaller contaminants, to concentrate the solution, or to affect a buffer exchange using diafiltration.
- the species of interest is that which permeates through the filter, and the objective is typically to remove larger contaminants.
- the retained species are generally particulates, organelles, bacteria or other microorganisms, while those that permeate are proteins, colloids, peptides, small molecules and ions.
- the retained species are typically proteins and, in general, macromolecules, while those that permeate are peptides, ions and, in general, small molecules.
- DFF direct flow filtration
- a raw or semi-conditioned process stream that contains high-value materials is often highly viscous or highly contaminated.
- DFF separation approaches are difficult or challenging due to blinding of the membrane with the solute present in the feed stream. Additionally, these processes often require high pressure to maintain a reasonable flux of permeate.
- tangential flow filtration (TFF) devices also known as cross-flow filtration devices, have one inlet, one retentate outlet and at least one permeate outlet.
- Tangential flow denotes a filtration configuration in which a flowing fluid is directed along the surface of a filter medium, substantially parallel (tangential) to the surface of the filter medium.
- the solute adsorbs or absorbs to the surface or the pores of the membrane as the eluent flows over the surface.
- the purified portion of fluid that passes through such filter medium has a velocity component which is “cross-wise”, i.e., perpendicular to the direction of the fluid flowing along the surface of such filter medium.
- the retentate (or decantate) can be repeatedly re-circulated with the objective of improving filtration efficiency and enhancing the permeate yield.
- the re-circulated retentate solution pathway runs parallel to the membrane surface and is pumped past the membrane with sufficient velocity to ensure a surface cleaning action.
- a relatively small amount of permeate is collected during each retentate volume-pass, and thus a significant processing time is typically associated with TFF procedures.
- a second liquid can be used to elute the material adsorbed or absorbed to the membrane for harvesting.
- Crossflow filtration or tangential filtration is a well known filtration process.
- Turbulent flow must be minimized in these systems, so as to not physically disassociate a desired substance from the membrane surface. Turbulence is flow dominated by recirculation, eddies, and apparent randomness. Flow in which turbulence is not exhibited is called laminar. A steady, laminar flow is desired.
- filtration devices tend to clog when used over an extended period of time and must be timely replaced. Clogging of a filtration device occurs: (1) when the membrane pores become obstructed, typically with trapped cells, particulate matter, cell debris or the like, or (2) when the feed channel (into a TFF device) becomes obstructed by solids or colloidal material and/or cell debris. This clogging of the feed channel or membrane pores results in a decreased liquid flow across the porous filter membrane. The result is a change in system pressure which, if not properly addressed, runs the risk of serious detriment to the operation which incorporates the filtration procedure.
- devices are available for these applications.
- devices are categorized by configuration into categories including the following: flat plate (for example, cassette or plate and frame), spiral (or spiral wound), tubular, or hollow fiber.
- flat plate for example, cassette or plate and frame
- spiral or spiral wound
- tubular or hollow fiber.
- the choice of device configuration is driven by reliability, performance, and cost for each specific application.
- Flat plate or cassette devices consist of membranes cast on plates; the plates are then reliably stacked.
- the devices may or may not have flexible screens in the feed channels to support the membranes.
- An appealing advantage of a configuration such as this is its very compact design.
- channel height control defined by plate-to-plate interaction and distance, must be very carefully considered
- Tubular devices consist of a membrane cast on the inside surface or outside diameter of a porous support tube.
- a feed solution is pumped through the center of the tube at velocities as high as 20 ft/s. These cross-flow velocities minimize the formation of a concentration polarization layer on the membrane surface, promoting high and stable flux and easy cleaning.
- the permeate is driven through the membrane. Despite the apparent advantages of using a system such as this, the cost tends to be high.
- Spiral-wound devices consist of multiple layers of folded membrane, feed screen, and permeate screen wound around a center permeate collection tube ( FIG. 23 ). Typically found in water purification applications, these devices are also compact and can operate at low pressure to save energy, but are suitable for high pressure applications as well. The cost per membrane area is typically low.
- Typical spiral wound filters consist of about 1 to about 6 spiral wound elements coupled in a serial flow mode and placed in a cylindrical pressure vessel. Between two membranes in the roll is placed a permeable porous medium for conduction of fluid, the concentrate spacer, to ensure that the concentrate can flow over the membrane in order to be distributed all over the surface and to continuously rinse the membrane from accumulating solids.
- the filter elements are kept tightly wound by a hard, impermeable shell. In this configuration flow in and out of the filter element will be through the ends in an axial direction.
- the invention relates to a fluid treatment device comprising
- the invention relates to a fluid treatment device comprising
- the invention relates to any one of the aforementioned fluid treatment devices, wherein the composite material is arranged in a substantially coplanar stack of substantially coextensive sheets, a substantially tubular configuration, or a substantially spiral wound configuration.
- the invention relates to any one of the aforementioned fluid treatment devices, wherein the macroporous cross-linked gel is a neutral or charged hydrogel, a polyelectrolyte gel, a hydrophobic gel, a neutral gel, or a gel comprising functional groups.
- the invention relates to any one of the aforementioned fluid treatment devices, wherein said functional groups are selected from the group consisting of amino acid ligands, antigen and antibody ligands, dye ligands, biological molecules, biological ions, and metal affinity ligands.
- the invention relates to any one of the aforementioned fluid treatment devices, wherein said functional groups are metal affinity ligands. In certain embodiments, the invention relates to any one of the aforementioned fluid treatment devices, further comprising a plurality of metal ions complexed to a plurality of said metal affinity ligands. In certain embodiments, the invention relates to any one of the aforementioned fluid treatment devices, wherein said metal affinity ligands are iminodicarboxylic acid ligands; and said metal ions are nickel.
- the invention relates to any one of the aforementioned fluid treatment devices, wherein said functional groups are biological molecules or biological ions. In certain embodiments, the invention relates to any one of the aforementioned fluid treatment devices, wherein said functional groups are Protein A.
- the invention relates to a method comprising the step of:
- the invention relates to any one of the aforementioned methods, further comprising the step of
- the invention relates to any one of the aforementioned methods, wherein the first fluid is passed along a fluid flow path substantially perpendicular to the pores of the support member.
- the invention relates to any one of the aforementioned methods, further comprising the step of
- the invention relates to any one of the aforementioned methods, wherein the first fluid is a suspension of cells or a suspension of aggregates.
- the invention relates to any one of the aforementioned methods, wherein the substance is a biological molecule or biological ion. In certain embodiments, the invention relates to any one of the aforementioned methods, wherein the biological molecule or biological ion is a protein; and the protein comprises exposed His amino acid residues. In certain embodiments, the invention relates to any one of the aforementioned methods, wherein the biological molecule or biological ion is a monoclonal antibody.
- the invention relates to any one of the aforementioned methods, wherein the substance is a metal-containing particle, or a metal-containing ion.
- the invention relates to any one of the aforementioned methods, wherein the first fluid is waste water.
- the invention relates to any one of the aforementioned methods, wherein the first fluid comprises egg white; and the substance is lysozyme.
- FIG. 1 depicts the results of dead-end compared to cross-flow modes for viral capture using an ion-exchange membrane. In both cases, the lower value obtained with dead-end flow was due to fouling of the membrane during the experiment.
- FIG. 2 depicts a chromatogram from the elution of a mixture proteins (ovalbumin and lysozyme) captured directly from unprocessed egg whites using ion-exchange membranes in cross-flow mode. The results demonstrate that proteins can be selectively removed from an unprocessed, highly viscous feed stream.
- a mixture proteins ovalbumin and lysozyme
- FIG. 3 depicts chromatograms of eluent fluids from egg white-loaded ion-exchange membranes. Curves show selectivity of elution, based on buffer (saline solution) selection. This series of curves demonstrates the ability selectively to separate (i.e., chromatographically) captured target materials in high purity, or as mixtures essentially free from other constituents.
- FIG. 4 depicts a schematic of the cross-flow and capture steps (top and middle), and a trans-membrane collection step (bottom).
- FIG. 5 depicts the effects of wrap design on device performance showing that coarse mesh spacers lead to improved performance in separating lysozyme from egg white using ion-exchange membrane.
- FIG. 6 depicts a wrapped column device inserted into a housing. Inlet cap not shown for clarity.
- FIG. 7 depicts a simplified cross-section of a cassette showing trans-membrane flow of target material as indicated by arrows. Harvesting could also be accomplished by cross-flow, if required, using a fluid that selectively eluted the bound target materials.
- FIG. 8 depicts a schematic illustration of a typical cassette design. Flow is shown with trans-membrane harvesting that is occurring simultaneously with a flowing feed stream.
- FIG. 9 depicts a cross-section of a disposable or semi-disposable housing for a 25 mm syringe column comprising a disk-shaped filtration membrane for lab-scale use.
- FIG. 10 depicts top view (top left), side view (right), and actual size views (bottom left) of the outlet half of the syringe tip filters for use in the housing shown in FIG. 9 and FIG. 11 . All units in the drawings are in inches.
- FIG. 11 depicts a cross-section of the disposable or semi-disposable housing for a 25 mm syringe column comprising a disk-shaped filtration membrane for lab-scale use.
- FIG. 12 depicts a cross-section of the disposable or semi-disposable housing for a 50 mm syringe column comprising a disk-shaped filtration membrane for lab-scale use.
- FIG. 13 depicts the drainage grid in the housing depicted in FIG. 12 for use with a 50 mm disk-shaped membrane.
- FIG. 14 depicts an inlet flow deflector in a reusable stainless steel housing for a 50 mm syringe column comprising a disk-shaped filtration membrane for lab-scale use.
- FIG. 15 depicts a stainless steel holder for use as a reusable housing for a 25 mm disk-shaped membrane for lab-scale use.
- FIG. 16 depicts a component of a reusable stainless steel housing for lab-scale syringe columns.
- FIG. 17 depicts two components of a reusable stainless steel housing for lab-scale syringe columns.
- FIG. 18 depicts a maxi spin column (left), and a device for supporting a cut disk membrane within the column (right).
- FIG. 19 depicts the dimensions of a maxi spin column.
- FIG. 20 depicts the dimensions of a maxi spin column with a device for supporting a cut disk membrane within the column.
- FIG. 21 depicts a mini spin column with a device for supporting a cut disk membrane within the column.
- FIG. 22 depicts the dimensions of a mini spin column with a device for supporting a cut disk membrane within the column.
- FIG. 23 depicts an exemplary configuration of a spiral wound device.
- Each envelope is separated by a feed spacer. Fluid flow is directed such that raw fluid travels on the outside of each envelope and is forced through the membrane. The permeate travels along the permeate spacer to the permeate collection pipe.
- FIG. 24 depicts an exemplary synthetic scheme for incorporation of a metal affinity ligand into the membrane.
- the metal affinity ligand is the sodium salt of iminodiacetic acid (IDA(Na) 2 ).
- FIG. 25 depicts an exemplary synthetic scheme for incorporation of a metal affinity ligand into the membrane.
- the metal affinity ligand is ethylenediamine (EDA).
- FIG. 26 depicts an exemplary synthetic scheme for incorporation of a metal affinity ligand into the membrane.
- the metal affinity ligand is hexamethylenediamine (HMDA).
- FIG. 27 depicts an exemplary synthetic scheme for incorporation of a metal affinity ligand into the membrane.
- the metal affinity ligand is diethanolamine.
- FIG. 28 depicts an exemplary synthetic scheme for incorporation of a metal affinity ligand into the membrane.
- the metal affinity ligand is pentaethylenehexamine (PEHA).
- FIG. 29 depicts an exemplary synthetic scheme for incorporation of a metal affinity ligand into the membrane.
- the metal affinity ligand is triethylenetetramine (TETA).
- FIG. 30 depicts an exemplary synthetic scheme for incorporation of a metal affinity ligand into the membrane.
- the metal affinity ligand is the sodium salt of tris(carboxymethyl)ethylene diamine (TED(Na) 3 ).
- a hydrophilic, high binding, high throughput chromatography membrane that is effective for selective capture of target materials, such as bio-molecules, from raw or dirty process streams.
- This capture process can be accomplished by binding of the target molecules at the surface or near surface of the membrane media (“cross-flow” mode), as opposed to the more typical trans-membrane mode.
- the captured target species can be collected in a highly purified form in subsequent procedures. These final steps are chromatographic in nature and allow for controlled separation of the target materials.
- the collection step and the separation step can be done in either tangential flow or in trans-membrane flow or combinations thereof. See, e.g., FIG. 1 .
- Exemplary device designs suitable for this process include those in which the membrane is incorporated into a modified cassette, wrap, or spiral-wound cross-flow separation device designed for low-shear fluid-flow, and minimization of uncontrolled or undesired trans-membrane flow.
- such devices were found to be effective for separating proteins or viruses from highly viscous and or highly contaminated feed streams with a minimum of process fluid flux across the membrane.
- the cross flow (tangential flow) format allows for greater flexibility in washing and eluting the target molecule(s).
- the cross flow devices can be run in feed-to-retentate mode and perform a surface ion exchange or affinity separation. Washing can be done in feed-to-retentate mode, feed-to-permeate or permeate-to-feed mode, or in a sequential mode.
- hydrophilic, high performance chromatography membrane into a modified cross flow device provides a separation device that purifies target molecules from highly viscous or high particulate feed streams, and completes both clarification and capture of target species with no intervening steps.
- the materials and constructs described here do not preclude the use of the same membrane materials in traditional device designs, such as pleated dead-end capsules.
- these products can produce highly purified proteins, vaccines, or nutraceuticals from feed streams that cannot be processed directly with current commercial technology.
- the devices and methods of the present invention allow for faster processing of large volumes of feed streams than any current technology.
- lysozyme can be easily separated from egg white with high recovery and high purity.
- the invention relates to a device that displays superior performance in comparison to know devices.
- the devices may tolerate about 10 ⁇ to about 100 ⁇ higher throughput than resins.
- the devices may display up to about 25 ⁇ higher binding capacity than existing chromatographic membranes and resins.
- the invention relates to a device that is scalable and produces predictable results in the transitions from Lab to Pilot to Production, unlike conventional resin products.
- the invention relates to a device that encompasses a robust technology.
- the superior mechanical strength of the devices and the inherent hydrophilicity of the composite membranes lead to longer in-process product lifetimes and more consistent performance.
- the invention relates to a device that may be available as a single use or multi-cycle disposable unit. This flexibility may eliminate costly and time consuming cleaning and storage validation. Furthermore, the devices of the invention enable simple process and may improve regulatory compliance.
- the invention relates to separation processes that may require reduced buffer usage.
- using devices of the present invention may eliminate the need for column cleaning, equilibration, or storage in expensive buffers.
- the devices of the invention may tolerate higher concentration feed stream, so no dilution may be needed.
- using the devices described herein may lower capital expenses and may offer significant operational cost savings for a client.
- the devices of the invention may have a lower initial cost and faster delivery.
- the devices allow for lower staffing requirements and reduced maintenance costs.
- the invention relates to a device with a small footprint.
- the devices of the invention exhibit higher binding capacity and require less floor space than typical resin bed chromatography devices.
- an element means one element or more than one element.
- an inorganic metal oxide associated with an stabilizing compound refers to the presence of either weak or strong or both interactions between molecules.
- weak interactions may include, for example, electrostatic, van der Waals, or hydrogen-bonding interactions.
- Stronger interactions also referred to as being chemically bonded, refer to, for example, covalent, ionic, or coordinative bonds between two molecules.
- associated with also refers to a compound that may be physically intertwined within the foldings of another molecule, even when none of the above types of bonds are present.
- an inorganic compound may be considered as being in association with a polymer by virtue of it existing within the interstices of the polymer.
- polymer is used to mean a large molecule formed by the union of repeating units (monomers).
- polymer also encompasses copolymers.
- co-polymer is used to mean a polymer of at least two or more different monomers.
- a co-polymer can be comprised of a cross-linker and a monomer, if the cross-linker is a difunctional monomer.
- two phase fluid is used to mean a fluid comprising a liquid phase in which either substantially solid particles are dispersed therethrough, or a first liquid phase in which droplets or particles of a second liquid phase immiscible with such first liquid phase are dispersed through such first liquid phase.
- a “multiphase fluid” is used to mean a fluid comprising a first liquid phase in which at least one additional second solid or liquid phase is dispersed therethrough.
- particle is used to mean a discreet liquid droplet or a solid object, with a characteristic dimension such as a diameter or length of between about one nanometer, and about one-tenth of a meter.
- particle size is used to mean a number-average or weight-average particle size as measured by conventional particle size measuring techniques well known to those skilled in the art, such as dynamic or static light-scattering, sedimentation field-flow fractionation, photon-correlation spectroscopy, or disk centrifugation.
- an effective average particle size of less than about 1000 nm it is meant that at least about 90% of the particles have a number-average or weight-average particle size of less than about 1000 nm when measured by at least one of the above-noted techniques.
- the particular size of particles in a fluid being processed will depend upon the particular application.
- interstices is used to mean a space, especially a small or narrow one, between things or parts.
- dispersion is used to mean any fluid comprising a liquid phase in which substantially solid particles are suspended, and remain suspended, at least temporarily.
- slurry is used to mean any fluid comprising a liquid phase in which substantially solid particles are present. Such particles may or may not be suspended in such fluid.
- emulsion is used to mean any fluid comprising a first liquid phase within which droplets or particles of a substantially liquid second phase are suspended, and remain suspended, at least temporarily.
- droplets and particles are used interchangeably herein.
- crossflow in reference to filtration is used to mean a filtration configuration in which a flowing fluid is directed along the surface of a filter medium, and the portion of fluid that passes through such filter medium has a velocity component which is “cross-wise”, i.e., perpendicular to the direction of the fluid flowing along the surface of such filter medium.
- tangential filtration is used to mean a filtration process in which a flowing fluid is directed substantially parallel (i.e., tangential) to the surface of a filter medium, and a portion of fluid passes through such filter medium to provide a permeate.
- tangential filtration and “crossflow filtration” are often used interchangeably in the art.
- permeate is used to mean the portion of the fluid that passes through the filter medium and out through a first outlet port in the filter device that is operatively connected to such filter medium.
- decantate is used to mean the portion of the fluid that flows along the surface of the filter medium, but does not pass through such filter medium, and passes out through a second outlet port in the filter device that is operatively connected to such filter medium.
- Crossflow filtration and tangential filtration are well known filtration processes.
- Egg white refers to the clear, aqueous liquid contained within an egg, as opposed to the yellow egg yolk.
- Egg white typically comprises about 15% proteins dissolved or suspended in water.
- Egg white proteins typically include ovalbumin, ovotransferrin, ovomucoid, globulins, lysozyme, ovomucin, and avidin.
- the invention relates to a fluid treatment device comprising
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the composite material is arranged in a substantially coplanar stack of substantially coextensive sheets, a substantially tubular configuration, or a substantially spiral wound configuration.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the composite material has 2 to 10 separate support members.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein a plurality of hollow porous fibers are arranged in a bundle.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the bundle is encased in a shell or a vessel.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein a plurality of bundles is encased in a shell or a vessel.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the hollow porous fiber comprises a cap, a plug, or a seal. In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the hollow porous fiber comprises a cap, a plug, or a seal on both ends. In certain embodiments, the end of the hollow porous fiber is “potted” such that the inside of the fiber is isolated from the outside of the fiber. In certain embodiments, this is accomplished through the use of a tubesheet. In certain embodiments, the potting material to form the tubesheet may be comprised of any suitable material.
- the potting material can be in liquid form when preparing the tubesheet and can thereafter be solidified, e.g., by cooling, curing, or the like.
- the solidified potting material should exhibit sufficient structural strength for providing a tubesheet and be relatively inert moieties to which it will be exposed during fluid separation operation.
- the potting material may be organic material (for example, epoxy), inorganic material, or organic material containing inorganic material, and the potting material may be natural or synthetic.
- typical inorganic materials include glasses, ceramics, cermets, metals and the like.
- the hollow porous fiber may be of any convenient configuration.
- the hollow porous fiber is circular, hexagonal, trilobal, or the like in cross-section and may have ridges, grooves, or the like extending inwardly or outwardly from the walls of the hollow porous fibers.
- the hollow porous fiber may have an inner diameter of about 20 microns to about 200 microns.
- the hollow porous fiber may have an inner diameter of about 40 microns.
- the hollow porous fiber may have a hollow ratio (being the area of the fiber bore divided by the area of the total cross-section of the fiber) of about 10% to about 50% percent.
- the hollow porous fiber may have a hollow ratio of about 20%.
- the hollow porous fiber may be fabricated from various polymers such as cellulose, cellulose esters, cellulose ethers, polyamides, silicone resins, polyurethane resins, unsaturated polyester resins or the like, or ceramics.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the composite material is a pleated membrane.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is substantially cylindrical.
- the housing unit has an inner diameter of from about 5 cm to about 50 cm.
- the thickness of the walls of the housing unit may be adapted to the specific operation conditions.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is disposable or reusable.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is plastic or stainless steel.
- the invention relates to a fluid treatment device comprising a housing unit, wherein the housing unit comprises
- any one of the above-mentioned fluid treatment elements is across the fluid flow path.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the composite material comprises:
- the fluid treatment devices comprise the above-mentioned composite material, wherein a plurality of hollow porous fibers is arranged in a bundle. In certain embodiments, the fluid treatment devices comprise the above-mentioned composite material, wherein the bundle is encased in a shell. In certain embodiments, the fluid treatment devices comprise the above-mentioned composite material, wherein the bundle is encased in a vessel. In certain embodiments, the fluid treatment devices comprise the above-mentioned composite material, wherein a plurality of bundles is encased in a shell. In certain embodiments, the fluid treatment devices comprise the above-mentioned composite material, wherein a plurality of bundles is encased in a vessel.
- the invention relates to a fluid treatment device comprising
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the plurality of housing units are arranged in series.
- the invention relates to any one of the above-mentioned fluid treatment devices, comprising from about 2 to about 10 housing units.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the composite material is arranged in a substantially coextensive stack of substantially coplanar sheets; a substantially tubular configuration; or a substantially spiral wound configuration.
- the inlet or the outlet is a press fit attachment point, a luer lock attachment point, or a hose barb attachment point.
- the inlet is a press fit, luer lock, or hose barb attachment points.
- the outlet is a press fit, luer lock, or hose barb attachment points.
- the inlet and the outlet are different kinds of attachment points from one another.
- the inlet and the outlet are both press fit attachment points.
- the inlet and the outlet are both luer lock attachment points.
- the inlet and the outlet are both hose barb attachment points.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the composite material is a cut disk membrane.
- the cut disks are intended to be used in re-usable housings.
- the cut disks are intended to be used in disposable housings.
- the cut disk membrane is substantially circular in shape.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the composite material is a cut disk membrane.
- the cut disk membrane is from about 15 to about 60 mm in diameter. In certain embodiments, the cut disk membrane is from about 20 to about 55 mm in diameter. In certain embodiments, the cut disk membrane is about 25 mm in diameter. In certain embodiments, the cut disk membrane is about 50 mm in diameter. For visualization of certain embodiments, see FIGS. 9-17 .
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a syringe tip.
- the housing unit is a syringe tip.
- syringe column is used interchangeably with the term “syringe tip.”
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a syringe column; and the composite material is in the form of a cut disk.
- the syringe column housing unit is semi-disposable.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a spin column. In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a spin column; and the composite material is in the form of a cut disk.
- a spin column is a tube with an upper and a lower half. The lower half is closed at the bottom. In between the two halves is a cut disk membrane held or suspended in some manner.
- a user loads the top half with a liquid containing the target (or contaminate) solute and places the spin column into a centrifuge. The centrifuge forces the liquid through the membrane when run at sufficient RPM. Once removed from the centrifuge, the lower half of the device can be removed and the liquid collected (if needed) or the top half can be eluted with additional buffer to remove the retained solute.
- the spin columns can be made in many sizes.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a spin column; and the spin column has a capacity of from about 0.1 mL to about 60 mL.
- the volume of the spin column refer to the quantity of feed stream that may be processed by an exemplary fluid treatment device.
- the spin column has a capacity of from about 0.3 mL to about 55 mL.
- the spin column has a capacity of about 0.5 mL.
- the spin column has a capacity of about 2 mL.
- the spin column has a capacity of up to about 50 mL.
- FIGS. 18-22 For visualization of certain embodiments, see, e.g., FIGS. 18-22 .
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a cassette configuration.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a tubular configuration.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a spiral wound configuration.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a plate and frame configuration.
- the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit comprises a fluid treatment element, wherein the fluid treatment element comprises a hollow porous membrane.
- the invention relates to fluid treatment elements.
- the fluid treatment element is a cartridge for use in a fluid treatment device of the present invention.
- the invention relates to fluid treatment elements comprising membranes.
- the invention relates to fluid treatment elements comprising composite materials for use as membranes.
- the fluid treatment elements are disposable or reusable.
- the invention relates to any one of the above-mentioned fluid treatment elements, wherein the element comprises a hollow, generally cylindrical form.
- the fluid treatment elements of the present invention accommodate high solid density materials. In certain embodiments, the fluid treatment elements of the present invention are used for their strength. In certain embodiments, the fluid treatment elements of the present invention are used in heavy duty applications. In certain embodiments, the fluid treatment elements of the present invention can tolerate elevated temperatures for sustained periods.
- the fluid treatment elements of the present invention exhibit reduced capture time in chromatography applications. In certain embodiments, the fluid treatment elements of the present invention exhibit high binding capacities.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements comprising a composite material.
- the invention comprises a composite material for use as a membrane.
- the composite materials used as membranes in the present invention are described in U.S. Pat. No. 7,316,919; and U.S. patent application Ser. Nos. 11/950,562, 12/108,178, 12/244,940, 12/250,861, 12/211,618, and 12/250,869; all of which are hereby incorporated by reference.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous crosslinked gel of the composite material has macropores of average size between about 25 nm and about 1500 nm. In certain embodiments, the macroporous crosslinked gel has macropores of average size between about 50 nm and about 1000 nm. In certain embodiments, the macroporous crosslinked gel has macropores of average size of about 700 nm. In certain embodiments, the macroporous crosslinked gel has macropores of average size of about 300 nm.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is a hydrogel, a polyelectrolyte gel, a hydrophobic gel, a neutral gel, or a gel comprising functional groups.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is a neutral or charged hydrogel; and the neutral or charged hydrogel is selected from the group consisting of cross-linked poly(vinyl alcohol), poly(acrylamide), poly(isopropylacrylamide), poly(vinylpyrrolidone), poly(hydroxymethyl acrylate), poly(ethylene oxide), copolymers of acrylic acid or methacrylic acid with acrylamide, isopropylacrylamide, or vinylpyrrolidone, copolymers of acrylamide-2-methyl-1-propanesulfonic acid with acrylamide, isopropylacrylamide, or vinylpyrrolidone, copolymers of (3-acrylamido-propyl)trimethylammonium chloride with acrylamide, isopropylacrylamide, or N-vinyl-pyrrolidone, and copolymers of diallyldimethylammonium chloride
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is a polyelectrolyte gel; and the polyelectrolyte gel is selected from the group consisting of cross-linked poly(acrylamido-2-methyl-1-propanesulfonic acid) and its salts, poly(acrylic acid) and its salts, poly(methacrylic acid) and its salts, poly(styrenesulfonic acid) and its salts, poly(vinylsulfonic acid) and its salts, poly(alginic acid) and its salts, poly[(3-acrylamidopropyl)trimethylammonium] salts, poly(diallyldimethylammonium) salts, poly(4-vinyl-N-methylpyridinium) salts, poly(vinylbenzyl-N-trimethylammonium) salts, and poly(ethyleneimine) and its salts
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is a hydrophobic gel; and the hydrophobic gel is selected from the group consisting of cross-linked polymers or copolymers of ethyl acrylate, n-butyl acrylate, propyl acrylate, octyl acrylate, dodecyl acrylate, octadecylacrylamide, stearyl acrylate, and styrene.
- the macroporous cross-linked gel of the composite material is a hydrophobic gel
- the hydrophobic gel is selected from the group consisting of cross-linked polymers or copolymers of ethyl acrylate, n-butyl acrylate, propyl acrylate, octyl acrylate, dodecyl acrylate, octadecylacrylamide, stearyl acrylate
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is a neutral gel; and the neutral gel is selected from the group consisting of cross-linked polymers or copolymers of acrylamide, N,N-dimethylacrylamide, N-methacryloylacrylamide, N-methyl-N-vinylacetamide, and N-vinylpyrrolidone.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is a gel comprising functional groups.
- the macroporous cross-linked gel of the composite material comprises monomers, wherein the monomers comprise functional groups.
- the functional groups are thiols or protected thiols.
- the macroporous cross-linked gel comprises monomers, wherein the monomers are selected from the group consisting of allyl 3-mercaptopropionate thioacetate, (S-benzoyl-3-mercapto-2-hydroxypropyl)-2-methyl-2-propenoate, (S-2,2-dimethylpropanoyl-3-mercapto-2-hydroxypropyl)-2-methyl-2-propenoate, (S-acetyl-3-mercapto-2-acetylpropyl)-2-methyl-2-propenoate, (S-acetyl-3-mercapto-2-hydroxypropyl)-2-methyl-2-propenoate, (S-acetyl-3-mercapto-2-acetoacetylpropyl)-2-methyl-2-propenoate, (S-acetyl-3-mercapto-2-acetoacetylpropyl)-2-methyl-2-propenoate, (S-acetyl-3-mercapto-2-tetrahydro
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises functional groups; and the functional groups are selected from the group consisting of amino acid ligands, antigen and antibody ligands, dye ligands, biological molecules, biological ions, and metal affinity ligands.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises functional groups; and said functional groups are metal affinity ligands. In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises functional groups; said functional groups are metal affinity ligands; and a plurality of metal ions are complexed to a plurality of said metal affinity ligands.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are polydentate ligands.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are octadentate, hexadentate, tetradentate, tridentate or bidentate ligands.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are tetradentate ligands.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are tridentate ligands.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are bidentate ligands.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are iminodicarboxylic acid ligands.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are iminodiacetic acid ligands.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are salts of iminodiacetic acid ligands.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are sodium salts of iminodiacetic acid ligands. See, e.g., FIG. 24 .
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are potassium salts of iminodiacetic acid ligands.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands comprise ethylenediamine moieties. See, e.g., FIG. 25 .
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands comprise hexamethylenediamine moieties. See, e.g., FIG. 26 .
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands comprise diethanolamine moieties. See, e.g., FIG. 27 .
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands comprise pentaethylenehexamine moieties. See, e.g., FIG. 28 .
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands comprise triethylenetetramine moieties. See, e.g., FIG. 29 .
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands comprise tris(carboxymethyl)ethylene diamine. See, e.g., FIG. 30 .
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands comprise conjugate bases of carboxylic acids.
- the conjugate bases are available as salts.
- the conjugate bases are available as sodium salts or potassium salts.
- the conjugate bases are available as sodium salts.
- the conjugate bases are available as potassium salts.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; and said metal ions are transition metal ions, lanthanide ions, poor metal ions or alkaline earth metal ions.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; and said metal ions are selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; and said metal ions are nickel or zirconium.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; and said metal ions are nickel.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; and said metal ions are zirconium.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are octadentate, hexadentate, tetradentate, tridentate or bidentate ligands; and said metal ions are transition metal ions, lanthanide ions, poor metal ions or alkaline earth metal ions.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are octadentate, hexadentate, tetradentate, tridentate or bidentate ligands; and said metal ions are selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are octadentate, hexadentate, tetradentate, tridentate or bidentate ligands; and said metal ions are nickel or zirconium.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are octadentate, hexadentate, tetradentate, tridentate or bidentate ligands; and said metal ions are nickel.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are octadentate, hexadentate, tetradentate, tridentate or bidentate ligands; and said metal ions are zirconium.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tetradentate ligands; and said metal ions are transition metal ions, lanthanide ions, poor metal ions or alkaline earth metal ions.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tetradentate ligands; and said metal ions are selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tetradentate ligands; and said metal ions are nickel or zirconium.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tetradentate ligands; and said metal ions are nickel.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tetradentate ligands; and said metal ions are zirconium.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tridentate ligands; and said metal ions are transition metal ions, lanthanide ions, poor metal ions or alkaline earth metal ions.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tridentate ligands; and said metal ions are selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tridentate ligands; and said metal ions are nickel or zirconium.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tridentate ligands; and said metal ions are nickel.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tridentate ligands; and said metal ions are zirconium.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are bidentate ligands; and said metal ions are transition metal ions, lanthanide ions, poor metal ions or alkaline earth metal ions.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are bidentate ligands; and said metal ions are selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are bidentate ligands; and said metal ions are nickel or zirconium.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are bidentate ligands; and said metal ions are nickel.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are bidentate ligands; and said metal ions are zirconium.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodicarboxylic acid ligands; and said metal ions are transition metal ions, lanthanide ions, poor metal ions or alkaline earth metal ions.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodicarboxylic acid ligands; and said metal ions are selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodicarboxylic acid ligands; and said metal ions are nickel or zirconium.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodicarboxylic acid ligands; and said metal ions are nickel.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodicarboxylic acid ligands; and said metal ions are zirconium.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodiacetic acid ligands; and said metal ions are transition metal ions, lanthanide ions, poor metal ions or alkaline earth metal ions.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodiacetic acid ligands; and said metal ions are selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodiacetic acid ligands; and said metal ions are nickel or zirconium.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodiacetic acid ligands; and said metal ions are nickel.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodiacetic acid ligands; and said metal ions are zirconium.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises functional groups; and the functional groups are biological molecules or biological ions.
- the biological molecules or biological ions are selected from the group consisting of albumins, lysozyme, viruses, cells, ⁇ -globulins of human and animal origins, immunoglobulins of both human and animal origins, proteins of recombinant or natural origin including, polypeptides of synthetic or natural origin, interleukin-2 and its receptor, enzymes, monoclonal antibodies, antigens, lectins, bacterial immunoglobulin-binding proteins, trypsin and its inhibitor, cytochrome C, myoglobulin, recombinant human interleukin, recombinant fusion protein, Protein A, Protein G, Protein L, Peptide H, nucleic acid derived products, DNA of either synthetic or natural origin, and RNA of either synthetic or natural origin.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises Protein A.
- Protein A is a 40-60 kDa MSCRAMM surface protein originally found in the cell wall of the bacteria Staphylococcus aureus . It is encoded by the spa gene and its regulation is controlled by DNA topology, cellular osmolarity, and a two-component system called ArlS-ArlR. It has found use in biochemical research because of its ability to bind immunoglobulins. It binds proteins from many of mammalian species, most notably IgGs. It binds with the Fc region of immunoglobulins through interaction with the heavy chain.
- the bacteria will bind IgG molecules in the wrong orientation (in relation to normal antibody function) on their surface which disrupts opsonization and phagocytosis. It binds with high affinity to human IgG1 and IgG2 as well as mouse IgG2a and IgG2b. Protein A binds with moderate affinity to human IgM, IgA and IgE as well as to mouse IgG3 and IgG1. It does not react with human IgG3 or IgD, nor will it react to mouse IgM, IgA or IgE.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous crosslinked gel of the composite material comprises a macromonomer.
- the macromonomer is selected from the group consisting of poly(ethylene glycol) acrylate and poly(ethylene glycol) methacrylate.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is cross-linked by N,N-methylenebisacrylamide or a polyfunctional macromonomer.
- the macroporous cross-linked gel of the composite material is cross-linked by a polyfunctional macromonomer; and the polyfunctional macromonomer is selected from the group consisting of poly(ethylene glycol) diacrylate and poly(ethylene glycol) dimethacrylate.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is cross-linked by N,N-methylenebisacrylamide.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is a positively charged hydrogel comprising a co-polymer of (3-acrylamidopropyl)trimethylammonium chloride (APTAC) and N-(hydroxymethyl)acrylamide cross-linked by N,N′-methylenebisacrylamide.
- ATAC (3-acrylamidopropyl)trimethylammonium chloride
- N-(hydroxymethyl)acrylamide cross-linked by N,N′-methylenebisacrylamide.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material is a membrane; and the macroporous cross-linked gel bears charged moieties.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material is a membrane for use as a filter in size exclusion separation.
- the fluid treatment devices or elements of the invention comprise any one of the above-mentioned composite materials, wherein the composite materials comprise negatively-charged moieties.
- Negatively-charged membranes repel foulants at the membrane surface resulting in higher flux, easier cleanings, and lower system costs.
- the fluid treatment devices or elements of the invention comprise any one of the above-mentioned composite materials, wherein the composite materials are hydrophilic in nature. Foulants are typically hydrophobic species.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the support member of the composite material consists essentially of polymeric material in the form of a membrane that has a thickness of from about 10 ⁇ m to about 500 ⁇ m and comprises pores of average size between about 0.1 to about 25 ⁇ m.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the support member of the composite material consists essentially of a polyolefin.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the support member of the composite material comprises a polymeric material selected from the group consisting of polysulfones, polyethersulfones, polyphenyleneoxides, polycarbonates, polyesters, cellulose and cellulose derivatives.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the support member of the composite material consists essentially of polymeric material in the form of a fibrous fabric that has a thickness of from about 10 ⁇ m to about 2000 ⁇ m and comprises pores of average size from about 0.1 to about 25 ⁇ m.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the support member of the composite material comprises a stack of 2 to 10 separate support members.
- the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite materials are disk-shaped, thereby forming cut disk membranes.
- the cut disk membranes are from about 5 mm in diameter to about 100 mm in diameter. In certain embodiments, the cut disk membranes are from about 10 mm in diameter to about 75 mm in diameter. In certain embodiments, the cut disk membranes are from about 15 mm in diameter to about 55 mm in diameter.
- the cut disk membranes are about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 55 mm in diameter. In certain embodiments, the cut disk membranes are about 18 mm in diameter. In certain embodiments, the cut disk membranes are about 25 mm in diameter. In certain embodiments, the cut disk membranes are about 50 mm in diameter. In certain embodiments, the cut disk membranes are made by simply cutting from sheets of composite material.
- the invention relates to a method comprising the step of:
- the invention relates to any one of the above-mentioned methods, further comprising the step of
- the invention relates to any one of the above-mentioned methods, wherein the first fluid is passed along a fluid flow path substantially perpendicular to the pores of the support member.
- the invention relates to any one of the above-mentioned methods, further comprising the step of
- the invention relates to any one of the above-mentioned methods, wherein the second fluid is passed through the macropores of the composite material, thereby releasing the substance from the composite material.
- the invention relates to any one of the above-mentioned methods, wherein the second fluid is passed along the fluid flow path substantially perpendicular to the pores of the support member, thereby releasing the substance from the composite material.
- the invention relates to any one of the above-mentioned methods, wherein the substance is separated based on size exclusion.
- the invention relates to any one of the above-mentioned methods, wherein the macroporous gel displays a specific interaction for the substance.
- the invention relates to any one of the above-mentioned methods, wherein the specific interactions are electrostatic interactions, affinity interactions, or hydrophobic interactions.
- the invention relates to any one of the above-mentioned methods, wherein the specific interactions are electrostatic interactions, the composite material bears charges on the macroporous gel; the substance is charged; and the substance is separated based on Donnan exclusion.
- the invention relates to any one of the above-mentioned methods, wherein the first fluid is a suspension of cells or a suspension of aggregates.
- the invention relates to any one of the above-mentioned methods, wherein the substance is a biological molecule or biological ion.
- the invention relates to any one of the above-mentioned methods, wherein the biological molecule or biological ion is selected from the group consisting of albumins, lysozyme, viruses, cells, ⁇ -globulins of human and animal origins, immunoglobulins of both human and animal origins, proteins of recombinant or natural origin including, polypeptides of synthetic or natural origin, interleukin-2 and its receptor, enzymes, monoclonal antibodies, trypsin and its inhibitor, cytochrome C, myoglobulin, recombinant human interleukin, recombinant fusion protein, nucleic acid derived products, DNA of either synthetic or natural origin, and RNA of either synthetic or natural origin.
- the biological molecule or biological ion is selected from the group consisting of albumins, lysozyme, viruses, cells, ⁇ -globulins of human and animal origins, immunoglobulins of both human and animal origins, proteins of recombinant or natural
- the invention relates to any one of the above-mentioned methods, wherein the biological molecule or biological ion is a protein; and the protein comprises exposed amino acid residues selected from the group consisting of Glu, Asp, Try, Arg, Lys, Met, and His.
- the invention relates to any one of the above-mentioned methods, wherein the biological molecule or biological ion is a protein; and the protein comprises exposed His amino acid residues.
- the invention relates to any one of the above-mentioned methods, wherein the biological molecule or biological ion is a monoclonal antibody.
- the invention relates to any one of the above-mentioned methods, wherein the substance is a metal-containing particle, or a metal-containing ion.
- the invention relates to any one of the above-mentioned methods, wherein the metal-containing particle or metal-containing ion comprises a transition metal, a lanthanide, a poor metal, or an alkaline earth metal.
- the invention relates to any one of the above-mentioned methods, wherein the metal-containing particle or metal-containing ion comprises a metal selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- the metal-containing particle or metal-containing ion comprises a metal selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- the invention relates to any one of the above-mentioned methods, wherein the first fluid is waste water.
- the invention relates to any one of the above-mentioned methods, wherein the first fluid is waste water from ore refining, or seawater.
- the invention relates to any one of the above-mentioned methods, wherein the substance is lead or mercury.
- the invention relates to any one of the above-mentioned methods, wherein the substance is platinum, palladium, copper, gold, or silver.
- the invention relates to any one of the above-mentioned methods, wherein the fluid is waste water; and the metal-containing particle or metal-containing ion comprises lead or mercury.
- the invention relates to any one of the above-mentioned methods, wherein the first fluid is waste water from ore refining; and the metal-containing particle or metal-containing ion comprises lead or mercury.
- the invention relates to any one of the above-mentioned methods, wherein the first fluid is seawater; and the metal-containing particle or metal-containing ion comprises platinum, palladium, copper, gold, or silver.
- the invention relates to any one of the above-mentioned methods, wherein the first fluid comprises egg white.
- the invention relates to any one of the above-mentioned methods, wherein the first fluid comprises egg white; and the substance is lysozyme.
- the invention relates to a method in which, in tangential flow separation mode, no pre-processing of the raw reaction mixtures is required due to the high specificity of the composite materials in the devices of the present invention.
- the invention relates to a method in which separations can be carried out on a large scale.
- the invention relates to a method in which separations can be carried out in a shorter amount of time.
- the invention relates to a method in which the devices have a high binding capacity.
- the invention relates to a method that comprises two steps collecting the desired substance onto the composite material and harvesting the desired substance from the composite material.
- the first step is run in tangential separation mode.
- the first step is run in tangential separation mode and the second step is run in direct filtration mode with a second fluid.
- the invention relates to a method of separating a substance from a fluid, comprising the step of:
- the invention relates to a method of separating a substance from a fluid, comprising the step of:
- the invention relates to the above-mentioned method, wherein the fluid is passed over the surface of the composite material; and the substance is adsorbed or absorbed onto the surface of the composite material.
- the invention relates to the above-mentioned method, wherein the fluid is passed through the macropores of the composite material; and the substance is adsorbed or absorbed within the macropores of the composite material.
- the invention relates to a method of separating a substance from a fluid, comprising the step of:
- the invention relates to the above-mentioned method, wherein the fluid is passed over the surface of the composite material; the substance is adsorbed or absorbed onto the surface of the composite material; and the second fluid is passed through the macropores of the composite material, thereby releasing the substance from the composite material.
- the invention relates to the above-mentioned method, wherein the fluid is passed over the surface of the composite material; the substance is adsorbed or absorbed onto the surface of the composite material; and the second fluid is passed over the surface of the composite material, thereby releasing the substance from the surface of the composite material.
- the invention relates to the above-mentioned method, wherein the fluid is passed through the macropores of the composite material; the substance is adsorbed or absorbed within the macropores of the composite material; and the second fluid is passed over the surface of the composite material, thereby releasing the substance from the composite material.
- the invention relates to the above-mentioned method, wherein the fluid is passed through the macropores of the composite material; the substance is adsorbed or absorbed within the macropores of the composite material; and the second fluid is passed through the macropores of the composite material, thereby releasing the substance from the composite material.
- the invention relates to any one of the above-mentioned methods, wherein the substance is radioactive.
- the invention relates to a method of separating a substance from a fluid, comprising the steps of:
- the fluid comprises egg white; and the substance is lysozyme.
- the invention relates to the above-mentioned method, wherein the fluid is passed over the surface of the fluid treatment element; and the substance is adsorbed or absorbed onto the surface of the fluid treatment element.
- the invention relates to a method of separating a substance from a first fluid, comprising the steps of:
- the first fluid comprises egg white; and the substance is lysozyme.
- the invention relates to the above-mentioned method, wherein the fluid is passed over the surface of the fluid treatment element; the substance is adsorbed or absorbed onto the surface of the fluid treatment element; and the second fluid is passed through the macropores of the fluid treatment element, thereby releasing the substance from the macropores.
- the invention relates to the above-mentioned method, wherein the fluid is passed over the surface of the fluid treatment element; the substance is adsorbed or absorbed onto the surface of the fluid treatment element; and the second fluid is passed over the surface of the fluid treatment element, thereby releasing the substance from the surface of the fluid treatment element.
- FIG. 1 shows two experiments in which a specific device was run as a dead-end and as cross-flow device.
- the material of interest is a virus.
- the capture of the cross-flow device exceeded the dead-end version, as indicated by the amount to the pure target material capture after washing and elution.
- the membrane can selectively adsorb two protein materials from the feed stream and then, through the use of an altering buffer fluid, selectively elute the target bio-molecules.
- FIGS. 2 and 3 illustrate this effect.
- the initial feed stream of egg white was exposed to a membrane surface in cross-flow mode. Once the feed stream was removed and the membrane washed, both Ovalbumin and lysozyme were found adhered to the membrane ( FIG. 2 ). Under specific buffer conditions, the proteins were selectively eluted ( FIG. 3 ), which demonstrates the chromatographic nature of the membrane in cross-flow mode.
- FIG. 5 The effect of selecting an optimal spacer material in a simple wrapped design was observed and is depicted in FIG. 5 .
- a roll was made by layering the necessary membrane sheet between two identical spacer sheets and rolling the multi-layered structure into a column. This column was then placed into a metal tube housing that was fitted with end-caps which have both an inlet(s) and outlet(s) attached ( FIG. 6 ).
- the larger spacer material and loose-wind structure enabled the ideal cross-flow or tangential-flow adsorption.
- this design eliminated any direct trans-membrane flow, as the process fluid was run on either side of the membrane.
- the improvements stemmed, at least partially, from the low shear environment.
- the purified lysozyme control was run on the device and was used to represent 100% or maximum adsorption of the target species.
- the remaining data were generated directly from process fluid streams (egg whites).
- the spacer layer materials on either side of the membrane were identical but there is no requirement for this symmetry and the “roll” could have differing layers or one layer could be completely absent.
- the height of the feed channel may impact the ability to maximize the amount of adsorbed target molecule. Smaller feed channel heights may induce greater shear or turbulence at the membrane surface, which either inhibits adsorption or removes target material that does deposit.
- the channel height needs to be at least 10 mm and more ideally >20 mm, typically 23 mm ( FIG. 7 ).
- FIG. 23 depicts a spiral wound device.
- membranes of the current invention are incorporated into this device, highly contaminated or very viscous feed streams can be effectively separated into their desired parts.
- a 0.01 SQM Protein A cassette with an open channel, suspended screen design which enabled a fluid flow tangential to the plane of the membrane was evaluated using an un-clarified feed stream which contained the monoclonal antibody (mAb) target.
- mAb monoclonal antibody
- Traditional resin chromatographic separation processes cannot process un-clarified feed streams.
- the only method that had been demonstrated able to capture the mAb target on bench scale was an expanded bed column functioning in batch mode with a static soak. This modified expanded bed was uneconomical and impractical at larger scale.
- the cassettes were effective in capturing the target MAb product when used a simple flow through mode. This mode allowed the process stream to flow across the membrane such that debris in the fluid did not blind the membrane. Binding of the target species in this mode was a surface effect only.
- Lysis Procedure 270 g mAb 4420 pellet diluted 1 part pellet, 3 parts 10 ⁇ phosphate buffer solution (PBS), 1 part 5 ⁇ Pfenix lysis buffer. Homogenized for 5 minutes, and sonicated for 10 minutes. Loaded onto the membrane as an un-clarified and undiluted feed stream.
- PBS phosphate buffer solution
- Membrane Procedure A membrane cassette with an active surface area of 0.01 m 2 and pore size of 0.3 ⁇ m was equilibrated in PBS at pH 7.4. This device was then loaded by complete system recirculation with lysed mAb 4420 for one hour. The device was then washed with 1 L of 1 ⁇ PBS pH 7.4, and eluted using a 10 minute recirculation of 0.1 M Glycine at pH 2.9 followed by 100 mL system flush with 0.1 M Glycine pH 2.9. The feed was run in flow through mode at 100 mL/min with permeate shut off which limited the device to surface binding only from the un-clarified lysate. A gel electrophoresis qualitative analysis indicated that significant amounts of mAb had been captured.
- the cross-flow product provided a simple, on-off bind-elute capture process that could capture and concentrate intact mAb (observed binding was in the range of 5-10 mg/mL) as well as a lot of contaminants.
- membrane could serve as a scalable capture method for un-clarified mAb Pseudomonas feed streams.
- a 0.02 SQM IMAC-Ni (iminodiacetic acid complexed to Ni) cassette with an open channel, suspended screen design which enabled a fluid flow tangential to the plane of the membrane was evaluated using a feed stream containing a his-tagged protein target.
- Traditional resin-based chromatographic separation processes cannot process un-clarified feed streams.
- the cassettes were effective in capturing the target product in a simple flow through mode. This mode allowed the process stream to flow across the membrane such that debris in the fluid did not blind the membrane. Binding of the target species in this mode was a surface effect only. The product was able to be run with multiple cycles with no loss in binding capacity.
- Membrane Procedure A membrane cassette with an active surface area of 0.02 m 2 was equilibrated in 50 mM PBS, 500 mM NaCl, 5% (wt) glycerol and 25 mM Imidazole at pH 8.0. The cassette was then run with the liquefied cell harvest material at a 100 mL/min feed rate with no permeate flow. This was flowed by elution using 500 mL 1 ⁇ PBS, 500 mM Imidazole at pH 7.4. This process was repeated 3 times in sequence with the follow details:
- the IMAC-Ni product yielded excellent purification characteristics (observed binding was in the range of 60-80 mg/mL) without optimization. Despite manufacturers designation as “single-use,” 7 ⁇ reuse demonstrated for IMAC membrane without the need for EDTA strip and re-charge.
Abstract
Described herein are fluid treatment devices for use in tangential flow filtration, comprising a housing unit and a composite material, wherein the composite material comprises: a support member comprising a plurality of pores extending through the support member; and a non-self-supporting macroporous cross-linked gel comprising macropores having an average size of 10 nm to 3000 nm, said macroporous gel being located in the pores of the support member. The invention also relates to a method of separating a substance from a fluid, comprising the step of placing the fluid in contact with an inventive device, thereby adsorbing or absorbing the substance to the composite material contained therein.
Description
- This application claims the benefit of priority to U.S. Provisional Patent Application Ser. No. 61/093,600, filed Sep. 2, 2008; and U.S. Provisional Patent Application Ser. No. 61/102,797, filed Oct. 3, 2008; both of which are hereby incorporated by reference in their entirety.
- Membrane-based water treatment processes were first introduced in the 1970s. Since then, membrane-based separation technologies have been utilized in a number of other industries. In the pharmaceutical and biotechnology industries, the use of preparative chromatography, direct flow filtration (DFF) and tangential flow filtration (TFF), including micro-, ultra-, nano-filtration and diafiltration are well-established methods for the separation of dissolved molecules or suspended particulates. Ultrafiltration (UF) and microfiltration (MF) membranes have become essential to separation and purification in the manufacture of biomolecules. Biomolecular manufacturing, regardless of its scale, generally employs one or more steps using filtration. The attractiveness of these membrane separations rests on several features including, for example, high separation power, and simplicity, requiring only the application of pressure differentials between the feed stream and the permeate. This simple and reliable one-stage filtering of the sample into two fractions makes membrane separation a valuable approach to separation and purification.
- Notably, the separation and recovery of biomolecules, such as enzymes and glycoproteins, are critical cost-determining steps in most of the down-stream processes in the biotechnology industry. For example, separation of lysozyme from crude sources, such as egg white, has been achieved by salt precipitation (U.S. Pat. No. 4,504,583), or ion exchange techniques (U.S. Pat. Nos. 4,705,755; 4,966,851; 4,518,695; and 4,104,125). Due to the viscous, highly concentrated nature of egg white, and the nature of the other protein constituents, recovering high-purity lysozyme in good yield is extremely laborious and costly.
- In one class of membrane separations, the species of interest is that which is retained by the membrane, in which case the objective of the separation is typically to remove smaller contaminants, to concentrate the solution, or to affect a buffer exchange using diafiltration. In another class of membrane separations, the species of interest is that which permeates through the filter, and the objective is typically to remove larger contaminants. In MF, the retained species are generally particulates, organelles, bacteria or other microorganisms, while those that permeate are proteins, colloids, peptides, small molecules and ions. In UF the retained species are typically proteins and, in general, macromolecules, while those that permeate are peptides, ions and, in general, small molecules.
- In “dead-end,” “normal flow,” or “direct flow” filtration (DFF), a filtration device is used that has one inlet and one outlet. The total (100%) solution volume is forced through a porous filter. DFF devices are commonly single-use devices. Such membrane filters or depth filters are commercially available in different filter area sizes as well as different pore sizes. Depending upon the selected pore size, molecules or particulates smaller than the average membrane pore size will pass (together with solvent) through the filter. Thus, direct flow filtration (DFF) devices allow for the selective removal of particulates, bacteria, viruses, cell debris, and large macromolecules.
- Conventional filters in which all of the fluid entering the filter housing passes through the filter element (DFF) typically operate at low shear near the surface of the filter medium. Thus, when a highly flocculating dispersion is delivered into a conventional filter device by a conventional delivery system, flocs ordinarily tend to form near the surface of the filter medium. The flow field moves the flocs onto the surface and into the bulk of the filter medium, ultimately resulting in plugging of the filter. In practice, a plugged filter may cause a significant amount of downtime for a filter change.
- A raw or semi-conditioned process stream that contains high-value materials is often highly viscous or highly contaminated. As such, DFF separation approaches are difficult or challenging due to blinding of the membrane with the solute present in the feed stream. Additionally, these processes often require high pressure to maintain a reasonable flux of permeate.
- In contrast, tangential flow filtration (TFF) devices, also known as cross-flow filtration devices, have one inlet, one retentate outlet and at least one permeate outlet. Tangential flow denotes a filtration configuration in which a flowing fluid is directed along the surface of a filter medium, substantially parallel (tangential) to the surface of the filter medium. In this configuration, the solute adsorbs or absorbs to the surface or the pores of the membrane as the eluent flows over the surface. The purified portion of fluid that passes through such filter medium has a velocity component which is “cross-wise”, i.e., perpendicular to the direction of the fluid flowing along the surface of such filter medium. In TFF, the retentate (or decantate) can be repeatedly re-circulated with the objective of improving filtration efficiency and enhancing the permeate yield. The re-circulated retentate solution pathway runs parallel to the membrane surface and is pumped past the membrane with sufficient velocity to ensure a surface cleaning action. However, only a relatively small amount of permeate is collected during each retentate volume-pass, and thus a significant processing time is typically associated with TFF procedures. If an appropriate membrane is selected for a specific separation, a second liquid can be used to elute the material adsorbed or absorbed to the membrane for harvesting.
- Crossflow filtration or tangential filtration is a well known filtration process. Reference may be had e.g., to U.S. Pat. Nos. 5,681,464, 6,461,513; 6,331,253, 6,475,071, 5,783,085, 4,790,942, the disclosures of which are incorporated herein by reference. Reference may also be had to “Filter and Filtration Handbook”, 4th Ed., T. Christopher Dickenson, Elsevier Advanced Technology, 1997, the disclosure of which is incorporated herein by reference.
- In TFF careful attention must be paid in the device design, as flow dynamics play an important role in the efficiency of the system. Turbulent flow must be minimized in these systems, so as to not physically disassociate a desired substance from the membrane surface. Turbulence is flow dominated by recirculation, eddies, and apparent randomness. Flow in which turbulence is not exhibited is called laminar. A steady, laminar flow is desired.
- For optimal results, both DFF and TFF demand careful attention to filter porosity and filter area, as well as required differential pressures and selected pump rates. However, filtration devices tend to clog when used over an extended period of time and must be timely replaced. Clogging of a filtration device occurs: (1) when the membrane pores become obstructed, typically with trapped cells, particulate matter, cell debris or the like, or (2) when the feed channel (into a TFF device) becomes obstructed by solids or colloidal material and/or cell debris. This clogging of the feed channel or membrane pores results in a decreased liquid flow across the porous filter membrane. The result is a change in system pressure which, if not properly addressed, runs the risk of serious detriment to the operation which incorporates the filtration procedure.
- As such, the choice of membrane in each of the filtration techniques is critical to the efficiency and success of the separation. Composite membranes with high specificity and high binding capacity have been described in U.S. Pat. No. 7,316,919, and US Patent Application Publication Nos. 2008/0314831 and 2008/0312416, which are hereby incorporated by reference in their entirety. These materials are highly versatile and can be designed for specific separation situations.
- A wide variety of devices are available for these applications. Typically, devices are categorized by configuration into categories including the following: flat plate (for example, cassette or plate and frame), spiral (or spiral wound), tubular, or hollow fiber. The choice of device configuration is driven by reliability, performance, and cost for each specific application.
- Flat plate or cassette devices consist of membranes cast on plates; the plates are then reliably stacked. The devices may or may not have flexible screens in the feed channels to support the membranes. An appealing advantage of a configuration such as this is its very compact design. However, channel height control, defined by plate-to-plate interaction and distance, must be very carefully considered
- Tubular devices consist of a membrane cast on the inside surface or outside diameter of a porous support tube. Typically, a feed solution is pumped through the center of the tube at velocities as high as 20 ft/s. These cross-flow velocities minimize the formation of a concentration polarization layer on the membrane surface, promoting high and stable flux and easy cleaning. The permeate is driven through the membrane. Despite the apparent advantages of using a system such as this, the cost tends to be high.
- Spiral-wound devices consist of multiple layers of folded membrane, feed screen, and permeate screen wound around a center permeate collection tube (
FIG. 23 ). Typically found in water purification applications, these devices are also compact and can operate at low pressure to save energy, but are suitable for high pressure applications as well. The cost per membrane area is typically low. - Typical spiral wound filters consist of about 1 to about 6 spiral wound elements coupled in a serial flow mode and placed in a cylindrical pressure vessel. Between two membranes in the roll is placed a permeable porous medium for conduction of fluid, the concentrate spacer, to ensure that the concentrate can flow over the membrane in order to be distributed all over the surface and to continuously rinse the membrane from accumulating solids. The filter elements are kept tightly wound by a hard, impermeable shell. In this configuration flow in and out of the filter element will be through the ends in an axial direction.
- An unmet need exists in many applications where high contaminate feed streams will immediately plug or blind the membrane media in a typical DFF mode or, when the membranes employed are incapable of any appreciable substrate capture, in cross-flow modes. Utilizing versatile, high performance, high throughput membranes capable of high binding capacities in filtration devices would provide separation systems with performances far exceeding any known technology in a variety of art areas.
- In certain embodiments, the invention relates to a fluid treatment device comprising
-
- a housing unit, wherein the housing unit comprises
- (a) an inlet and an outlet;
- (b) a fluid flow path between the inlet and the outlet; and
- (c) a composite material within the housing unit, wherein the composite material comprises
- a support member comprising a plurality of pores extending through the support member; and
- a non-self-supporting macroporous cross-linked gel comprising macropores having an average size of 10 nm to 3000 nm, said macroporous gel being located in the pores of the support member;
- wherein said macropores of said macroporous cross-linked gel are smaller than said pores of said support member;
wherein the pores of the support member are substantially perpendicular to the fluid flow path.
- In certain embodiments, the invention relates to a fluid treatment device comprising
-
- a plurality of housing units, wherein each housing unit comprises
- (a) an inlet and an outlet;
- (b) a fluid flow path between the inlet and the outlet; and
- (c) a composite material within the housing unit, wherein the composite material comprises
- a support member comprising a plurality of pores extending through the support member; and
- a non-self-supporting macroporous cross-linked gel comprising macropores having an average size of 10 nm to 3000 nm, said macroporous gel being located in the pores of the support member;
- wherein said macropores of said macroporous cross-linked gel are smaller than said pores of said support member; and
wherein the pores of the support member are substantially perpendicular to the fluid flow path.
- In certain embodiments, the invention relates to any one of the aforementioned fluid treatment devices, wherein the composite material is arranged in a substantially coplanar stack of substantially coextensive sheets, a substantially tubular configuration, or a substantially spiral wound configuration.
- In certain embodiments, the invention relates to any one of the aforementioned fluid treatment devices, wherein the macroporous cross-linked gel is a neutral or charged hydrogel, a polyelectrolyte gel, a hydrophobic gel, a neutral gel, or a gel comprising functional groups.
- In certain embodiments, the invention relates to any one of the aforementioned fluid treatment devices, wherein said functional groups are selected from the group consisting of amino acid ligands, antigen and antibody ligands, dye ligands, biological molecules, biological ions, and metal affinity ligands.
- In certain embodiments, the invention relates to any one of the aforementioned fluid treatment devices, wherein said functional groups are metal affinity ligands. In certain embodiments, the invention relates to any one of the aforementioned fluid treatment devices, further comprising a plurality of metal ions complexed to a plurality of said metal affinity ligands. In certain embodiments, the invention relates to any one of the aforementioned fluid treatment devices, wherein said metal affinity ligands are iminodicarboxylic acid ligands; and said metal ions are nickel.
- In certain embodiments, the invention relates to any one of the aforementioned fluid treatment devices, wherein said functional groups are biological molecules or biological ions. In certain embodiments, the invention relates to any one of the aforementioned fluid treatment devices, wherein said functional groups are Protein A.
- In certain embodiments, the invention relates to a method comprising the step of:
-
- contacting a first fluid comprising a substance with a composite material in any one of the aforementioned fluid treatment devices, thereby adsorbing or absorbing the substance onto the composite material.
- In certain embodiments, the invention relates to any one of the aforementioned methods, further comprising the step of
-
- placing the first fluid in an inlet of the fluid treatment device.
- In certain embodiments, the invention relates to any one of the aforementioned methods, wherein the first fluid is passed along a fluid flow path substantially perpendicular to the pores of the support member.
- In certain embodiments, the invention relates to any one of the aforementioned methods, further comprising the step of
-
- contacting a second fluid with the substance adsorbed or absorbed onto the composite material, thereby releasing the substance from the composite material.
- In certain embodiments, the invention relates to any one of the aforementioned methods, wherein the first fluid is a suspension of cells or a suspension of aggregates.
- In certain embodiments, the invention relates to any one of the aforementioned methods, wherein the substance is a biological molecule or biological ion. In certain embodiments, the invention relates to any one of the aforementioned methods, wherein the biological molecule or biological ion is a protein; and the protein comprises exposed His amino acid residues. In certain embodiments, the invention relates to any one of the aforementioned methods, wherein the biological molecule or biological ion is a monoclonal antibody.
- In certain embodiments, the invention relates to any one of the aforementioned methods, wherein the substance is a metal-containing particle, or a metal-containing ion.
- In certain embodiments, the invention relates to any one of the aforementioned methods, wherein the first fluid is waste water.
- In certain embodiments, the invention relates to any one of the aforementioned methods, wherein the first fluid comprises egg white; and the substance is lysozyme.
-
FIG. 1 depicts the results of dead-end compared to cross-flow modes for viral capture using an ion-exchange membrane. In both cases, the lower value obtained with dead-end flow was due to fouling of the membrane during the experiment. -
FIG. 2 depicts a chromatogram from the elution of a mixture proteins (ovalbumin and lysozyme) captured directly from unprocessed egg whites using ion-exchange membranes in cross-flow mode. The results demonstrate that proteins can be selectively removed from an unprocessed, highly viscous feed stream. -
FIG. 3 depicts chromatograms of eluent fluids from egg white-loaded ion-exchange membranes. Curves show selectivity of elution, based on buffer (saline solution) selection. This series of curves demonstrates the ability selectively to separate (i.e., chromatographically) captured target materials in high purity, or as mixtures essentially free from other constituents. -
FIG. 4 depicts a schematic of the cross-flow and capture steps (top and middle), and a trans-membrane collection step (bottom). -
FIG. 5 depicts the effects of wrap design on device performance showing that coarse mesh spacers lead to improved performance in separating lysozyme from egg white using ion-exchange membrane. -
FIG. 6 depicts a wrapped column device inserted into a housing. Inlet cap not shown for clarity. -
FIG. 7 depicts a simplified cross-section of a cassette showing trans-membrane flow of target material as indicated by arrows. Harvesting could also be accomplished by cross-flow, if required, using a fluid that selectively eluted the bound target materials. -
FIG. 8 depicts a schematic illustration of a typical cassette design. Flow is shown with trans-membrane harvesting that is occurring simultaneously with a flowing feed stream. -
FIG. 9 depicts a cross-section of a disposable or semi-disposable housing for a 25 mm syringe column comprising a disk-shaped filtration membrane for lab-scale use. -
FIG. 10 depicts top view (top left), side view (right), and actual size views (bottom left) of the outlet half of the syringe tip filters for use in the housing shown inFIG. 9 andFIG. 11 . All units in the drawings are in inches. -
FIG. 11 depicts a cross-section of the disposable or semi-disposable housing for a 25 mm syringe column comprising a disk-shaped filtration membrane for lab-scale use. -
FIG. 12 depicts a cross-section of the disposable or semi-disposable housing for a 50 mm syringe column comprising a disk-shaped filtration membrane for lab-scale use. -
FIG. 13 depicts the drainage grid in the housing depicted inFIG. 12 for use with a 50 mm disk-shaped membrane. -
FIG. 14 depicts an inlet flow deflector in a reusable stainless steel housing for a 50 mm syringe column comprising a disk-shaped filtration membrane for lab-scale use. -
FIG. 15 depicts a stainless steel holder for use as a reusable housing for a 25 mm disk-shaped membrane for lab-scale use. -
FIG. 16 depicts a component of a reusable stainless steel housing for lab-scale syringe columns. -
FIG. 17 depicts two components of a reusable stainless steel housing for lab-scale syringe columns. -
FIG. 18 depicts a maxi spin column (left), and a device for supporting a cut disk membrane within the column (right). -
FIG. 19 depicts the dimensions of a maxi spin column. -
FIG. 20 depicts the dimensions of a maxi spin column with a device for supporting a cut disk membrane within the column. -
FIG. 21 depicts a mini spin column with a device for supporting a cut disk membrane within the column. -
FIG. 22 depicts the dimensions of a mini spin column with a device for supporting a cut disk membrane within the column. -
FIG. 23 depicts an exemplary configuration of a spiral wound device. There are three series of concentric envelopes, wherein each envelope has a spacer material inside and three of the sides are sealed. Each envelope is separated by a feed spacer. Fluid flow is directed such that raw fluid travels on the outside of each envelope and is forced through the membrane. The permeate travels along the permeate spacer to the permeate collection pipe. -
FIG. 24 depicts an exemplary synthetic scheme for incorporation of a metal affinity ligand into the membrane. In this case, the metal affinity ligand is the sodium salt of iminodiacetic acid (IDA(Na)2). -
FIG. 25 depicts an exemplary synthetic scheme for incorporation of a metal affinity ligand into the membrane. In this case, the metal affinity ligand is ethylenediamine (EDA). -
FIG. 26 depicts an exemplary synthetic scheme for incorporation of a metal affinity ligand into the membrane. In this case, the metal affinity ligand is hexamethylenediamine (HMDA). -
FIG. 27 depicts an exemplary synthetic scheme for incorporation of a metal affinity ligand into the membrane. In this case, the metal affinity ligand is diethanolamine. -
FIG. 28 depicts an exemplary synthetic scheme for incorporation of a metal affinity ligand into the membrane. In this case, the metal affinity ligand is pentaethylenehexamine (PEHA). -
FIG. 29 depicts an exemplary synthetic scheme for incorporation of a metal affinity ligand into the membrane. In this case, the metal affinity ligand is triethylenetetramine (TETA). -
FIG. 30 depicts an exemplary synthetic scheme for incorporation of a metal affinity ligand into the membrane. In this case, the metal affinity ligand is the sodium salt of tris(carboxymethyl)ethylene diamine (TED(Na)3). - Disclosed is a hydrophilic, high binding, high throughput chromatography membrane that is effective for selective capture of target materials, such as bio-molecules, from raw or dirty process streams. This capture process can be accomplished by binding of the target molecules at the surface or near surface of the membrane media (“cross-flow” mode), as opposed to the more typical trans-membrane mode. The captured target species can be collected in a highly purified form in subsequent procedures. These final steps are chromatographic in nature and allow for controlled separation of the target materials. Importantly, the collection step and the separation step can be done in either tangential flow or in trans-membrane flow or combinations thereof. See, e.g.,
FIG. 1 . - Exemplary device designs suitable for this process include those in which the membrane is incorporated into a modified cassette, wrap, or spiral-wound cross-flow separation device designed for low-shear fluid-flow, and minimization of uncontrolled or undesired trans-membrane flow. For example, such devices were found to be effective for separating proteins or viruses from highly viscous and or highly contaminated feed streams with a minimum of process fluid flux across the membrane. The cross flow (tangential flow) format allows for greater flexibility in washing and eluting the target molecule(s). The cross flow devices can be run in feed-to-retentate mode and perform a surface ion exchange or affinity separation. Washing can be done in feed-to-retentate mode, feed-to-permeate or permeate-to-feed mode, or in a sequential mode.
- The incorporation of the hydrophilic, high performance chromatography membrane into a modified cross flow device provides a separation device that purifies target molecules from highly viscous or high particulate feed streams, and completes both clarification and capture of target species with no intervening steps. Moreover, the materials and constructs described here do not preclude the use of the same membrane materials in traditional device designs, such as pleated dead-end capsules. Importantly, these products can produce highly purified proteins, vaccines, or nutraceuticals from feed streams that cannot be processed directly with current commercial technology. Additionally, the devices and methods of the present invention allow for faster processing of large volumes of feed streams than any current technology.
- For example, due to the viscous, highly concentrated nature of egg white, typical filtration schemes prove to be problematic when trying to collect constituents present in relatively low concentrations. Using the devices and methods of the present invention, lysozyme can be easily separated from egg white with high recovery and high purity.
- In certain embodiments, the invention relates to a device that displays superior performance in comparison to know devices. In certain embodiments, the devices may tolerate about 10× to about 100× higher throughput than resins. In certain embodiments, the devices may display up to about 25× higher binding capacity than existing chromatographic membranes and resins.
- In certain embodiments, the invention relates to a device that is scalable and produces predictable results in the transitions from Lab to Pilot to Production, unlike conventional resin products.
- In certain embodiments, the invention relates to a device that encompasses a robust technology. In certain embodiments, the superior mechanical strength of the devices and the inherent hydrophilicity of the composite membranes lead to longer in-process product lifetimes and more consistent performance.
- In certain embodiments, the invention relates to a device that may be available as a single use or multi-cycle disposable unit. This flexibility may eliminate costly and time consuming cleaning and storage validation. Furthermore, the devices of the invention enable simple process and may improve regulatory compliance.
- In certain embodiments, the invention relates to separation processes that may require reduced buffer usage. In certain embodiments, using devices of the present invention may eliminate the need for column cleaning, equilibration, or storage in expensive buffers. In certain embodiments, the devices of the invention may tolerate higher concentration feed stream, so no dilution may be needed.
- In certain embodiments, using the devices described herein may lower capital expenses and may offer significant operational cost savings for a client. In certain embodiments, the devices of the invention may have a lower initial cost and faster delivery. In certain embodiments, the devices allow for lower staffing requirements and reduced maintenance costs.
- In certain embodiments, the invention relates to a device with a small footprint. In certain embodiments, the devices of the invention exhibit higher binding capacity and require less floor space than typical resin bed chromatography devices.
- For convenience, before further description of the present invention, certain terms employed in the specification, examples and appended claims are collected here. These definitions should be read in light of the remainder of the disclosure and understood as by a person of skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art.
- In describing the present invention, a variety of terms are used in the description. Standard terminology is widely used in filtration, fluid delivery, and general fluid processing art.
- The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.
- The term “associated with” as used herein in such phrases as, for example, “an inorganic metal oxide associated with an stabilizing compound,” refers to the presence of either weak or strong or both interactions between molecules. For example weak interactions may include, for example, electrostatic, van der Waals, or hydrogen-bonding interactions. Stronger interactions, also referred to as being chemically bonded, refer to, for example, covalent, ionic, or coordinative bonds between two molecules. The term “associated with” also refers to a compound that may be physically intertwined within the foldings of another molecule, even when none of the above types of bonds are present. For example, an inorganic compound may be considered as being in association with a polymer by virtue of it existing within the interstices of the polymer.
- The terms “comprise” and “comprising” are used in the inclusive, open sense, meaning that additional elements may be included.
- The term “including” is used to mean “including but not limited to.” “Including” and “including but not limited to” are used interchangeably.
- The term “polymer” is used to mean a large molecule formed by the union of repeating units (monomers). The term polymer also encompasses copolymers.
- The term “co-polymer” is used to mean a polymer of at least two or more different monomers. A co-polymer can be comprised of a cross-linker and a monomer, if the cross-linker is a difunctional monomer.
- The term “two phase fluid” is used to mean a fluid comprising a liquid phase in which either substantially solid particles are dispersed therethrough, or a first liquid phase in which droplets or particles of a second liquid phase immiscible with such first liquid phase are dispersed through such first liquid phase. A “multiphase fluid” is used to mean a fluid comprising a first liquid phase in which at least one additional second solid or liquid phase is dispersed therethrough.
- The term “particle” is used to mean a discreet liquid droplet or a solid object, with a characteristic dimension such as a diameter or length of between about one nanometer, and about one-tenth of a meter.
- The term “particle size” is used to mean a number-average or weight-average particle size as measured by conventional particle size measuring techniques well known to those skilled in the art, such as dynamic or static light-scattering, sedimentation field-flow fractionation, photon-correlation spectroscopy, or disk centrifugation. By “an effective average particle size of less than about 1000 nm” it is meant that at least about 90% of the particles have a number-average or weight-average particle size of less than about 1000 nm when measured by at least one of the above-noted techniques. The particular size of particles in a fluid being processed will depend upon the particular application.
- The term “interstices” is used to mean a space, especially a small or narrow one, between things or parts.
- The term “dispersion” is used to mean any fluid comprising a liquid phase in which substantially solid particles are suspended, and remain suspended, at least temporarily.
- The term “slurry” is used to mean any fluid comprising a liquid phase in which substantially solid particles are present. Such particles may or may not be suspended in such fluid.
- The term “emulsion” is used to mean any fluid comprising a first liquid phase within which droplets or particles of a substantially liquid second phase are suspended, and remain suspended, at least temporarily. In reference to discreet entities of a second liquid phase in a first liquid phase, the terms “droplets” and “particles” are used interchangeably herein.
- The term “crossflow” in reference to filtration is used to mean a filtration configuration in which a flowing fluid is directed along the surface of a filter medium, and the portion of fluid that passes through such filter medium has a velocity component which is “cross-wise”, i.e., perpendicular to the direction of the fluid flowing along the surface of such filter medium.
- The term “tangential filtration” is used to mean a filtration process in which a flowing fluid is directed substantially parallel (i.e., tangential) to the surface of a filter medium, and a portion of fluid passes through such filter medium to provide a permeate. The terms “tangential filtration” and “crossflow filtration” are often used interchangeably in the art.
- The term “permeate” is used to mean the portion of the fluid that passes through the filter medium and out through a first outlet port in the filter device that is operatively connected to such filter medium. The term “decantate” is used to mean the portion of the fluid that flows along the surface of the filter medium, but does not pass through such filter medium, and passes out through a second outlet port in the filter device that is operatively connected to such filter medium.
- Crossflow filtration and tangential filtration are well known filtration processes. Reference may be had to, e.g., U.S. Pat. Nos. 5,681,464, 6,461,513; 6,331,253, 6,475,071, 5,783,085, 4,790,942, the disclosures of which are incorporated herein by reference. Reference may also be had to “Filter and Filtration Handbook”, 4th Ed., T. Christopher Dickenson, Elsevier Advanced Technology, 1997, the disclosure of which is incorporated herein by reference.
- The term “egg white” refers to the clear, aqueous liquid contained within an egg, as opposed to the yellow egg yolk. Egg white typically comprises about 15% proteins dissolved or suspended in water. Egg white proteins typically include ovalbumin, ovotransferrin, ovomucoid, globulins, lysozyme, ovomucin, and avidin.
- In certain embodiment, the invention relates to a fluid treatment device comprising
-
- a housing unit, wherein the housing unit comprises
- (a) an inlet and an outlet;
- (b) a fluid flow path between the inlet and the outlet; and
- (c) a composite material within the housing unit, wherein the composite material comprises
- a support member comprising a plurality of pores extending through the support member; and
- a non-self-supporting macroporous cross-linked gel comprising macropores having an average size of 10 nm to 3000 nm, said macroporous gel being located in the pores of the support member;
- wherein said macropores of said macroporous cross-linked gel are smaller than said pores of said support member; and
wherein the pores of the support member are substantially perpendicular to the fluid flow path.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the composite material is arranged in a substantially coplanar stack of substantially coextensive sheets, a substantially tubular configuration, or a substantially spiral wound configuration.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the composite material has 2 to 10 separate support members.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein
-
- the support member is in the form of hollow porous fibers;
- each hollow porous fiber defines a lumen;
- the lumen is from about 20 μm to about 100 μm in diameter; and
- the lumen is substantially perpendicular to the pores in the hollow porous fiber support member.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein a plurality of hollow porous fibers are arranged in a bundle.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the bundle is encased in a shell or a vessel.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein a plurality of bundles is encased in a shell or a vessel.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the hollow porous fiber comprises a cap, a plug, or a seal. In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the hollow porous fiber comprises a cap, a plug, or a seal on both ends. In certain embodiments, the end of the hollow porous fiber is “potted” such that the inside of the fiber is isolated from the outside of the fiber. In certain embodiments, this is accomplished through the use of a tubesheet. In certain embodiments, the potting material to form the tubesheet may be comprised of any suitable material. In certain embodiments, the potting material can be in liquid form when preparing the tubesheet and can thereafter be solidified, e.g., by cooling, curing, or the like. In certain embodiments, the solidified potting material should exhibit sufficient structural strength for providing a tubesheet and be relatively inert moieties to which it will be exposed during fluid separation operation. In certain embodiments, the potting material may be organic material (for example, epoxy), inorganic material, or organic material containing inorganic material, and the potting material may be natural or synthetic. In certain embodiments, typical inorganic materials include glasses, ceramics, cermets, metals and the like.
- In certain embodiments, the hollow porous fiber may be of any convenient configuration. In certain embodiments, the hollow porous fiber is circular, hexagonal, trilobal, or the like in cross-section and may have ridges, grooves, or the like extending inwardly or outwardly from the walls of the hollow porous fibers. In certain embodiments, the hollow porous fiber may have an inner diameter of about 20 microns to about 200 microns. In certain embodiments, the hollow porous fiber may have an inner diameter of about 40 microns. In certain embodiments, the hollow porous fiber may have a hollow ratio (being the area of the fiber bore divided by the area of the total cross-section of the fiber) of about 10% to about 50% percent. In certain embodiments, the hollow porous fiber may have a hollow ratio of about 20%. In certain embodiments, the hollow porous fiber may be fabricated from various polymers such as cellulose, cellulose esters, cellulose ethers, polyamides, silicone resins, polyurethane resins, unsaturated polyester resins or the like, or ceramics.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the composite material is a pleated membrane.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is substantially cylindrical. In certain embodiments, the housing unit has an inner diameter of from about 5 cm to about 50 cm.
- In certain embodiments, the thickness of the walls of the housing unit may be adapted to the specific operation conditions.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is disposable or reusable.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is plastic or stainless steel.
- In certain embodiments, the invention relates to a fluid treatment device comprising a housing unit, wherein the housing unit comprises
- at least one inlet and at least one outlet; and
- a fluid flow path between the inlet and the outlet; wherein any one of the above-mentioned fluid treatment elements is across the fluid flow path.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the composite material comprises:
-
- (a) a support member comprising a plurality of pores extending through the support member; and
- (b) a non-self-supporting macroporous cross-linked gel comprising macropores having an average size of 10 nm to 3000 nm, said macroporous gel being located in the pores of the support member;
- wherein
- said macroporous cross-linked gel is present in the pores of the support member in an amount sufficient such that, in use, liquid passing through the composite material passes through said macropores of said macroporous cross-linked gel;
- said macropores of said macroporous cross-linked gel are smaller than said pores of said support member;
- the support member is in the form of hollow porous fibers;
- each hollow porous fiber defines a lumen;
- the lumen is from about 20 μm to about 100 μm in diameter; and
- the lumen is substantially perpendicular to the pores in the hollow porous fiber support member.
- In certain embodiments, the fluid treatment devices comprise the above-mentioned composite material, wherein a plurality of hollow porous fibers is arranged in a bundle. In certain embodiments, the fluid treatment devices comprise the above-mentioned composite material, wherein the bundle is encased in a shell. In certain embodiments, the fluid treatment devices comprise the above-mentioned composite material, wherein the bundle is encased in a vessel. In certain embodiments, the fluid treatment devices comprise the above-mentioned composite material, wherein a plurality of bundles is encased in a shell. In certain embodiments, the fluid treatment devices comprise the above-mentioned composite material, wherein a plurality of bundles is encased in a vessel.
- In certain embodiments, the invention relates to a fluid treatment device comprising
-
- a plurality of housing units, wherein each housing unit comprises
- (a) an inlet and an outlet;
- (b) a fluid flow path between the inlet and the outlet; and
- (c) a composite material within the housing unit, wherein the composite material comprises
- a support member comprising a plurality of pores extending through the support member; and
- a non-self-supporting macroporous cross-linked gel comprising macropores having an average size of 10 nm to 3000 nm, said macroporous gel being located in the pores of the support member;
- wherein said macropores of said macroporous cross-linked gel are smaller than said pores of said support member; and
wherein the pores of the support member are substantially perpendicular to the fluid flow path.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the plurality of housing units are arranged in series.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, comprising from about 2 to about 10 housing units.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the composite material is arranged in a substantially coextensive stack of substantially coplanar sheets; a substantially tubular configuration; or a substantially spiral wound configuration.
- In certain embodiments, wherein the inlet or the outlet is a press fit attachment point, a luer lock attachment point, or a hose barb attachment point. In certain embodiments, the inlet is a press fit, luer lock, or hose barb attachment points. In certain embodiments, the outlet is a press fit, luer lock, or hose barb attachment points. In certain embodiments, the inlet and the outlet are different kinds of attachment points from one another. In certain embodiments, the inlet and the outlet are both press fit attachment points. In certain embodiments, the inlet and the outlet are both luer lock attachment points. In certain embodiments, the inlet and the outlet are both hose barb attachment points.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the composite material is a cut disk membrane. In certain embodiments, the cut disks are intended to be used in re-usable housings. In certain embodiments, the cut disks are intended to be used in disposable housings. In certain embodiments, the cut disk membrane is substantially circular in shape.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the composite material is a cut disk membrane. In certain embodiments, the cut disk membrane is from about 15 to about 60 mm in diameter. In certain embodiments, the cut disk membrane is from about 20 to about 55 mm in diameter. In certain embodiments, the cut disk membrane is about 25 mm in diameter. In certain embodiments, the cut disk membrane is about 50 mm in diameter. For visualization of certain embodiments, see
FIGS. 9-17 . - In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a syringe tip. The term “syringe column” is used interchangeably with the term “syringe tip.”
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a syringe column; and the composite material is in the form of a cut disk. In certain embodiments, the syringe column housing unit is semi-disposable.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a spin column. In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a spin column; and the composite material is in the form of a cut disk. A spin column is a tube with an upper and a lower half. The lower half is closed at the bottom. In between the two halves is a cut disk membrane held or suspended in some manner. A user loads the top half with a liquid containing the target (or contaminate) solute and places the spin column into a centrifuge. The centrifuge forces the liquid through the membrane when run at sufficient RPM. Once removed from the centrifuge, the lower half of the device can be removed and the liquid collected (if needed) or the top half can be eluted with additional buffer to remove the retained solute. In certain embodiments, the spin columns can be made in many sizes.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a spin column; and the spin column has a capacity of from about 0.1 mL to about 60 mL. In certain embodiments, the volume of the spin column refer to the quantity of feed stream that may be processed by an exemplary fluid treatment device. In certain embodiments, the spin column has a capacity of from about 0.3 mL to about 55 mL. In certain embodiments, the spin column has a capacity of about 0.5 mL. In certain embodiments, the spin column has a capacity of about 2 mL. In certain embodiments, the spin column has a capacity of up to about 50 mL. For visualization of certain embodiments, see, e.g.,
FIGS. 18-22 . - In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a cassette configuration.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a tubular configuration.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a spiral wound configuration.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit is a plate and frame configuration.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices, wherein the housing unit comprises a fluid treatment element, wherein the fluid treatment element comprises a hollow porous membrane.
- In certain embodiments, the invention relates to fluid treatment elements. In certain embodiments, the fluid treatment element is a cartridge for use in a fluid treatment device of the present invention. In certain embodiments, the invention relates to fluid treatment elements comprising membranes. In certain embodiments, the invention relates to fluid treatment elements comprising composite materials for use as membranes.
- In certain embodiments, the fluid treatment elements are disposable or reusable.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment elements, wherein the element comprises a hollow, generally cylindrical form.
- In certain embodiments, the fluid treatment elements of the present invention accommodate high solid density materials. In certain embodiments, the fluid treatment elements of the present invention are used for their strength. In certain embodiments, the fluid treatment elements of the present invention are used in heavy duty applications. In certain embodiments, the fluid treatment elements of the present invention can tolerate elevated temperatures for sustained periods.
- In certain embodiments, the fluid treatment elements of the present invention exhibit reduced capture time in chromatography applications. In certain embodiments, the fluid treatment elements of the present invention exhibit high binding capacities.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements comprising a composite material. In certain embodiments, the invention comprises a composite material for use as a membrane.
- In certain embodiments, the composite materials used as membranes in the present invention are described in U.S. Pat. No. 7,316,919; and U.S. patent application Ser. Nos. 11/950,562, 12/108,178, 12/244,940, 12/250,861, 12/211,618, and 12/250,869; all of which are hereby incorporated by reference.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous crosslinked gel of the composite material has macropores of average size between about 25 nm and about 1500 nm. In certain embodiments, the macroporous crosslinked gel has macropores of average size between about 50 nm and about 1000 nm. In certain embodiments, the macroporous crosslinked gel has macropores of average size of about 700 nm. In certain embodiments, the macroporous crosslinked gel has macropores of average size of about 300 nm.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is a hydrogel, a polyelectrolyte gel, a hydrophobic gel, a neutral gel, or a gel comprising functional groups. In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is a neutral or charged hydrogel; and the neutral or charged hydrogel is selected from the group consisting of cross-linked poly(vinyl alcohol), poly(acrylamide), poly(isopropylacrylamide), poly(vinylpyrrolidone), poly(hydroxymethyl acrylate), poly(ethylene oxide), copolymers of acrylic acid or methacrylic acid with acrylamide, isopropylacrylamide, or vinylpyrrolidone, copolymers of acrylamide-2-methyl-1-propanesulfonic acid with acrylamide, isopropylacrylamide, or vinylpyrrolidone, copolymers of (3-acrylamido-propyl)trimethylammonium chloride with acrylamide, isopropylacrylamide, or N-vinyl-pyrrolidone, and copolymers of diallyldimethylammonium chloride with acrylamide, isopropylacrylamide, or vinylpyrrolidone. In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is a polyelectrolyte gel; and the polyelectrolyte gel is selected from the group consisting of cross-linked poly(acrylamido-2-methyl-1-propanesulfonic acid) and its salts, poly(acrylic acid) and its salts, poly(methacrylic acid) and its salts, poly(styrenesulfonic acid) and its salts, poly(vinylsulfonic acid) and its salts, poly(alginic acid) and its salts, poly[(3-acrylamidopropyl)trimethylammonium] salts, poly(diallyldimethylammonium) salts, poly(4-vinyl-N-methylpyridinium) salts, poly(vinylbenzyl-N-trimethylammonium) salts, and poly(ethyleneimine) and its salts. In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is a hydrophobic gel; and the hydrophobic gel is selected from the group consisting of cross-linked polymers or copolymers of ethyl acrylate, n-butyl acrylate, propyl acrylate, octyl acrylate, dodecyl acrylate, octadecylacrylamide, stearyl acrylate, and styrene. In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is a neutral gel; and the neutral gel is selected from the group consisting of cross-linked polymers or copolymers of acrylamide, N,N-dimethylacrylamide, N-methacryloylacrylamide, N-methyl-N-vinylacetamide, and N-vinylpyrrolidone.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is a gel comprising functional groups. In certain embodiments, the macroporous cross-linked gel of the composite material comprises monomers, wherein the monomers comprise functional groups. In certain embodiments, the functional groups are thiols or protected thiols. In certain embodiments, the macroporous cross-linked gel comprises monomers, wherein the monomers are selected from the group consisting of allyl 3-mercaptopropionate thioacetate, (S-benzoyl-3-mercapto-2-hydroxypropyl)-2-methyl-2-propenoate, (S-2,2-dimethylpropanoyl-3-mercapto-2-hydroxypropyl)-2-methyl-2-propenoate, (S-acetyl-3-mercapto-2-acetylpropyl)-2-methyl-2-propenoate, (S-acetyl-3-mercapto-2-hydroxypropyl)-2-methyl-2-propenoate, (S-acetyl-3-mercapto-2-acetoacetylpropyl)-2-methyl-2-propenoate, (S-acetyl-3-mercapto-2-tetrahydropyranyl)-2-methyl-2-propenoate, (S-acetyl-3-mercapto-2-(2-methoxy-2-propoxy))-2-methyl-2-propenoate, (S-acetyl-2-mercapto-3-acetylpropyl)-2-methyl-2-propenoate, S-acetyl-(1-allyloxy-3-mercapto-2-hydroxypropane), S-benzoyl-(1-allyloxy-3-mercapto-2-hydroxypropane) and S-2,2-dimethylpropanoyl-(1-allyloxy-3-mercapto-2-hydroxypropane).
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises functional groups; and the functional groups are selected from the group consisting of amino acid ligands, antigen and antibody ligands, dye ligands, biological molecules, biological ions, and metal affinity ligands.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises functional groups; and said functional groups are metal affinity ligands. In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises functional groups; said functional groups are metal affinity ligands; and a plurality of metal ions are complexed to a plurality of said metal affinity ligands.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are polydentate ligands.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are octadentate, hexadentate, tetradentate, tridentate or bidentate ligands.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are tetradentate ligands.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are tridentate ligands.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are bidentate ligands.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are iminodicarboxylic acid ligands.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are iminodiacetic acid ligands.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are salts of iminodiacetic acid ligands.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are sodium salts of iminodiacetic acid ligands. See, e.g.,
FIG. 24 . - In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands are potassium salts of iminodiacetic acid ligands.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands comprise ethylenediamine moieties. See, e.g.,
FIG. 25 . - In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands comprise hexamethylenediamine moieties. See, e.g.,
FIG. 26 . - In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands comprise diethanolamine moieties. See, e.g.,
FIG. 27 . - In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands comprise pentaethylenehexamine moieties. See, e.g.,
FIG. 28 . - In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands comprise triethylenetetramine moieties. See, e.g.,
FIG. 29 . - In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands comprise tris(carboxymethyl)ethylene diamine. See, e.g.,
FIG. 30 . - In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands; and said metal affinity ligands comprise conjugate bases of carboxylic acids. In certain embodiments, the conjugate bases are available as salts. In certain embodiments, the conjugate bases are available as sodium salts or potassium salts. In certain embodiments, the conjugate bases are available as sodium salts. In certain embodiments, the conjugate bases are available as potassium salts.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; and said metal ions are transition metal ions, lanthanide ions, poor metal ions or alkaline earth metal ions.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; and said metal ions are selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; and said metal ions are nickel or zirconium.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; and said metal ions are nickel.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; and said metal ions are zirconium.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are octadentate, hexadentate, tetradentate, tridentate or bidentate ligands; and said metal ions are transition metal ions, lanthanide ions, poor metal ions or alkaline earth metal ions.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are octadentate, hexadentate, tetradentate, tridentate or bidentate ligands; and said metal ions are selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are octadentate, hexadentate, tetradentate, tridentate or bidentate ligands; and said metal ions are nickel or zirconium.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are octadentate, hexadentate, tetradentate, tridentate or bidentate ligands; and said metal ions are nickel.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are octadentate, hexadentate, tetradentate, tridentate or bidentate ligands; and said metal ions are zirconium.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tetradentate ligands; and said metal ions are transition metal ions, lanthanide ions, poor metal ions or alkaline earth metal ions.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tetradentate ligands; and said metal ions are selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tetradentate ligands; and said metal ions are nickel or zirconium.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tetradentate ligands; and said metal ions are nickel.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tetradentate ligands; and said metal ions are zirconium.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tridentate ligands; and said metal ions are transition metal ions, lanthanide ions, poor metal ions or alkaline earth metal ions.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tridentate ligands; and said metal ions are selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tridentate ligands; and said metal ions are nickel or zirconium.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tridentate ligands; and said metal ions are nickel.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are tridentate ligands; and said metal ions are zirconium.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are bidentate ligands; and said metal ions are transition metal ions, lanthanide ions, poor metal ions or alkaline earth metal ions.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are bidentate ligands; and said metal ions are selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are bidentate ligands; and said metal ions are nickel or zirconium.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are bidentate ligands; and said metal ions are nickel.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are bidentate ligands; and said metal ions are zirconium.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodicarboxylic acid ligands; and said metal ions are transition metal ions, lanthanide ions, poor metal ions or alkaline earth metal ions.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodicarboxylic acid ligands; and said metal ions are selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodicarboxylic acid ligands; and said metal ions are nickel or zirconium.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodicarboxylic acid ligands; and said metal ions are nickel.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodicarboxylic acid ligands; and said metal ions are zirconium.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodiacetic acid ligands; and said metal ions are transition metal ions, lanthanide ions, poor metal ions or alkaline earth metal ions.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodiacetic acid ligands; and said metal ions are selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodiacetic acid ligands; and said metal ions are nickel or zirconium.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodiacetic acid ligands; and said metal ions are nickel.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises metal affinity ligands complexed to a plurality of metal ions; said metal affinity ligands are iminodiacetic acid ligands; and said metal ions are zirconium.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises functional groups; and the functional groups are biological molecules or biological ions. In certain embodiments, the biological molecules or biological ions are selected from the group consisting of albumins, lysozyme, viruses, cells, γ-globulins of human and animal origins, immunoglobulins of both human and animal origins, proteins of recombinant or natural origin including, polypeptides of synthetic or natural origin, interleukin-2 and its receptor, enzymes, monoclonal antibodies, antigens, lectins, bacterial immunoglobulin-binding proteins, trypsin and its inhibitor, cytochrome C, myoglobulin, recombinant human interleukin, recombinant fusion protein, Protein A, Protein G, Protein L, Peptide H, nucleic acid derived products, DNA of either synthetic or natural origin, and RNA of either synthetic or natural origin.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material comprises Protein A. Protein A is a 40-60 kDa MSCRAMM surface protein originally found in the cell wall of the bacteria Staphylococcus aureus. It is encoded by the spa gene and its regulation is controlled by DNA topology, cellular osmolarity, and a two-component system called ArlS-ArlR. It has found use in biochemical research because of its ability to bind immunoglobulins. It binds proteins from many of mammalian species, most notably IgGs. It binds with the Fc region of immunoglobulins through interaction with the heavy chain. The result of this type of interaction is that, in serum, the bacteria will bind IgG molecules in the wrong orientation (in relation to normal antibody function) on their surface which disrupts opsonization and phagocytosis. It binds with high affinity to human IgG1 and IgG2 as well as mouse IgG2a and IgG2b. Protein A binds with moderate affinity to human IgM, IgA and IgE as well as to mouse IgG3 and IgG1. It does not react with human IgG3 or IgD, nor will it react to mouse IgM, IgA or IgE.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous crosslinked gel of the composite material comprises a macromonomer. In certain embodiments, the macromonomer is selected from the group consisting of poly(ethylene glycol) acrylate and poly(ethylene glycol) methacrylate.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is cross-linked by N,N-methylenebisacrylamide or a polyfunctional macromonomer. In certain embodiments, the macroporous cross-linked gel of the composite material is cross-linked by a polyfunctional macromonomer; and the polyfunctional macromonomer is selected from the group consisting of poly(ethylene glycol) diacrylate and poly(ethylene glycol) dimethacrylate. In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is cross-linked by N,N-methylenebisacrylamide.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the macroporous cross-linked gel of the composite material is a positively charged hydrogel comprising a co-polymer of (3-acrylamidopropyl)trimethylammonium chloride (APTAC) and N-(hydroxymethyl)acrylamide cross-linked by N,N′-methylenebisacrylamide.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material is a membrane; and the macroporous cross-linked gel bears charged moieties.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite material is a membrane for use as a filter in size exclusion separation.
- In certain embodiments, the fluid treatment devices or elements of the invention comprise any one of the above-mentioned composite materials, wherein the composite materials comprise negatively-charged moieties. Negatively-charged membranes repel foulants at the membrane surface resulting in higher flux, easier cleanings, and lower system costs.
- In certain embodiments, the fluid treatment devices or elements of the invention comprise any one of the above-mentioned composite materials, wherein the composite materials are hydrophilic in nature. Foulants are typically hydrophobic species.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the support member of the composite material consists essentially of polymeric material in the form of a membrane that has a thickness of from about 10 μm to about 500 μm and comprises pores of average size between about 0.1 to about 25 μm.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the support member of the composite material consists essentially of a polyolefin.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the support member of the composite material comprises a polymeric material selected from the group consisting of polysulfones, polyethersulfones, polyphenyleneoxides, polycarbonates, polyesters, cellulose and cellulose derivatives.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the support member of the composite material consists essentially of polymeric material in the form of a fibrous fabric that has a thickness of from about 10 μm to about 2000 μm and comprises pores of average size from about 0.1 to about 25 μm.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the support member of the composite material comprises a stack of 2 to 10 separate support members.
- In certain embodiments, the invention relates to any one of the above-mentioned fluid treatment devices or elements, wherein the composite materials are disk-shaped, thereby forming cut disk membranes. In certain embodiments, the cut disk membranes are from about 5 mm in diameter to about 100 mm in diameter. In certain embodiments, the cut disk membranes are from about 10 mm in diameter to about 75 mm in diameter. In certain embodiments, the cut disk membranes are from about 15 mm in diameter to about 55 mm in diameter. In certain embodiments, the cut disk membranes are about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 55 mm in diameter. In certain embodiments, the cut disk membranes are about 18 mm in diameter. In certain embodiments, the cut disk membranes are about 25 mm in diameter. In certain embodiments, the cut disk membranes are about 50 mm in diameter. In certain embodiments, the cut disk membranes are made by simply cutting from sheets of composite material.
- In certain embodiments, the invention relates to a method comprising the step of:
-
- contacting a first fluid comprising a substance with a composite material in any one of the above-mentioned fluid treatment devices, thereby adsorbing or absorbing the substance onto the composite material.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, further comprising the step of
-
- placing the first fluid in an inlet of the fluid treatment device.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the first fluid is passed along a fluid flow path substantially perpendicular to the pores of the support member.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, further comprising the step of
-
- contacting a second fluid with the substance adsorbed or absorbed onto the composite material, thereby releasing the substance from the composite material.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the second fluid is passed through the macropores of the composite material, thereby releasing the substance from the composite material.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the second fluid is passed along the fluid flow path substantially perpendicular to the pores of the support member, thereby releasing the substance from the composite material.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the substance is separated based on size exclusion.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the macroporous gel displays a specific interaction for the substance.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the specific interactions are electrostatic interactions, affinity interactions, or hydrophobic interactions.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the specific interactions are electrostatic interactions, the composite material bears charges on the macroporous gel; the substance is charged; and the substance is separated based on Donnan exclusion.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the first fluid is a suspension of cells or a suspension of aggregates.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the substance is a biological molecule or biological ion.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the biological molecule or biological ion is selected from the group consisting of albumins, lysozyme, viruses, cells, γ-globulins of human and animal origins, immunoglobulins of both human and animal origins, proteins of recombinant or natural origin including, polypeptides of synthetic or natural origin, interleukin-2 and its receptor, enzymes, monoclonal antibodies, trypsin and its inhibitor, cytochrome C, myoglobulin, recombinant human interleukin, recombinant fusion protein, nucleic acid derived products, DNA of either synthetic or natural origin, and RNA of either synthetic or natural origin.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the biological molecule or biological ion is a protein; and the protein comprises exposed amino acid residues selected from the group consisting of Glu, Asp, Try, Arg, Lys, Met, and His.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the biological molecule or biological ion is a protein; and the protein comprises exposed His amino acid residues.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the biological molecule or biological ion is a monoclonal antibody.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the substance is a metal-containing particle, or a metal-containing ion.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the metal-containing particle or metal-containing ion comprises a transition metal, a lanthanide, a poor metal, or an alkaline earth metal.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the metal-containing particle or metal-containing ion comprises a metal selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the first fluid is waste water.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the first fluid is waste water from ore refining, or seawater.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the substance is lead or mercury.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the substance is platinum, palladium, copper, gold, or silver.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the fluid is waste water; and the metal-containing particle or metal-containing ion comprises lead or mercury.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the first fluid is waste water from ore refining; and the metal-containing particle or metal-containing ion comprises lead or mercury.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the first fluid is seawater; and the metal-containing particle or metal-containing ion comprises platinum, palladium, copper, gold, or silver.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the first fluid comprises egg white.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the first fluid comprises egg white; and the substance is lysozyme.
- In certain embodiments, the invention relates to a method in which, in tangential flow separation mode, no pre-processing of the raw reaction mixtures is required due to the high specificity of the composite materials in the devices of the present invention. In certain embodiments, the invention relates to a method in which separations can be carried out on a large scale. In certain embodiments, the invention relates to a method in which separations can be carried out in a shorter amount of time. In certain embodiments, the invention relates to a method in which the devices have a high binding capacity.
- In certain embodiments, the invention relates to a method that comprises two steps collecting the desired substance onto the composite material and harvesting the desired substance from the composite material. In certain embodiments, the first step is run in tangential separation mode. In certain embodiments, the first step is run in tangential separation mode and the second step is run in direct filtration mode with a second fluid.
- In certain embodiments, the invention relates to a method of separating a substance from a fluid, comprising the step of:
- placing the fluid in contact with a composite material in any one of the above-mentioned fluid treatment devices, thereby adsorbing or absorbing the substance to the composite material.
- In certain embodiments, the invention relates to a method of separating a substance from a fluid, comprising the step of:
- placing the fluid in an inlet of any one of the above-mentioned fluid treatment devices, thereby adsorbing or absorbing the substance to the composite material and producing a permeate; and collecting the permeate from an outlet of the fluid treatment device.
- In certain embodiments, the invention relates to the above-mentioned method, wherein the fluid is passed over the surface of the composite material; and the substance is adsorbed or absorbed onto the surface of the composite material.
- In certain embodiments, the invention relates to the above-mentioned method, wherein the fluid is passed through the macropores of the composite material; and the substance is adsorbed or absorbed within the macropores of the composite material.
- In certain embodiments, the invention relates to a method of separating a substance from a fluid, comprising the step of:
- placing the fluid in an inlet of any one of the above-mentioned fluid treatment devices, thereby adsorbing or absorbing the substance to the composite material;
collecting the permeate from an outlet of the fluid treatment device;
placing a second fluid in the inlet of the fluid treatment device, thereby releasing the substance from the composite material. - In certain embodiments, the invention relates to the above-mentioned method, wherein the fluid is passed over the surface of the composite material; the substance is adsorbed or absorbed onto the surface of the composite material; and the second fluid is passed through the macropores of the composite material, thereby releasing the substance from the composite material.
- In certain embodiments, the invention relates to the above-mentioned method, wherein the fluid is passed over the surface of the composite material; the substance is adsorbed or absorbed onto the surface of the composite material; and the second fluid is passed over the surface of the composite material, thereby releasing the substance from the surface of the composite material.
- In certain embodiments, the invention relates to the above-mentioned method, wherein the fluid is passed through the macropores of the composite material; the substance is adsorbed or absorbed within the macropores of the composite material; and the second fluid is passed over the surface of the composite material, thereby releasing the substance from the composite material.
- In certain embodiments, the invention relates to the above-mentioned method, wherein the fluid is passed through the macropores of the composite material; the substance is adsorbed or absorbed within the macropores of the composite material; and the second fluid is passed through the macropores of the composite material, thereby releasing the substance from the composite material.
- In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the substance is radioactive.
- In certain embodiments, the invention relates to a method of separating a substance from a fluid, comprising the steps of:
- placing the fluid in an inlet of any one of the above-mentioned fluid treatment devices, thereby adsorbing or absorbing the substance to the composite material and producing a permeate; and
- collecting the permeate from an outlet of the fluid treatment device,
- wherein the fluid comprises egg white; and the substance is lysozyme.
- In certain embodiments, the invention relates to the above-mentioned method, wherein the fluid is passed over the surface of the fluid treatment element; and the substance is adsorbed or absorbed onto the surface of the fluid treatment element.
- In certain embodiments, the invention relates to a method of separating a substance from a first fluid, comprising the steps of:
- placing the first fluid in an inlet of any one of the above-mentioned fluid treatment devices, thereby adsorbing or absorbing the substance to the composite material;
- collecting the permeate from an outlet of the fluid treatment device;
- placing a second fluid in the inlet of the fluid treatment device, thereby releasing the substance from the composite material,
- wherein the first fluid comprises egg white; and the substance is lysozyme.
- In certain embodiments, the invention relates to the above-mentioned method, wherein the fluid is passed over the surface of the fluid treatment element; the substance is adsorbed or absorbed onto the surface of the fluid treatment element; and the second fluid is passed through the macropores of the fluid treatment element, thereby releasing the substance from the macropores. In certain embodiments, the invention relates to the above-mentioned method, wherein the fluid is passed over the surface of the fluid treatment element; the substance is adsorbed or absorbed onto the surface of the fluid treatment element; and the second fluid is passed over the surface of the fluid treatment element, thereby releasing the substance from the surface of the fluid treatment element.
- The invention now being generally described, it will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.
- An example of the improvement of cross-flow technology versus dead-end technology can be realized when the two modes are compared directly to each other.
FIG. 1 shows two experiments in which a specific device was run as a dead-end and as cross-flow device. The material of interest is a virus. In both cases, the capture of the cross-flow device exceeded the dead-end version, as indicated by the amount to the pure target material capture after washing and elution. - The membrane can selectively adsorb two protein materials from the feed stream and then, through the use of an altering buffer fluid, selectively elute the target bio-molecules.
FIGS. 2 and 3 illustrate this effect. The initial feed stream of egg white was exposed to a membrane surface in cross-flow mode. Once the feed stream was removed and the membrane washed, both Ovalbumin and lysozyme were found adhered to the membrane (FIG. 2 ). Under specific buffer conditions, the proteins were selectively eluted (FIG. 3 ), which demonstrates the chromatographic nature of the membrane in cross-flow mode. - See
FIG. 4 . - The effect of selecting an optimal spacer material in a simple wrapped design was observed and is depicted in
FIG. 5 . In this design, a roll was made by layering the necessary membrane sheet between two identical spacer sheets and rolling the multi-layered structure into a column. This column was then placed into a metal tube housing that was fitted with end-caps which have both an inlet(s) and outlet(s) attached (FIG. 6 ). The larger spacer material and loose-wind structure enabled the ideal cross-flow or tangential-flow adsorption. Importantly, this design eliminated any direct trans-membrane flow, as the process fluid was run on either side of the membrane. Thus, the improvements stemmed, at least partially, from the low shear environment. The purified lysozyme control was run on the device and was used to represent 100% or maximum adsorption of the target species. The remaining data were generated directly from process fluid streams (egg whites). In this embodiment, the spacer layer materials on either side of the membrane were identical but there is no requirement for this symmetry and the “roll” could have differing layers or one layer could be completely absent. - The height of the feed channel may impact the ability to maximize the amount of adsorbed target molecule. Smaller feed channel heights may induce greater shear or turbulence at the membrane surface, which either inhibits adsorption or removes target material that does deposit. The channel height needs to be at least 10 mm and more ideally >20 mm, typically 23 mm (
FIG. 7 ). - Screen changes have not been identified as a driver for performance in cassette design.
-
FIG. 23 depicts a spiral wound device. When membranes of the current invention are incorporated into this device, highly contaminated or very viscous feed streams can be effectively separated into their desired parts. - A 0.01 SQM Protein A cassette with an open channel, suspended screen design which enabled a fluid flow tangential to the plane of the membrane was evaluated using an un-clarified feed stream which contained the monoclonal antibody (mAb) target. Traditional resin chromatographic separation processes cannot process un-clarified feed streams. The only method that had been demonstrated able to capture the mAb target on bench scale was an expanded bed column functioning in batch mode with a static soak. This modified expanded bed was uneconomical and impractical at larger scale. On the other hand, the cassettes were effective in capturing the target MAb product when used a simple flow through mode. This mode allowed the process stream to flow across the membrane such that debris in the fluid did not blind the membrane. Binding of the target species in this mode was a surface effect only.
- Lysis Procedure: 270 g mAb 4420 pellet diluted 1 part pellet, 3
parts 10× phosphate buffer solution (PBS), 1 part 5× Pfenix lysis buffer. Homogenized for 5 minutes, and sonicated for 10 minutes. Loaded onto the membrane as an un-clarified and undiluted feed stream. - Membrane Procedure: A membrane cassette with an active surface area of 0.01 m2 and pore size of 0.3 μm was equilibrated in PBS at pH 7.4. This device was then loaded by complete system recirculation with lysed mAb 4420 for one hour. The device was then washed with 1 L of 1×PBS pH 7.4, and eluted using a 10 minute recirculation of 0.1 M Glycine at pH 2.9 followed by 100 mL system flush with 0.1 M Glycine pH 2.9. The feed was run in flow through mode at 100 mL/min with permeate shut off which limited the device to surface binding only from the un-clarified lysate. A gel electrophoresis qualitative analysis indicated that significant amounts of mAb had been captured.
- Conclusion: The cross-flow product provided a simple, on-off bind-elute capture process that could capture and concentrate intact mAb (observed binding was in the range of 5-10 mg/mL) as well as a lot of contaminants. With development, membrane could serve as a scalable capture method for un-clarified mAb Pseudomonas feed streams.
- A 0.02 SQM IMAC-Ni (iminodiacetic acid complexed to Ni) cassette with an open channel, suspended screen design which enabled a fluid flow tangential to the plane of the membrane was evaluated using a feed stream containing a his-tagged protein target. Traditional resin-based chromatographic separation processes cannot process un-clarified feed streams. In this experiment, the cassettes were effective in capturing the target product in a simple flow through mode. This mode allowed the process stream to flow across the membrane such that debris in the fluid did not blind the membrane. Binding of the target species in this mode was a surface effect only. The product was able to be run with multiple cycles with no loss in binding capacity.
- Lysis Procedure: 8 L of cell harvest material was diluted with 2 L of 5× Pfenix Lysis Buffer. This mixture was allowed to mix for 2 hours until the material had liquefied.
- Membrane Procedure: A membrane cassette with an active surface area of 0.02 m2 was equilibrated in 50 mM PBS, 500 mM NaCl, 5% (wt) glycerol and 25 mM Imidazole at pH 8.0. The cassette was then run with the liquefied cell harvest material at a 100 mL/min feed rate with no permeate flow. This was flowed by elution using 500
mL 1×PBS, 500 mM Imidazole at pH 7.4. This process was repeated 3 times in sequence with the follow details: -
- Run 1: 1 L of Lysate was centrifuged and diluted by a factor of 5 in equilibration buffer. The device was then loaded by complete system recirculation for 1 hour time and material was able to permeate through the pores at 20 PSIg inlet pressure. A gel electrophoresis qualitative analysis indicated that significant amounts his-tagged protein had been captured.
- Run 2: 1 L of Lysate was only centrifuged prior to use. The device was then loaded by complete system recirculation for 1 hour time and material was able to permeate through the pores at 20 PSIg inlet pressure. A gel electrophoresis qualitative analysis indicated that significant amounts his-tagged protein had been captured
- Run 3: 1 L of Lysate was used without pre-treatment. The device was then loaded by complete system recirculation for 15, 30, 45, 60 minute load times. The device was eluted after each cycle and the membrane not stripped (cleaned) between elutions. When the permeate line was closed, no back pressure increase to system was observed during load indicating that the membrane had not blinded.
- Conclusion: The IMAC-Ni product yielded excellent purification characteristics (observed binding was in the range of 60-80 mg/mL) without optimization. Despite manufacturers designation as “single-use,” 7× reuse demonstrated for IMAC membrane without the need for EDTA strip and re-charge.
- All of the U.S. patents and U.S. patent application publications cited herein are hereby incorporated by reference.
- Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims (44)
1. A fluid treatment device comprising
a housing unit, wherein the housing unit comprises
(a) an inlet and an outlet;
(b) a fluid flow path between the inlet and the outlet; and
(c) a composite material within the housing unit, wherein the composite material comprises
a support member comprising a plurality of pores extending through the support member; and
a non-self-supporting macroporous cross-linked gel comprising macropores having an average size of 10 nm to 3000 nm, said macroporous gel being located in the pores of the support member;
wherein said macropores of said macroporous cross-linked gel are smaller than said pores of said support member; and
wherein the pores of the support member are substantially perpendicular to the fluid flow path.
2. The fluid treatment device of claim 1 , wherein the composite material is arranged in a substantially coplanar stack of substantially coextensive sheets, a substantially tubular configuration, or a substantially spiral wound configuration.
3. The fluid treatment device of claim 1 , wherein
the support member is in the form of hollow porous fibers;
each hollow porous fiber defines a lumen;
the lumen is from about 20 μm to about 100 μm in diameter; and
the lumen is substantially perpendicular to the pores in the hollow porous fiber support member.
4. The fluid treatment device of claim 3 , wherein a plurality of hollow porous fibers are arranged in a bundle.
5. The fluid treatment device of claim 1 , wherein the housing unit is substantially cylindrical.
6. The fluid treatment device of claim 1 , wherein the housing unit is disposable or reusable.
7. The fluid treatment device of claim 1 , wherein the housing unit is plastic or stainless steel.
8. The fluid treatment device of claim 1 , wherein the inlet or the outlet is a press fit attachment point, a luer lock attachment point, or a hose barb attachment point.
9. The fluid treatment device of claim 1 , wherein the macroporous cross-linked gel is a hydrogel, a polyelectrolyte gel, a hydrophobic gel, a neutral gel, or a gel comprising functional groups.
10. The fluid treatment device of claim 9 , wherein the macroporous cross-linked gel is a gel comprising functional groups; and said functional groups are selected from the group consisting of amino acid ligands, antigen and antibody ligands, dye ligands, biological molecules, biological ions, and metal affinity ligands.
11. The fluid treatment device of claim 10 , wherein said functional groups are metal affinity ligands.
12. The fluid treatment device of claim 11 , further comprising a plurality of metal ions complexed to a plurality of said metal affinity ligands.
13. The fluid treatment device of claim 11 , wherein said metal affinity ligands are octadentate, hexadentate, tetradentate, tridentate or bidentate ligands.
14. The fluid treatment device of claim 11 , wherein said metal affinity ligands are iminodicarboxylic acid ligands.
15. The fluid treatment device of claim 11 , wherein said metal affinity ligands are iminodiacetic acid ligands.
16. The fluid treatment device of claim 12 , wherein said metal ions are transition metal ions, lanthanide ions, poor metal ions or alkaline earth metal ions.
17. The fluid treatment device of claim 12 , wherein said metal ions are selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
18. The fluid treatment device of claim 12 , wherein said metal affinity ligands are iminodicarboxylic acid ligands; and said metal ions are nickel.
19. The fluid treatment device of claim 10 , wherein said functional groups are biological molecules or biological ions.
20. The fluid treatment device of claim 19 , wherein said functional groups are selected from the group consisting of albumins, lysozyme, viruses, cells, γ-globulins of human and animal origins, immunoglobulins of both human and animal origins, proteins of recombinant or natural origin including, polypeptides of synthetic or natural origin, interleukin-2 and its receptor, enzymes, monoclonal antibodies, antigens, lectins, bacterial immunoglobulin-binding proteins, trypsin and its inhibitor, cytochrome C, myoglobulin, recombinant human interleukin, recombinant fusion protein, Protein A, Protein G, Protein L, Peptide H, nucleic acid derived products, DNA of either synthetic or natural origin, and RNA of either synthetic or natural origin.
21. The fluid treatment device of claim 19 , wherein said functional groups are Protein A.
22. The fluid treatment device of claim 1 , wherein the macroporous crosslinked gel is cross-linked by N,N′-methylenebisacrylamide or a polyfunctional macromonomer.
23. The fluid treatment device of claim 1 , wherein the support member consists essentially of polymeric material in the form of a membrane that has a thickness of from about 10 μm to about 500 μm and comprises pores of average size between about 0.1 to about 25 μm.
24. The fluid treatment device of claim 1 , wherein the support member consists essentially of a polyolefin.
25. A method comprising the step of:
contacting a first fluid comprising a substance with a composite material in a fluid treatment device of claim 1 , thereby adsorbing or absorbing the substance onto the composite material.
26. The method of claim 25 , further comprising the step of
placing the first fluid in an inlet of the fluid treatment device.
27. The method of claim 26 , wherein the first fluid is passed along a fluid flow path substantially perpendicular to the pores of the support member.
28. The method of claim 27 , further comprising the step of
contacting a second fluid with the substance adsorbed or absorbed onto the composite material, thereby releasing the substance from the composite material.
29. The method of claim 28 , wherein the second fluid is passed through the macropores of the composite material, thereby releasing the substance from the composite material.
30. The method of claim 28 , wherein the second fluid is passed along the fluid flow path substantially perpendicular to the pores of the support member, thereby releasing the substance from the composite material.
31. The method of claim 25 , wherein the macroporous gel displays a specific interaction for the substance; and the specific interactions are electrostatic interactions, affinity interactions, or hydrophobic interactions.
32. The method of claim 31 , wherein the specific interactions are electrostatic interactions, the composite material bears charges on the macroporous gel; the substance is charged; and the substance is separated based on Donnan exclusion.
33. The method of claim 27 , wherein the first fluid is a suspension of cells or a suspension of aggregates.
34. The method of claim 27 , wherein the substance is a biological molecule or biological ion.
35. The method of claim 34 , wherein the biological molecule or biological ion is selected from the group consisting of albumins, lysozyme, viruses, cells, γ-globulins of human and animal origins, immunoglobulins of both human and animal origins, proteins of recombinant or natural origin including, polypeptides of synthetic or natural origin, interleukin-2 and its receptor, enzymes, monoclonal antibodies, trypsin and its inhibitor, cytochrome C, myoglobulin, recombinant human interleukin, recombinant fusion protein, nucleic acid derived products, DNA of either synthetic or natural origin, and RNA of either synthetic or natural origin.
36. The method of claim 34 , wherein the biological molecule or biological ion is a protein; and the protein comprises exposed amino acid residues selected from the group consisting of Glu, Asp, Try, Arg, Lys, Met, and His.
37. The method of claim 34 , wherein the biological molecule or biological ion is a protein; and the protein comprises exposed His amino acid residues.
38. The method of claim 34 , wherein the biological molecule or biological ion is a monoclonal antibody.
39. The method of claim 27 , wherein the substance is a metal-containing particle, or a metal-containing ion.
40. The method of claim 39 , wherein the metal-containing particle or metal-containing ion comprises a transition metal, a lanthanide, a poor metal, or an alkaline earth metal.
41. The method of claim 39 , wherein the metal-containing particle or metal-containing ion comprises a metal selected from the group consisting of nickel, zirconium, lanthanum, cerium, manganese, titanium, cobalt, iron, copper, zinc, silver, gallium, platinum, palladium, lead, mercury, cadmium and gold.
42. The method of claim 27 , wherein the first fluid is waste water.
43. The method of claim 27 , wherein the first fluid comprises egg white.
44. The method of claim 27 , wherein the first fluid comprises egg white; and the substance is lysozyme.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/551,762 US20100059443A1 (en) | 2008-09-02 | 2009-09-01 | Chromatography Membranes, Devices Containing Them, and Methods of Use Thereof |
US15/427,447 US10800808B2 (en) | 2008-09-02 | 2017-02-08 | Chromatography membranes, devices containing them, and methods of use thereof |
US16/100,515 US10981949B2 (en) | 2008-09-02 | 2018-08-10 | Chromatography membranes, devices containing them, and methods of use thereof |
US17/203,076 US11884701B2 (en) | 2008-09-02 | 2021-03-16 | Chromatography membranes, devices containing them, and methods of use thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9360008P | 2008-09-02 | 2008-09-02 | |
US10279708P | 2008-10-03 | 2008-10-03 | |
US12/551,762 US20100059443A1 (en) | 2008-09-02 | 2009-09-01 | Chromatography Membranes, Devices Containing Them, and Methods of Use Thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/427,447 Continuation US10800808B2 (en) | 2008-09-02 | 2017-02-08 | Chromatography membranes, devices containing them, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100059443A1 true US20100059443A1 (en) | 2010-03-11 |
Family
ID=41797806
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/551,762 Abandoned US20100059443A1 (en) | 2008-09-02 | 2009-09-01 | Chromatography Membranes, Devices Containing Them, and Methods of Use Thereof |
US15/427,447 Active US10800808B2 (en) | 2008-09-02 | 2017-02-08 | Chromatography membranes, devices containing them, and methods of use thereof |
US16/100,515 Active US10981949B2 (en) | 2008-09-02 | 2018-08-10 | Chromatography membranes, devices containing them, and methods of use thereof |
US17/203,076 Active 2030-01-18 US11884701B2 (en) | 2008-09-02 | 2021-03-16 | Chromatography membranes, devices containing them, and methods of use thereof |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/427,447 Active US10800808B2 (en) | 2008-09-02 | 2017-02-08 | Chromatography membranes, devices containing them, and methods of use thereof |
US16/100,515 Active US10981949B2 (en) | 2008-09-02 | 2018-08-10 | Chromatography membranes, devices containing them, and methods of use thereof |
US17/203,076 Active 2030-01-18 US11884701B2 (en) | 2008-09-02 | 2021-03-16 | Chromatography membranes, devices containing them, and methods of use thereof |
Country Status (7)
Country | Link |
---|---|
US (4) | US20100059443A1 (en) |
EP (1) | EP2334413A4 (en) |
JP (1) | JP5767584B2 (en) |
KR (4) | KR102028628B1 (en) |
AU (1) | AU2009288234B2 (en) |
CA (1) | CA2736814C (en) |
WO (1) | WO2010027955A2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080242822A1 (en) * | 2007-04-02 | 2008-10-02 | West Richard A | Polyurethane formulation using protein-based material |
WO2011058439A1 (en) * | 2009-11-13 | 2011-05-19 | Natrix Separations, Inc. | Hydrophobic interaction chromatography membranes, and methods of use thereof |
WO2012037101A2 (en) * | 2010-09-14 | 2012-03-22 | Natrix Separations Inc. | Chromatography membranes for the purification of chiral compounds |
WO2014063125A1 (en) * | 2012-10-18 | 2014-04-24 | Innovaprep Llc | Liquid to liquid biological particle fractionation and concentration |
JP2014518765A (en) * | 2011-05-17 | 2014-08-07 | ナトリックス セパレイションズ インコーポレーテッド | Layered tubular membrane for chromatography and method of use thereof |
WO2014134147A1 (en) * | 2013-02-26 | 2014-09-04 | Natrix Separations Inc. | Mixed-mode chromatography membranes |
US9410007B2 (en) | 2012-09-27 | 2016-08-09 | Rhodia Operations | Process for making silver nanostructures and copolymer useful in such process |
US9575059B2 (en) | 2012-06-05 | 2017-02-21 | 3M Innovative Properties Company | Lanthanum-based concentration agents for microorganisms |
US10315133B2 (en) * | 2010-09-28 | 2019-06-11 | Sartorius Stedim Biotech Gmbh | Method for separating viruses from a contaminant-containing liquid |
US10800808B2 (en) | 2008-09-02 | 2020-10-13 | Merck Millipore Ltd. | Chromatography membranes, devices containing them, and methods of use thereof |
US20210069648A1 (en) * | 2019-09-06 | 2021-03-11 | Repligen Corporation | Scale-down tangential flow depth filtration systems and methods of filtration using same |
EP4299156A1 (en) * | 2022-06-29 | 2024-01-03 | Sartorius Stedim Biotech GmbH | Tangential flow filtration/chromatography systems, use thereof, and methods of separation |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013529931A (en) * | 2010-07-02 | 2013-07-25 | レンブラント・エンタープライジーズ・インコーポレイテッド | Isolated egg protein and egg lipid materials and methods for producing them |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
JP6360482B2 (en) | 2012-09-17 | 2018-07-18 | ダブリュー・アール・グレース・アンド・カンパニー−コーンW R Grace & Co−Conn | Chromatographic carrier and device |
EP2969095A4 (en) * | 2013-03-14 | 2017-01-04 | Natrix Separations Inc. | Chromatography membranes stable under caustic conditions |
EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
WO2015109068A1 (en) | 2014-01-16 | 2015-07-23 | W. R. Grace & Co.-Conn. | Affinity chromatography media and chromatography devices |
JP6914189B2 (en) | 2014-05-02 | 2021-08-04 | ダブリュー・アール・グレース・アンド・カンパニー−コーンW R Grace & Co−Conn | Functionalized Carrier Materials and Methods for Making and Using Functionalized Carrier Materials |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
BR112017026193B1 (en) | 2015-06-05 | 2021-09-14 | W.R. Grace & Co-Conn | ADSORBENTS, ADSORBENT PRODUCTION METHOD AND ADSORBENT USE |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
DE102017007808A1 (en) * | 2017-08-17 | 2019-02-21 | Sartorius Stedim Biotech Gmbh | Protein purification device |
KR20220066413A (en) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | Acoustic transducer drive and controller |
JP7294772B2 (en) * | 2018-04-11 | 2023-06-20 | 株式会社島津製作所 | Field flow fractionation device |
JP7455389B2 (en) | 2018-05-30 | 2024-03-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Microfluidic filtration devices and methods for dissociation of tissue and cell aggregates and enrichment of single cells |
WO2023012206A1 (en) | 2021-08-05 | 2023-02-09 | Merck Patent Gmbh | Method for reducing endotoxin levels in nucleic acid purification |
WO2023170028A1 (en) | 2022-03-10 | 2023-09-14 | Merck Patent Gmbh | Method for reducing endotoxin levels in nucleic acid purification |
WO2023174974A1 (en) | 2022-03-18 | 2023-09-21 | Merck Patent Gmbh | Methods and compositions for purifying adeno associated virus particles |
WO2023174965A1 (en) | 2022-03-18 | 2023-09-21 | Merck Patent Gmbh | Methods and compositions for purifying small extracellular vesicles |
Citations (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3209915A (en) * | 1962-03-06 | 1965-10-05 | Aircraft Appliances And Equipm | Filter |
US3417870A (en) * | 1965-03-22 | 1968-12-24 | Gulf General Atomic Inc | Reverse osmosis purification apparatus |
US3473668A (en) * | 1966-03-30 | 1969-10-21 | Norris Filters Ltd | Stacked filter elements |
US3623610A (en) * | 1968-10-25 | 1971-11-30 | Danske Sukkerfab | Reverse osmosis apparatus |
US3695444A (en) * | 1968-12-24 | 1972-10-03 | Ionics | Membrane support |
US3713921A (en) * | 1971-04-01 | 1973-01-30 | Gen Electric | Geometry control of etched nuclear particle tracks |
US3875085A (en) * | 1972-10-11 | 1975-04-01 | Ici Australia Ltd | Process of making amphoteric polymeric compositions from snake-cage resins |
US3939105A (en) * | 1974-06-18 | 1976-02-17 | Union Carbide Corporation | Microporous polyurethane hydrogels, method and composites with natural and other synthetic fibers or films |
US3997482A (en) * | 1974-01-14 | 1976-12-14 | Ceskoslovenska Akademie Ved | Hydrophilic polymeric carriers of biologically active compounds and method of preparing the same |
US4104125A (en) * | 1977-02-28 | 1978-08-01 | The Green Cross Corporation | Process for producing human lysozyme |
US4108804A (en) * | 1975-12-23 | 1978-08-22 | Toru Seita | Process for preparation of chromatography solid supports comprising a nucleic acid base-epoxy group containing porous gel |
US4133764A (en) * | 1974-12-18 | 1979-01-09 | Rhone-Poulenc Industries | Retaining device for apparatus having semi-permeable membranes |
US4170540A (en) * | 1978-03-31 | 1979-10-09 | Hooker Chemicals & Plastics Corp. | Method for forming microporous membrane materials |
US4224415A (en) * | 1958-07-18 | 1980-09-23 | Rohm And Haas Company | Polymerization processes and products therefrom |
US4230697A (en) * | 1978-07-03 | 1980-10-28 | Morinaga Milk Industry Co. Ltd. | Virus-inactivated HGI-glycoprotein capable of stimulating proliferation and differentiation of human granulocyte, process for preparing same and leukopenia curative containing same |
US4275056A (en) * | 1978-03-20 | 1981-06-23 | Morinaga Milk Industry Co., Ltd. | HGI-Glycoprotein capable of stimulating proliferation and differentiation of human granulocyte, process for preparing same and leukopenia curative containing same |
US4397892A (en) * | 1980-03-04 | 1983-08-09 | Bor-,Mubor-,es Cipoipari kutato Intezet | Process for the production of chemically bonded non-woven sheet materials containing a binder of microheteroporous structure |
US4473474A (en) * | 1980-10-27 | 1984-09-25 | Amf Inc. | Charge modified microporous membrane, process for charge modifying said membrane and process for filtration of fluid |
US4504583A (en) * | 1982-06-02 | 1985-03-12 | Kewpie Kabushiki Kaisha | Process for crystallizing egg white lysozyme |
US4518695A (en) * | 1982-05-29 | 1985-05-21 | Kewpie Kabushiki Kaisha | Process for eluting egg white lysozyme |
US4525374A (en) * | 1984-02-27 | 1985-06-25 | Manresa, Inc. | Treating hydrophobic filters to render them hydrophilic |
US4525527A (en) * | 1982-01-25 | 1985-06-25 | American Colloid Company | Production process for highly water absorbable polymer |
US4601828A (en) * | 1983-02-07 | 1986-07-22 | Yale University | Transfer of macromolecules from a chromatographic substrate to an immobilizing matrix |
US4678844A (en) * | 1985-03-04 | 1987-07-07 | Agency Of Industrial Science & Technology | Chelate, crosslinked polyethyleneimine resin having 2-hydroxy benzoyl group |
US4705755A (en) * | 1982-05-31 | 1987-11-10 | Kewpie Kabushiki Kaisha | Apparatus for collecting lysozyme from egg white by adsorption |
US4836928A (en) * | 1984-04-28 | 1989-06-06 | Terumo Kabushiki Kaisha | Separation method, separation device and separation apparatus for separating body fluid into respective components |
US4923610A (en) * | 1987-12-10 | 1990-05-08 | Ceskoslovenska akademive ved and Akademia Nauk SSSR | Macroporous polymeric membranes for the separation of polymers and a method of their application |
US4944879A (en) * | 1989-07-27 | 1990-07-31 | Millipore Corporation | Membrane having hydrophilic surface |
US4966851A (en) * | 1986-12-01 | 1990-10-30 | The University Of British Columbia | Process for isolation of lysozyme and avidin from egg white |
US4999171A (en) * | 1987-04-03 | 1991-03-12 | Sumitomo Chemical Co. Ltd. | Process for recovery of gallium by chelate resin |
US5019270A (en) * | 1989-07-06 | 1991-05-28 | Perseptive Biosystems, Inc. | Perfusive chromatography |
US5059659A (en) * | 1987-05-29 | 1991-10-22 | Harry P. Gregor | Surface treatments to impart hydrophilicity |
US5114585A (en) * | 1988-03-01 | 1992-05-19 | Gelman Sciences, Inc. | Charged porous filter |
US5130343A (en) * | 1991-03-13 | 1992-07-14 | Cornell Research Foundation, Inc. | Process for producing uniform macroporous polymer beads |
US5137633A (en) * | 1991-06-26 | 1992-08-11 | Millipore Corporation | Hydrophobic membrane having hydrophilic and charged surface and process |
US5147541A (en) * | 1990-11-14 | 1992-09-15 | Koch Membrane Systems, Inc. | Spiral filtration module with strengthened membrane leaves and method of constructing same |
US5160627A (en) * | 1990-10-17 | 1992-11-03 | Hoechst Celanese Corporation | Process for making microporous membranes having gel-filled pores, and separations methods using such membranes |
US5176832A (en) * | 1991-10-23 | 1993-01-05 | The Dow Chemical Company | Chromatographic separation of sugars using porous gel resins |
US5228989A (en) * | 1989-07-06 | 1993-07-20 | Perseptive Biosystems, Inc. | Perfusive chromatography |
US5277915A (en) * | 1987-10-30 | 1994-01-11 | Fmc Corporation | Gel-in-matrix containing a fractured hydrogel |
US5282971A (en) * | 1993-05-11 | 1994-02-01 | Pall Corporation | Positively charged polyvinylidene fluoride membrane |
US5316680A (en) * | 1992-10-21 | 1994-05-31 | Cornell Research Foundation, Inc. | Multimodal chromatographic separation media and process for using same |
US5334310A (en) * | 1991-10-21 | 1994-08-02 | Cornell Research Foundation, Inc. | Column with macroporous polymer media |
US5403482A (en) * | 1993-10-12 | 1995-04-04 | Gelman Sciences Inc. | Self-supporting, pleated, spirally wound filter and the corresponding process of making |
US5422284A (en) * | 1987-07-16 | 1995-06-06 | E. I. Du Pont De Nemours And Company | Method of performing affinity separation using immobilized flocculating agent on chromatographic support |
US5460720A (en) * | 1993-08-12 | 1995-10-24 | Schneider; Burnett M. | Pleated membrane crossflow fluid separation device |
US5470469A (en) * | 1994-09-16 | 1995-11-28 | E. I. Du Pont De Nemours And Company | Hollow fiber cartridge |
US5593576A (en) * | 1992-06-19 | 1997-01-14 | Biosepra, Inc. | Passivated porous polymer supports and methods for the preparation and use of same |
US5593729A (en) * | 1992-10-21 | 1997-01-14 | Cornell Research Foundation, Inc. | Pore-size selective modification of porous materials |
US5599453A (en) * | 1992-06-19 | 1997-02-04 | Biosepra Inc. | Passivated porous supports and methods for the preparation and use of same |
US5646001A (en) * | 1991-03-25 | 1997-07-08 | Immunivest Corporation | Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof |
US5648390A (en) * | 1992-08-07 | 1997-07-15 | The United States Of America As Represented By The Secretary Of Agriculture | Repellents for ants |
US5681464A (en) * | 1993-07-20 | 1997-10-28 | Alfa Laval Brewery Systems Ab | Filter for cross-flow filtration |
US5723601A (en) * | 1992-03-18 | 1998-03-03 | Pharmacia Biotech Ab | Super porous polysaccharide gels |
US5728457A (en) * | 1994-09-30 | 1998-03-17 | Cornell Research Foundation, Inc. | Porous polymeric material with gradients |
US5756717A (en) * | 1995-05-24 | 1998-05-26 | Perseptive Biosystems, Inc | Protein imaging |
US5780688A (en) * | 1992-10-10 | 1998-07-14 | Veba Oel Ag | Supported-catalyst and use of same |
US5783085A (en) * | 1982-12-13 | 1998-07-21 | Estate Of William F. Mclaughlin | Blood fractionation method |
US5906734A (en) * | 1992-06-19 | 1999-05-25 | Biosepra Inc. | Passivated porous polymer supports and methods for the preparation and use of same |
US5929214A (en) * | 1997-02-28 | 1999-07-27 | Cornell Research Foundation, Inc. | Thermally responsive polymer monoliths |
US5972634A (en) * | 1994-10-19 | 1999-10-26 | The General Hospital Corporation | Diagnostic assay for Alzheimer's disease: assessment of Aβ abnormalities |
US6033784A (en) * | 1995-04-07 | 2000-03-07 | Jacobsen; Mogens Havsteen | Method of photochemical immobilization of ligands using quinones |
US6086769A (en) * | 1996-09-16 | 2000-07-11 | Commodore Separation Technologies, Inc. | Supported liquid membrane separation |
US6143174A (en) * | 1996-09-05 | 2000-11-07 | Sartorius Ag | Filtration unit with pleated filtering elements |
US6258276B1 (en) * | 1996-10-18 | 2001-07-10 | Mcmaster University | Microporous membranes and uses thereof |
US6271278B1 (en) * | 1997-05-13 | 2001-08-07 | Purdue Research Foundation | Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties |
US6277489B1 (en) * | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
US20020005383A1 (en) * | 1998-04-06 | 2002-01-17 | Nicolas Voute | Large pore volume composite mineral oxide beads, their preparation and their applications for adsorption and chromatography |
US6461513B1 (en) * | 2000-05-19 | 2002-10-08 | Filtration Solutions, Inc. | Secondary-flow enhanced filtration system |
US6475071B1 (en) * | 2000-08-25 | 2002-11-05 | Micron Technology, Inc. | Cross flow slurry filtration apparatus and method |
US6635420B1 (en) * | 1997-09-08 | 2003-10-21 | Roche Diagnostics Gmbh | Purification of substances from a biological sample |
US6635104B2 (en) * | 2000-11-13 | 2003-10-21 | Mcmaster University | Gas separation device |
US6766817B2 (en) * | 2001-07-25 | 2004-07-27 | Tubarc Technologies, Llc | Fluid conduction utilizing a reversible unsaturated siphon with tubarc porosity action |
US6780327B1 (en) * | 1999-02-25 | 2004-08-24 | Pall Corporation | Positively charged membrane |
US6780582B1 (en) * | 1998-07-14 | 2004-08-24 | Zyomyx, Inc. | Arrays of protein-capture agents and methods of use thereof |
US20040203149A1 (en) * | 2003-02-19 | 2004-10-14 | Childs Ronald F. | Composite materials comprising supported porous gels |
US6824975B2 (en) * | 2000-10-13 | 2004-11-30 | Dexall Biomedical Labs, Inc | Incorporation of selective binding substances in a solid phase assay device |
US6911148B1 (en) * | 1999-09-14 | 2005-06-28 | Sartorius Ag | Adsorptive membrane device for treating particle-laden liquid feeds |
US6951880B2 (en) * | 2002-05-16 | 2005-10-04 | Genelabs Technologies, Inc. | Aryl and heteroaryl compounds as antibacterial and antifungal agents |
US6984604B2 (en) * | 2001-11-26 | 2006-01-10 | Invista North America S.A.R.L. | Supported bis(phosphorus) ligands and their use in the catalysis |
US6986847B2 (en) * | 2002-05-10 | 2006-01-17 | New Jersey Institute Of Technology | Method and apparatus for isolation and purification of biomolecules |
US7048855B2 (en) * | 2000-12-22 | 2006-05-23 | Ge Osmonics, Inc. | Cross flow filtration materials and cartridges |
US20060175256A1 (en) * | 2004-12-09 | 2006-08-10 | Board Of Trustees Of Michigan State University | Ceramic membrane water filtration |
US7163803B2 (en) * | 2001-06-07 | 2007-01-16 | Electrophoretics Limited | Method for characterizing polypeptides |
US20070212281A1 (en) * | 2002-12-10 | 2007-09-13 | Ecolab, Inc. | Deodorizing and sanitizing employing a wicking device |
US20080017578A1 (en) * | 2004-04-08 | 2008-01-24 | Childs Ronald F | Membrane Stacks |
US7507420B2 (en) * | 2001-05-31 | 2009-03-24 | Medarex, Inc. | Peptidyl prodrugs and linkers and stabilizers useful therefor |
US7598371B2 (en) * | 2000-11-06 | 2009-10-06 | University Of Houston | Nucleic acid separation using immobilized metal affinity chromatography |
US7824548B2 (en) * | 2004-02-05 | 2010-11-02 | Millipore Corporation | Porous adsorptive or chromatographic media |
Family Cites Families (207)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5146647B2 (en) | 1973-03-31 | 1976-12-10 | ||
JPS525431B2 (en) | 1973-05-14 | 1977-02-14 | ||
US4198238A (en) | 1978-06-22 | 1980-04-15 | Hercules Incorporated | Photopolymerizable composition |
US4381775A (en) | 1980-02-05 | 1983-05-03 | Takeda Chemical Industries, Ltd. | Method for low pressure filtration of plasma from blood |
JPS56110625A (en) | 1980-02-05 | 1981-09-01 | Takeda Chem Ind Ltd | Separating method of blood plasma and apparatus for the same |
US4377481A (en) | 1980-11-14 | 1983-03-22 | Abcor, Inc. | Blended, polymeric, matrix membrane and process of making and using same |
CA1200158A (en) | 1982-02-05 | 1986-02-04 | Peter J. Degen | Surface modified polyamide membrane |
CA1226112A (en) | 1982-09-09 | 1987-09-01 | Minnesota Mining And Manufacturing Company | Microporous sheet material, method of making and articles made therewith |
US4790942A (en) | 1983-12-20 | 1988-12-13 | Membrex Incorporated | Filtration method and apparatus |
JPH043623Y2 (en) | 1985-03-29 | 1992-02-04 | ||
JPS6214903A (en) | 1985-07-11 | 1987-01-23 | Fuji Photo Film Co Ltd | Process of turning hydrophobic microporous filter membrane hydrophilic |
JPS6239636A (en) | 1985-08-14 | 1987-02-20 | Mitsubishi Rayon Co Ltd | Production of hydrophilic organic polymer substrate |
JPS62186940A (en) | 1986-02-10 | 1987-08-15 | Kanegafuchi Chem Ind Co Ltd | Adsorbent for lipoprotein |
GB8608430D0 (en) | 1986-04-07 | 1986-05-14 | Raychem Ltd | Porous polymer article |
JPS62258702A (en) | 1986-04-30 | 1987-11-11 | Sagami Chem Res Center | Polymer membrane for optical resolution of amino acid |
US5122558A (en) | 1986-12-09 | 1992-06-16 | The Dow Chemical Company | Static dissipative interpolymers |
US4888116A (en) | 1987-01-15 | 1989-12-19 | The Dow Chemical Company | Method of improving membrane properties via reaction of diazonium compounds or precursors |
JPS6419024A (en) | 1987-07-15 | 1989-01-23 | Tosoh Corp | Separation of immunoglobulin g subclass |
JPH0752568Y2 (en) | 1987-10-29 | 1995-11-29 | 鐘淵化学工業株式会社 | Position detector |
JPH0734861B2 (en) | 1987-10-30 | 1995-04-19 | エフ・エム・シー・コーポレーション | Gel-containing matrix containing crushed hydrogel |
JPH01180048A (en) | 1988-01-11 | 1989-07-18 | Nec Corp | Information processing system by data driving process |
DE3803341A1 (en) | 1988-02-04 | 1989-08-10 | Sartorius Gmbh | FLUID-OPEN-ENDING SITES HAVING POROESE MEMBRANE FILTERS AND THEIR USE |
US5268306A (en) | 1988-02-29 | 1993-12-07 | Boehringer Mannheim Gmbh | Preparation of a solid phase matrix containing a bound specific binding pair |
US4897191A (en) | 1988-05-27 | 1990-01-30 | Zenon Environmental Inc. | Tubular membrane module with fluid shear protection |
JPH076057B2 (en) | 1988-06-07 | 1995-01-25 | 株式会社村田製作所 | Holder for masking |
ATE175681T1 (en) | 1988-10-17 | 1999-01-15 | Hemasure Inc | METHOD FOR THE COVALENT SURFACE MODIFICATION OF HYDROPHOBIC POLYMERS AND PRODUCTS THEREOF |
US4957620A (en) * | 1988-11-15 | 1990-09-18 | Hoechst Celanese Corporation | Liquid chromatography using microporous hollow fibers |
DE3918430A1 (en) | 1989-06-06 | 1990-12-20 | Sommer Werner Dr Ing | Sorption and membrane solvent vapour sepn. processes - are combined in multi-wall structure |
ATE179901T1 (en) | 1989-07-06 | 1999-05-15 | Perseptive Biosystems Inc | CHROMATOGRAPHY METHOD |
US5227063A (en) | 1989-10-03 | 1993-07-13 | Zenon Environmental Inc. | Tubular membrane module |
JPH03143532A (en) | 1989-10-30 | 1991-06-19 | Yuasa Battery Co Ltd | Production of filter element |
US5019139A (en) | 1989-12-22 | 1991-05-28 | The Dow Chemical Company | Valve membrane combination |
FR2659384B1 (en) | 1990-03-07 | 1995-09-15 | Ungemach Pierre | DEVICE FOR CURING AND CLEANING WELLS AFFECTED BY DEPOSITS AND INCRUSTATIONS. |
US5100549A (en) | 1990-03-26 | 1992-03-31 | Zenon Environmental Inc. | Tubular membrane module |
GB9019724D0 (en) * | 1990-09-10 | 1990-10-24 | Fujisawa Pharmaceutical Co | Cephalosporin c acylase |
US5269931A (en) | 1990-09-17 | 1993-12-14 | Gelman Sciences Inc. | Cationic charge modified microporous membranes |
CA2090970A1 (en) | 1990-09-20 | 1992-04-02 | Raymond Singleton | Polymer membrane |
KR100216669B1 (en) | 1990-10-30 | 1999-09-01 | 스프레이그 로버트 월터 | Articles having a hydrophilic polymeric shell and method for preparing the same |
US5252222A (en) | 1990-12-03 | 1993-10-12 | Pall Corporation | Filter for parenteral systems and method of using thereof |
JPH04292602A (en) | 1991-03-22 | 1992-10-16 | Tokyo Organ Chem Ind Ltd | Production of porous surface-type cross-linked copolymer bead |
US5114582A (en) | 1991-04-12 | 1992-05-19 | W. R. Grace & Co.-Conn. | Filter element and spiral-wound membrane cartridge containing same |
US5143616A (en) | 1991-05-15 | 1992-09-01 | Pall Corporation | Composite structure and method of making |
US5225120A (en) | 1991-09-13 | 1993-07-06 | Dow Corning Corporation | Method for preparing tubing and hollow fibers from non-crosslinked polyvinyl alcohol hydrogels |
US5211728A (en) | 1991-09-30 | 1993-05-18 | The Dow Chemical Company | Clamshell retainer used in hollow fiber membrane devices |
WO1993013849A1 (en) | 1992-01-14 | 1993-07-22 | Daikin Industries, Ltd. | Filter and filter element |
US5317932A (en) | 1992-02-28 | 1994-06-07 | The Dow Chemical Company | Sample probe |
US5232593A (en) | 1992-03-04 | 1993-08-03 | Zenon Environmental Inc. | Cartridge of hollow fiber membrane wafers and module containing stacked cartridges |
US5221477A (en) | 1992-06-05 | 1993-06-22 | The Dow Chemical Company | Apparatus and method for reversed permeation membrane extraction of compounds from sample solutions |
US5275726A (en) | 1992-07-29 | 1994-01-04 | Exxon Research & Engineering Co. | Spiral wound element for separation |
JP3278912B2 (en) | 1992-07-30 | 2002-04-30 | 栗田工業株式会社 | Vessel connection structure of membrane separation device |
JP3398985B2 (en) | 1992-09-17 | 2003-04-21 | 大日本インキ化学工業株式会社 | Manufacturing method of sensor |
US5284584A (en) | 1992-12-31 | 1994-02-08 | Hoechst Celanese Corporation | Hollow fiber membrane fabric - containing cartridges and modules having solvent-resistant thermoplastic tube sheets, and methods for making the same |
GB2275626B (en) | 1993-02-11 | 1996-10-23 | Pall Corp | An affinity separation device and its use for immunoglobulin separation |
DE4328407C1 (en) | 1993-08-24 | 1994-09-01 | Sartorius Gmbh | Coil module sterilisable by the action of heat |
US5433861A (en) | 1993-09-17 | 1995-07-18 | The Dow Chemical Company | Permanent deformation and use of sulfonated halopolymer articles |
CA2137970A1 (en) | 1994-01-10 | 1995-07-11 | Lloyd R. White | Cartridge sorption device |
DE4418156A1 (en) | 1994-05-25 | 1995-11-30 | Basf Ag | Process for the preparation of stable water-in-oil emulsions of hydrolyzed polymers of N-vinylamides and their use |
FR2720953B1 (en) | 1994-06-08 | 1996-08-30 | Tami Ind | Multichannel inorganic element for the filtration of a fluid. |
JP3557655B2 (en) | 1994-07-12 | 2004-08-25 | 栗田工業株式会社 | Membrane separation device using internal pressure type tubular membrane module |
JP3460322B2 (en) | 1994-08-09 | 2003-10-27 | 栗田工業株式会社 | Backwashing method for membrane separation device using internal pressure type tubular membrane module |
US5695653A (en) * | 1994-12-23 | 1997-12-09 | Pall Corporation | Device and method for separating components from a biological fluid |
JPH08206474A (en) | 1995-02-06 | 1996-08-13 | Kurita Water Ind Ltd | Membrane separator |
US5650496A (en) | 1995-04-14 | 1997-07-22 | Cephalon, Inc. | IGF-I purification process |
JP3849151B2 (en) | 1995-04-17 | 2006-11-22 | 栗田工業株式会社 | Immersion membrane separator |
JPH08281084A (en) | 1995-04-17 | 1996-10-29 | Kurita Water Ind Ltd | Immersion type membrane separation device |
US5733452A (en) | 1995-04-21 | 1998-03-31 | Pall Corporation | Filter and end cap assembly including a porous layer for sealing with a potting material and method for making the assembly |
JP3536466B2 (en) | 1995-08-09 | 2004-06-07 | 栗田工業株式会社 | Membrane separation device with hollow tubular membrane |
US5833860A (en) | 1995-08-28 | 1998-11-10 | Millipore Investment Holdings Limited | Centrifugal adsorptive sample preparation device and method |
JPH11512341A (en) | 1995-09-14 | 1999-10-26 | ポール コーポレイション | Method and apparatus for removing iron from aqueous liquids |
JP3562066B2 (en) | 1995-10-05 | 2004-09-08 | 栗田工業株式会社 | Membrane separation device with hollow tubular membrane |
JP3671477B2 (en) | 1995-10-12 | 2005-07-13 | 栗田工業株式会社 | Cleaning method for submerged membrane separator |
JPH09119684A (en) | 1995-10-24 | 1997-05-06 | Daikin Ind Ltd | Moisture moving device |
DE19540876A1 (en) | 1995-11-02 | 1997-05-07 | Gessner & Co Gmbh | Multi-layer separation units |
WO1997017129A1 (en) | 1995-11-09 | 1997-05-15 | University Of Toledo | Immunoprotective membrane |
US6509098B1 (en) | 1995-11-17 | 2003-01-21 | Massachusetts Institute Of Technology | Poly(ethylene oxide) coated surfaces |
DE19543955C2 (en) | 1995-11-25 | 1998-12-24 | Sartorius Gmbh | Integrity testable filtration unit with hydrophilic, porous membranes |
DE19543954A1 (en) | 1995-11-25 | 1997-05-28 | Sartorius Gmbh | Pressure-stable, porous polymeric tubular membrane for tubular modules and processes for their manufacture |
US5904846A (en) | 1996-01-16 | 1999-05-18 | Corning Costar Corporation | Filter cartridge having track etched membranes and methods of making same |
US5882521A (en) | 1996-04-18 | 1999-03-16 | Waters Investment Ltd. | Water-wettable chromatographic media for solid phase extraction |
US5647979A (en) | 1996-06-14 | 1997-07-15 | Bio-Rad Laboratories, Inc. | One-step preparation of separation media for reversed-phase chromatography |
US5762789A (en) | 1996-06-28 | 1998-06-09 | Millipore Corporation | Disposable membrane module with low-dead volume |
DE19626196A1 (en) | 1996-06-29 | 1998-01-02 | Sartorius Gmbh | Filtration unit with a cartridge-like filter element |
ES2259947T3 (en) | 1996-07-08 | 2006-11-01 | Pall Corporation | POLYMER MEMBRANE WITH POSITIVE LOAD. |
JP3959758B2 (en) | 1996-08-23 | 2007-08-15 | 栗田工業株式会社 | Immersion membrane separator |
JPH1076144A (en) | 1996-09-05 | 1998-03-24 | Kurita Water Ind Ltd | Membrane separator by hollow tubular membranes |
US6190557B1 (en) | 1996-12-09 | 2001-02-20 | Nitto Denko Corporation | Spiral wound type membrane element, running method and washing method thereof |
JPH10180048A (en) | 1996-12-27 | 1998-07-07 | Kurita Water Ind Ltd | Immersion type membrane separator |
US5897779A (en) | 1997-02-13 | 1999-04-27 | Minnesota Mining And Manufacturing Company | Spiral wound extraction cartridge |
FR2761899B1 (en) | 1997-04-15 | 1999-05-28 | Commissariat Energie Atomique | METHOD AND INSTALLATION FOR TANGENTIAL FILTRATION OF A VISCOUS LIQUID |
US5976380A (en) | 1997-05-01 | 1999-11-02 | Millipore Corporation | Article of manufacture including a surface modified membrane and process |
JPH1133370A (en) | 1997-07-22 | 1999-02-09 | Yuasa Corp | Immersion type membrane element |
JP3275789B2 (en) | 1997-08-15 | 2002-04-22 | 栗田工業株式会社 | Membrane filtration device |
US6153098A (en) | 1997-09-03 | 2000-11-28 | Filtration Systems, Inc. | Spiral wound filter with central barrier |
WO1999013958A1 (en) | 1997-09-15 | 1999-03-25 | Pall Corporation | Fluid treatment arrangement |
KR100217311B1 (en) | 1997-10-20 | 1999-09-01 | 이서봉 | Manufacturing method of complex membrane having hydrophilic coating layer on hydrophobic support membrane |
DE69810352T2 (en) | 1997-11-04 | 2003-10-30 | Millipore Corp | MEMBRANE FILTER |
KR100236921B1 (en) * | 1998-01-31 | 2000-01-15 | 장문석 | Immersion type hollow fiber membrane module and method for treating waste water by using the same |
US6207053B1 (en) | 1998-03-12 | 2001-03-27 | Celgard Inc. | Thermoplastic, unibody transfer device |
GB9816118D0 (en) | 1998-07-23 | 1998-09-23 | Pall Corp | Filter assemblies |
SE9802882D0 (en) | 1998-08-28 | 1998-08-28 | Amersham Pharm Biotech Ab | Composite material and its use |
JP2000070683A (en) | 1998-09-02 | 2000-03-07 | Toray Ind Inc | Hollow fiber membrane type permeation membrane module |
CA2343402A1 (en) | 1998-09-09 | 2000-03-16 | Pall Corporation | Fluid treatment elements, methods for cleaning fluid treatment elements and methods for treating fluids |
US20030006186A1 (en) | 1998-10-05 | 2003-01-09 | Pulek John L. | Spiral wound depth filter |
US6391200B2 (en) | 1998-10-05 | 2002-05-21 | Cuno Incorporated | Filter and method of filtering a fluid |
SE9803838D0 (en) | 1998-11-09 | 1998-11-09 | Knut Irgum | A chromatography method and a column material useful in said method |
FR2785831B1 (en) | 1998-11-18 | 2001-11-23 | Orelis | POROUS MONOLITHE SUPPORT OF A FILTER ELEMENT AND FILTER ELEMENT |
US6468657B1 (en) | 1998-12-04 | 2002-10-22 | The Regents Of The University Of California | Controllable ion-exchange membranes |
US6824679B1 (en) | 1998-12-17 | 2004-11-30 | Millipore Corporation | Hollow fiber separation module and methods for manufacturing same |
AU1689900A (en) | 1998-12-22 | 2000-07-12 | Toray Industries, Inc. | Materials for removing bacterial components |
KR100607021B1 (en) | 1999-01-29 | 2006-08-01 | 엔테그리스, 아이엔씨. | Perfluorinated thermoplastic filter cartridge |
DE19905645C1 (en) | 1999-02-11 | 2000-10-26 | Sartorius Gmbh | Filter attachment for vacuum filtration |
FR2789908B1 (en) | 1999-02-19 | 2002-05-31 | Ceramiques Tech Soc D | TABLE OF FILTRATION ELEMENTS, SEPARATION OR REACTION, MODULE COMPRISING SUCH A TABLE AND METHODS OF MANUFACTURING SUCH A TABLE AND SUCH A MODULE |
JP4271871B2 (en) | 1999-02-25 | 2009-06-03 | ポール・コーポレーション | Positively charged membrane |
EP1163044B1 (en) | 1999-02-25 | 2004-07-21 | Pall Corporation | Negatively charged membrane |
JP2000246067A (en) | 1999-03-03 | 2000-09-12 | Daicel Chem Ind Ltd | Flat membrane module |
CA2367571A1 (en) | 1999-03-17 | 2000-09-21 | Foster-Miller, Inc. | Responsive gels and methods of use thereof |
JP2000291988A (en) | 1999-04-08 | 2000-10-20 | Daikin Ind Ltd | Permeable film unit |
US6322703B1 (en) | 1999-04-20 | 2001-11-27 | Asahi Kasei Kabushiki Kaisha | Method for purifying aqueous suspension |
EP1189685B1 (en) | 1999-05-14 | 2006-04-12 | Pall Corporation | Charged membrane |
US6953686B1 (en) | 1999-05-28 | 2005-10-11 | Cambrex Bio Science Baltimore, Inc. | Methods of DNA purification and purified DNA |
DE69927674D1 (en) | 1999-06-08 | 2006-02-23 | Nitto Denko Corp | Membrane module for separation of liquids and process for its preparation |
DE60028210T2 (en) | 1999-07-30 | 2007-03-08 | Genentech, Inc., South San Francisco | LOADED FILTRATION MEMBRANES AND ITS USES |
JP2001038158A (en) | 1999-08-03 | 2001-02-13 | Toray Ind Inc | Separation membrane for organic liquid mixture |
JP2001038155A (en) | 1999-08-03 | 2001-02-13 | Toray Ind Inc | Separation membrane for organic liquid mixture |
JP2001038157A (en) | 1999-08-03 | 2001-02-13 | Toray Ind Inc | Separation membrane for organic liquid mixture |
US6391209B1 (en) | 1999-08-04 | 2002-05-21 | Mykrolis Corporation | Regeneration of plating baths |
JP2001146404A (en) | 1999-11-16 | 2001-05-29 | Daikin Ind Ltd | Apparatus for producing hydrogen gas |
FR2805331B1 (en) | 2000-02-21 | 2002-05-31 | Ceramiques Tech Soc D | MULTICHANNEL ELEMENT AND METHOD FOR MANUFACTURING SUCH AN ELEMENT |
JP3951549B2 (en) | 2000-04-14 | 2007-08-01 | 栗田工業株式会社 | Cylindrical membrane element and cleaning method thereof |
AU2001275042A1 (en) | 2000-05-31 | 2002-01-30 | Fendya, Thomas J | Membrane packets, methods for making membrane packets, and membrane packet assemblies |
EP1286745A1 (en) | 2000-06-05 | 2003-03-05 | Cuno Incorporated | Expansion resistant filter cartridge |
CA2415837A1 (en) | 2000-07-13 | 2002-01-24 | Pall Corporation | Filter cartridges with pleated filter media |
US6436213B1 (en) | 2000-08-24 | 2002-08-20 | Pti Advanced Filtration, Inc. | Enhanced electro-deposition device and method |
CN1468278A (en) | 2000-10-05 | 2004-01-14 | �ն��о������ | Uv-assisted grafting of pes and psf membranes |
JP2002166146A (en) | 2000-11-30 | 2002-06-11 | Ube Ind Ltd | Optical resolution cell using membrane and optical resolution method using thereof |
JP4358507B2 (en) | 2000-12-01 | 2009-11-04 | ミリポア・コーポレイション | Chemical process system with multi-functional barrier filter |
JP2002186839A (en) | 2000-12-20 | 2002-07-02 | Daikin Ind Ltd | Gas dissolving device |
JP2002248324A (en) | 2001-02-26 | 2002-09-03 | Kurita Water Ind Ltd | Membrane separation apparatus and its backwashing method |
JP4779220B2 (en) | 2001-03-21 | 2011-09-28 | 東レ株式会社 | Liquid filtration method, pigment dispersed color paste, transparent protective film forming material, alignment film material for liquid crystal display device, and resist for photolithography |
US20020148769A1 (en) | 2001-04-13 | 2002-10-17 | Andreas Deuschle | Spacer for membrane stacks |
WO2002096538A1 (en) | 2001-05-29 | 2002-12-05 | Pall Corporation | Tubular membrane and method of making |
EP1409118B1 (en) | 2001-06-29 | 2010-07-07 | Millipore Corporation | Method of making a laminated edge filter structure |
DE60212637T2 (en) | 2001-07-20 | 2007-05-24 | Mcmaster University, Hamilton | ASYMMETRIC FILLED MICROPOROUS MEMBRANES |
MXPA04002252A (en) * | 2001-09-10 | 2004-06-29 | Procter & Gamble | Consumable container comprising a filter. |
US6887384B1 (en) | 2001-09-21 | 2005-05-03 | The Regents Of The University Of California | Monolithic microfluidic concentrators and mixers |
JP5062798B2 (en) | 2001-10-04 | 2012-10-31 | 東レ株式会社 | Method for producing hollow fiber membrane |
RU2236382C2 (en) | 2001-10-16 | 2004-09-20 | Открытое акционерное общество "Володар" | Apparatus "hydromagnetron" for magnetic processing of liquid |
KR100354613B1 (en) | 2001-11-06 | 2002-10-11 | 박헌휘 | Repairable immersed hollow fiber membrane module |
JP3849495B2 (en) | 2001-11-12 | 2006-11-22 | 栗田工業株式会社 | Internal pressure tubular membrane module |
NL1019374C2 (en) | 2001-11-15 | 2003-05-16 | Norit Holding N V | Method for manufacturing a filter module, such a filter module, whether or not included in a filter system. |
DE10160855A1 (en) | 2001-12-12 | 2003-06-26 | Schumacher Umwelt Trenntech | Filter element and filter device for cross-flow filtration |
JP2003181247A (en) | 2001-12-17 | 2003-07-02 | Nitto Denko Corp | Treatment system having spiral membrane element and its operating method |
JP2003225661A (en) | 2002-02-05 | 2003-08-12 | Asahi Kasei Corp | Cross flow type filtration apparatus and filtration method |
US20030155243A1 (en) | 2002-02-21 | 2003-08-21 | Eet Corporation | Multi-path split cell spacer and electrodialysis stack design |
JP3831942B2 (en) | 2002-03-01 | 2006-10-11 | 栗田工業株式会社 | Membrane separator |
WO2003089506A1 (en) | 2002-04-22 | 2003-10-30 | Purdue Research Foundation | Hydrogels having enhanced elasticity and mechanical strength properties |
JP2003326140A (en) | 2002-05-10 | 2003-11-18 | Daicen Membrane Systems Ltd | Hollow-fiber membrane module |
JP2003326139A (en) | 2002-05-10 | 2003-11-18 | Daicen Membrane Systems Ltd | Hollow-fiber membrane module |
US6926823B2 (en) | 2002-06-03 | 2005-08-09 | Varian, Inc. | Polymer with superior polar retention for sample pretreatment |
US7073671B2 (en) | 2002-06-07 | 2006-07-11 | Millipore Corporation | Microporous membrane substrate having caustic stable, low protein binding surface |
AU2003252132A1 (en) | 2002-07-24 | 2004-02-09 | Cuno, Inc. | Polymeric surface treatment of filter media |
JP2004067402A (en) | 2002-08-01 | 2004-03-04 | Asahi Denka Kogyo Kk | Purification method of hydrogen peroxide solution |
JP2004089761A (en) | 2002-08-29 | 2004-03-25 | Japan Organo Co Ltd | Spiral membrane element, reverse osmosis membrane module and reverse osmosis membrane apparatus |
EP1546283B1 (en) | 2002-09-24 | 2012-06-20 | E.I. Du Pont De Nemours And Company | Electrically conducting organic polymer/nanoparticle composites and methods for use thereof |
WO2004028660A1 (en) | 2002-09-26 | 2004-04-08 | Cuno Incorporated | Filterement including filtration media with multi-layer pleat support |
FR2845082B1 (en) | 2002-09-26 | 2006-02-10 | Millipore Corp | MODULE FOR PURIFYING A FLUID, IN PARTICULAR WATER |
JP4650921B2 (en) | 2003-04-03 | 2011-03-16 | 日東電工株式会社 | Spiral type separation membrane element |
WO2005021439A2 (en) | 2003-05-02 | 2005-03-10 | Cuno Incorporated | Crossflow filtration system with quick dry change elements |
WO2004110132A2 (en) | 2003-06-12 | 2004-12-23 | E.I. Dupont De Nemours And Company | Water vapor permeable hydrophilic membranes and devices made there-from and process for using the devices |
US7452697B2 (en) | 2003-09-25 | 2008-11-18 | Allergan, Inc. | Chromatographic method and system for purifying a botulinum toxin |
US20050142280A1 (en) | 2003-10-20 | 2005-06-30 | Kim Kwon I. | System and method for synthesizing a polymer membrane |
JP2005211819A (en) | 2004-01-30 | 2005-08-11 | Daikin Ind Ltd | Porous element and air purification apparatus |
WO2005094963A1 (en) | 2004-03-29 | 2005-10-13 | Pall Corporation | Pleated, crossflow fluid treatment elements |
WO2005118106A2 (en) * | 2004-06-03 | 2005-12-15 | Entegris, Inc. | Fluid filtration apparatus with feed and outlet side vent |
AU2005251838B2 (en) | 2004-06-07 | 2011-04-21 | Merck Millipore Ltd. | Stable composite material comprising supported porous gels |
JP4748655B2 (en) | 2004-06-25 | 2011-08-17 | ミリポア・コーポレイション | Ultrafiltration membrane and manufacturing method |
JP2006021129A (en) | 2004-07-08 | 2006-01-26 | Matsushita Electric Ind Co Ltd | Hydrogen permeable separation material and its manufacturing method |
WO2006015495A1 (en) | 2004-08-13 | 2006-02-16 | Mcmaster University | Composite material comprising a non-crosslinked gel polymer |
KR20070062988A (en) | 2004-09-30 | 2007-06-18 | 맥마스터 유니버시티 | Composite material comprising layered hydrophilic coatings |
EP1793929A1 (en) | 2004-09-30 | 2007-06-13 | Pall Corporation | Catalytically active porous element |
JP2006102662A (en) | 2004-10-06 | 2006-04-20 | Matsushita Electric Ind Co Ltd | Hydrogen permeation separation material and production method therefor |
JP4599144B2 (en) | 2004-11-29 | 2010-12-15 | 独立行政法人産業技術総合研究所 | MARLINOITE TYPE ZEOLITE MEMBRANE AND METHOD FOR PRODUCING THE SAME |
US20090057222A1 (en) | 2004-12-22 | 2009-03-05 | Dressel Pte. Ltd. Company | Membrane card and method for the production and use thereof |
SE530221C2 (en) | 2005-02-28 | 2008-04-01 | Alfa Laval Corp Ab | Spiral wound membrane module with spacer element for permeate |
US7311825B2 (en) | 2005-05-02 | 2007-12-25 | Varian, Inc. | Polymer modified porous substrate for solid phase extraction |
EP1900691B1 (en) * | 2005-06-14 | 2020-01-08 | Asahi Kasei Kabushiki Kaisha | Apparatus for water treatment and method of treating water |
JP2009509749A (en) | 2005-09-28 | 2009-03-12 | ポール・コーポレーション | Fluid treatment assembly, fluid treatment element and methods of manufacturing the same |
JP2007111674A (en) | 2005-10-24 | 2007-05-10 | Nitto Denko Corp | Spiral separation membrane element |
JP4587937B2 (en) | 2005-10-31 | 2010-11-24 | 日東電工株式会社 | Spiral type separation membrane element |
JP2007136349A (en) | 2005-11-18 | 2007-06-07 | Daikin Ind Ltd | Porous membrane type air cleaner |
JP2007253089A (en) | 2006-03-24 | 2007-10-04 | Daikin Ind Ltd | Porous membrane type air-cleaning appliance |
GB0606144D0 (en) | 2006-03-28 | 2006-05-10 | Ge Healthcare Bio Sciences Ab | Automated crossflow filtration method and system |
JP5051815B2 (en) | 2006-05-23 | 2012-10-17 | 独立行政法人産業技術総合研究所 | Marinoite-type zeolite composite membrane and method for producing the same |
JP5051816B2 (en) | 2006-05-23 | 2012-10-17 | 独立行政法人産業技術総合研究所 | Philipsite type zeolite composite membrane and method for producing the same |
CN101220528B (en) | 2007-09-26 | 2010-10-06 | 天津工业大学 | Production method for oil suction fibre |
KR100941121B1 (en) | 2007-10-01 | 2010-02-10 | 한국화학연구원 | Spiral wound type of adsorbent module for ultra super cleanliness |
US20090107922A1 (en) | 2007-10-26 | 2009-04-30 | General Electric Company | Membrane, water treatment system, and associated method |
JP5146647B2 (en) | 2007-12-12 | 2013-02-20 | いすゞ自動車株式会社 | Grinding wheel and method for adjusting weight balance of grinding wheel |
CN101959583A (en) | 2008-02-08 | 2011-01-26 | 米利波尔公司 | Multi filtration cartridge filtration apparatus |
US20110006007A1 (en) | 2008-02-12 | 2011-01-13 | Gokhan Kuruc | Composite polymeric filtration media |
WO2010027955A2 (en) | 2008-09-02 | 2010-03-11 | Natrix Separations Inc. | Chromatography membranes, devices containing them, and methods of use thereof |
US20100108599A1 (en) | 2008-11-03 | 2010-05-06 | Kristof Vizvardi | Filtration membrane with tubular support |
EP2414321B1 (en) | 2009-03-31 | 2020-02-12 | 3M Innovative Properties Company | Hydrophobic monomers, hydrophobically-derivatized supports, and methods of making and using the same |
JP5302087B2 (en) | 2009-04-27 | 2013-10-02 | スリーエム イノベイティブ プロパティズ カンパニー | Tubular filter |
US8617293B2 (en) | 2009-08-10 | 2013-12-31 | General Electric Company | Membranes suitable for gas separation, and related articles and processes |
WO2011025698A1 (en) | 2009-08-28 | 2011-03-03 | Dow Global Technologies Llc | Filtration module including membrane sheet with capillary channels |
KR101920905B1 (en) | 2011-05-17 | 2019-02-13 | 나트릭스 세퍼레이션즈, 인코포레이티드 | Layered tubular membranes for chromatography, and methods of use thereof |
-
2009
- 2009-09-01 WO PCT/US2009/055582 patent/WO2010027955A2/en active Application Filing
- 2009-09-01 KR KR1020187020391A patent/KR102028628B1/en active IP Right Grant
- 2009-09-01 CA CA2736814A patent/CA2736814C/en active Active
- 2009-09-01 JP JP2011525281A patent/JP5767584B2/en active Active
- 2009-09-01 AU AU2009288234A patent/AU2009288234B2/en active Active
- 2009-09-01 US US12/551,762 patent/US20100059443A1/en not_active Abandoned
- 2009-09-01 KR KR1020197028510A patent/KR102178191B1/en active IP Right Grant
- 2009-09-01 KR KR1020177000086A patent/KR20170005184A/en active Application Filing
- 2009-09-01 EP EP09812102.3A patent/EP2334413A4/en active Pending
- 2009-09-01 KR KR1020117007319A patent/KR101694426B1/en active IP Right Grant
-
2017
- 2017-02-08 US US15/427,447 patent/US10800808B2/en active Active
-
2018
- 2018-08-10 US US16/100,515 patent/US10981949B2/en active Active
-
2021
- 2021-03-16 US US17/203,076 patent/US11884701B2/en active Active
Patent Citations (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4224415A (en) * | 1958-07-18 | 1980-09-23 | Rohm And Haas Company | Polymerization processes and products therefrom |
US4224415B1 (en) * | 1958-07-18 | 1993-07-13 | Rohm & Haas | |
US3209915A (en) * | 1962-03-06 | 1965-10-05 | Aircraft Appliances And Equipm | Filter |
US3417870A (en) * | 1965-03-22 | 1968-12-24 | Gulf General Atomic Inc | Reverse osmosis purification apparatus |
US3473668A (en) * | 1966-03-30 | 1969-10-21 | Norris Filters Ltd | Stacked filter elements |
US3623610A (en) * | 1968-10-25 | 1971-11-30 | Danske Sukkerfab | Reverse osmosis apparatus |
US3695444A (en) * | 1968-12-24 | 1972-10-03 | Ionics | Membrane support |
US3713921A (en) * | 1971-04-01 | 1973-01-30 | Gen Electric | Geometry control of etched nuclear particle tracks |
US3875085A (en) * | 1972-10-11 | 1975-04-01 | Ici Australia Ltd | Process of making amphoteric polymeric compositions from snake-cage resins |
US3997482A (en) * | 1974-01-14 | 1976-12-14 | Ceskoslovenska Akademie Ved | Hydrophilic polymeric carriers of biologically active compounds and method of preparing the same |
US3939105A (en) * | 1974-06-18 | 1976-02-17 | Union Carbide Corporation | Microporous polyurethane hydrogels, method and composites with natural and other synthetic fibers or films |
US4133764A (en) * | 1974-12-18 | 1979-01-09 | Rhone-Poulenc Industries | Retaining device for apparatus having semi-permeable membranes |
US4108804A (en) * | 1975-12-23 | 1978-08-22 | Toru Seita | Process for preparation of chromatography solid supports comprising a nucleic acid base-epoxy group containing porous gel |
US4104125A (en) * | 1977-02-28 | 1978-08-01 | The Green Cross Corporation | Process for producing human lysozyme |
US4275056A (en) * | 1978-03-20 | 1981-06-23 | Morinaga Milk Industry Co., Ltd. | HGI-Glycoprotein capable of stimulating proliferation and differentiation of human granulocyte, process for preparing same and leukopenia curative containing same |
US4170540A (en) * | 1978-03-31 | 1979-10-09 | Hooker Chemicals & Plastics Corp. | Method for forming microporous membrane materials |
US4230697A (en) * | 1978-07-03 | 1980-10-28 | Morinaga Milk Industry Co. Ltd. | Virus-inactivated HGI-glycoprotein capable of stimulating proliferation and differentiation of human granulocyte, process for preparing same and leukopenia curative containing same |
US4397892A (en) * | 1980-03-04 | 1983-08-09 | Bor-,Mubor-,es Cipoipari kutato Intezet | Process for the production of chemically bonded non-woven sheet materials containing a binder of microheteroporous structure |
US4473474A (en) * | 1980-10-27 | 1984-09-25 | Amf Inc. | Charge modified microporous membrane, process for charge modifying said membrane and process for filtration of fluid |
US4525527A (en) * | 1982-01-25 | 1985-06-25 | American Colloid Company | Production process for highly water absorbable polymer |
US4518695A (en) * | 1982-05-29 | 1985-05-21 | Kewpie Kabushiki Kaisha | Process for eluting egg white lysozyme |
US4705755A (en) * | 1982-05-31 | 1987-11-10 | Kewpie Kabushiki Kaisha | Apparatus for collecting lysozyme from egg white by adsorption |
US4504583A (en) * | 1982-06-02 | 1985-03-12 | Kewpie Kabushiki Kaisha | Process for crystallizing egg white lysozyme |
US5783085A (en) * | 1982-12-13 | 1998-07-21 | Estate Of William F. Mclaughlin | Blood fractionation method |
US4601828A (en) * | 1983-02-07 | 1986-07-22 | Yale University | Transfer of macromolecules from a chromatographic substrate to an immobilizing matrix |
US4525374A (en) * | 1984-02-27 | 1985-06-25 | Manresa, Inc. | Treating hydrophobic filters to render them hydrophilic |
US4836928A (en) * | 1984-04-28 | 1989-06-06 | Terumo Kabushiki Kaisha | Separation method, separation device and separation apparatus for separating body fluid into respective components |
US4678844A (en) * | 1985-03-04 | 1987-07-07 | Agency Of Industrial Science & Technology | Chelate, crosslinked polyethyleneimine resin having 2-hydroxy benzoyl group |
US4966851A (en) * | 1986-12-01 | 1990-10-30 | The University Of British Columbia | Process for isolation of lysozyme and avidin from egg white |
US4999171A (en) * | 1987-04-03 | 1991-03-12 | Sumitomo Chemical Co. Ltd. | Process for recovery of gallium by chelate resin |
US5059659A (en) * | 1987-05-29 | 1991-10-22 | Harry P. Gregor | Surface treatments to impart hydrophilicity |
US5422284A (en) * | 1987-07-16 | 1995-06-06 | E. I. Du Pont De Nemours And Company | Method of performing affinity separation using immobilized flocculating agent on chromatographic support |
US5277915A (en) * | 1987-10-30 | 1994-01-11 | Fmc Corporation | Gel-in-matrix containing a fractured hydrogel |
US4923610A (en) * | 1987-12-10 | 1990-05-08 | Ceskoslovenska akademive ved and Akademia Nauk SSSR | Macroporous polymeric membranes for the separation of polymers and a method of their application |
US4952349A (en) * | 1987-12-10 | 1990-08-28 | Ceskoslovenska Akademie Ved | Macroporous polymeric membranes for the separation of polymers and a method of their application |
US5114585A (en) * | 1988-03-01 | 1992-05-19 | Gelman Sciences, Inc. | Charged porous filter |
US5384042A (en) * | 1989-07-06 | 1995-01-24 | Perseptive Biosystems, Inc. | Perfusive chromatography |
US5228989A (en) * | 1989-07-06 | 1993-07-20 | Perseptive Biosystems, Inc. | Perfusive chromatography |
US5019270A (en) * | 1989-07-06 | 1991-05-28 | Perseptive Biosystems, Inc. | Perfusive chromatography |
US4944879A (en) * | 1989-07-27 | 1990-07-31 | Millipore Corporation | Membrane having hydrophilic surface |
US5160627A (en) * | 1990-10-17 | 1992-11-03 | Hoechst Celanese Corporation | Process for making microporous membranes having gel-filled pores, and separations methods using such membranes |
US5147541A (en) * | 1990-11-14 | 1992-09-15 | Koch Membrane Systems, Inc. | Spiral filtration module with strengthened membrane leaves and method of constructing same |
US5130343A (en) * | 1991-03-13 | 1992-07-14 | Cornell Research Foundation, Inc. | Process for producing uniform macroporous polymer beads |
US5646001A (en) * | 1991-03-25 | 1997-07-08 | Immunivest Corporation | Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof |
US5137633A (en) * | 1991-06-26 | 1992-08-11 | Millipore Corporation | Hydrophobic membrane having hydrophilic and charged surface and process |
US5334310A (en) * | 1991-10-21 | 1994-08-02 | Cornell Research Foundation, Inc. | Column with macroporous polymer media |
US5176832A (en) * | 1991-10-23 | 1993-01-05 | The Dow Chemical Company | Chromatographic separation of sugars using porous gel resins |
US5723601A (en) * | 1992-03-18 | 1998-03-03 | Pharmacia Biotech Ab | Super porous polysaccharide gels |
US5906734A (en) * | 1992-06-19 | 1999-05-25 | Biosepra Inc. | Passivated porous polymer supports and methods for the preparation and use of same |
US6045697A (en) * | 1992-06-19 | 2000-04-04 | Life Technologies, Inc. | Passivated porous polymer supports and methods for the preparation and use of same |
US5593576A (en) * | 1992-06-19 | 1997-01-14 | Biosepra, Inc. | Passivated porous polymer supports and methods for the preparation and use of same |
US5672276A (en) * | 1992-06-19 | 1997-09-30 | Biosepra Inc. | Passivated porous polymer supports and methods for the preparation and use of same |
US5599453A (en) * | 1992-06-19 | 1997-02-04 | Biosepra Inc. | Passivated porous supports and methods for the preparation and use of same |
US5648390A (en) * | 1992-08-07 | 1997-07-15 | The United States Of America As Represented By The Secretary Of Agriculture | Repellents for ants |
US5780688A (en) * | 1992-10-10 | 1998-07-14 | Veba Oel Ag | Supported-catalyst and use of same |
US5593729A (en) * | 1992-10-21 | 1997-01-14 | Cornell Research Foundation, Inc. | Pore-size selective modification of porous materials |
US5316680A (en) * | 1992-10-21 | 1994-05-31 | Cornell Research Foundation, Inc. | Multimodal chromatographic separation media and process for using same |
US5282971A (en) * | 1993-05-11 | 1994-02-01 | Pall Corporation | Positively charged polyvinylidene fluoride membrane |
US5681464A (en) * | 1993-07-20 | 1997-10-28 | Alfa Laval Brewery Systems Ab | Filter for cross-flow filtration |
US5460720A (en) * | 1993-08-12 | 1995-10-24 | Schneider; Burnett M. | Pleated membrane crossflow fluid separation device |
US5403482A (en) * | 1993-10-12 | 1995-04-04 | Gelman Sciences Inc. | Self-supporting, pleated, spirally wound filter and the corresponding process of making |
US5470469A (en) * | 1994-09-16 | 1995-11-28 | E. I. Du Pont De Nemours And Company | Hollow fiber cartridge |
US5728457A (en) * | 1994-09-30 | 1998-03-17 | Cornell Research Foundation, Inc. | Porous polymeric material with gradients |
US5972634A (en) * | 1994-10-19 | 1999-10-26 | The General Hospital Corporation | Diagnostic assay for Alzheimer's disease: assessment of Aβ abnormalities |
US6033784A (en) * | 1995-04-07 | 2000-03-07 | Jacobsen; Mogens Havsteen | Method of photochemical immobilization of ligands using quinones |
US5756717A (en) * | 1995-05-24 | 1998-05-26 | Perseptive Biosystems, Inc | Protein imaging |
US6143174A (en) * | 1996-09-05 | 2000-11-07 | Sartorius Ag | Filtration unit with pleated filtering elements |
US6086769A (en) * | 1996-09-16 | 2000-07-11 | Commodore Separation Technologies, Inc. | Supported liquid membrane separation |
US6258276B1 (en) * | 1996-10-18 | 2001-07-10 | Mcmaster University | Microporous membranes and uses thereof |
US5929214A (en) * | 1997-02-28 | 1999-07-27 | Cornell Research Foundation, Inc. | Thermally responsive polymer monoliths |
US6271278B1 (en) * | 1997-05-13 | 2001-08-07 | Purdue Research Foundation | Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties |
US6635420B1 (en) * | 1997-09-08 | 2003-10-21 | Roche Diagnostics Gmbh | Purification of substances from a biological sample |
US20020005383A1 (en) * | 1998-04-06 | 2002-01-17 | Nicolas Voute | Large pore volume composite mineral oxide beads, their preparation and their applications for adsorption and chromatography |
US6613234B2 (en) * | 1998-04-06 | 2003-09-02 | Ciphergen Biosystems, Inc. | Large pore volume composite mineral oxide beads, their preparation and their applications for adsorption and chromatography |
US6780582B1 (en) * | 1998-07-14 | 2004-08-24 | Zyomyx, Inc. | Arrays of protein-capture agents and methods of use thereof |
US6277489B1 (en) * | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
US7094347B2 (en) * | 1999-02-25 | 2006-08-22 | Pall Corporation | Positively charged membrane |
US6851561B2 (en) * | 1999-02-25 | 2005-02-08 | Pall Corporation | Positively charged membrane |
US6780327B1 (en) * | 1999-02-25 | 2004-08-24 | Pall Corporation | Positively charged membrane |
US6911148B1 (en) * | 1999-09-14 | 2005-06-28 | Sartorius Ag | Adsorptive membrane device for treating particle-laden liquid feeds |
US6461513B1 (en) * | 2000-05-19 | 2002-10-08 | Filtration Solutions, Inc. | Secondary-flow enhanced filtration system |
US6475071B1 (en) * | 2000-08-25 | 2002-11-05 | Micron Technology, Inc. | Cross flow slurry filtration apparatus and method |
US6824975B2 (en) * | 2000-10-13 | 2004-11-30 | Dexall Biomedical Labs, Inc | Incorporation of selective binding substances in a solid phase assay device |
US7598371B2 (en) * | 2000-11-06 | 2009-10-06 | University Of Houston | Nucleic acid separation using immobilized metal affinity chromatography |
US6635104B2 (en) * | 2000-11-13 | 2003-10-21 | Mcmaster University | Gas separation device |
US7048855B2 (en) * | 2000-12-22 | 2006-05-23 | Ge Osmonics, Inc. | Cross flow filtration materials and cartridges |
US7507420B2 (en) * | 2001-05-31 | 2009-03-24 | Medarex, Inc. | Peptidyl prodrugs and linkers and stabilizers useful therefor |
US7163803B2 (en) * | 2001-06-07 | 2007-01-16 | Electrophoretics Limited | Method for characterizing polypeptides |
US6918404B2 (en) * | 2001-07-25 | 2005-07-19 | Tubarc Technologies, Llc | Irrigation and drainage based on hydrodynamic unsaturated fluid flow |
US7066586B2 (en) * | 2001-07-25 | 2006-06-27 | Tubarc Technologies, Llc | Ink refill and recharging system |
US6766817B2 (en) * | 2001-07-25 | 2004-07-27 | Tubarc Technologies, Llc | Fluid conduction utilizing a reversible unsaturated siphon with tubarc porosity action |
US6984604B2 (en) * | 2001-11-26 | 2006-01-10 | Invista North America S.A.R.L. | Supported bis(phosphorus) ligands and their use in the catalysis |
US6986847B2 (en) * | 2002-05-10 | 2006-01-17 | New Jersey Institute Of Technology | Method and apparatus for isolation and purification of biomolecules |
US6951880B2 (en) * | 2002-05-16 | 2005-10-04 | Genelabs Technologies, Inc. | Aryl and heteroaryl compounds as antibacterial and antifungal agents |
US7285255B2 (en) * | 2002-12-10 | 2007-10-23 | Ecolab Inc. | Deodorizing and sanitizing employing a wicking device |
US20070212281A1 (en) * | 2002-12-10 | 2007-09-13 | Ecolab, Inc. | Deodorizing and sanitizing employing a wicking device |
US7316919B2 (en) * | 2003-02-19 | 2008-01-08 | Nysa Membrane Technologies | Composite materials comprising supported porous gels |
US20040203149A1 (en) * | 2003-02-19 | 2004-10-14 | Childs Ronald F. | Composite materials comprising supported porous gels |
US7824548B2 (en) * | 2004-02-05 | 2010-11-02 | Millipore Corporation | Porous adsorptive or chromatographic media |
US20080017578A1 (en) * | 2004-04-08 | 2008-01-24 | Childs Ronald F | Membrane Stacks |
US20060175256A1 (en) * | 2004-12-09 | 2006-08-10 | Board Of Trustees Of Michigan State University | Ceramic membrane water filtration |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080242822A1 (en) * | 2007-04-02 | 2008-10-02 | West Richard A | Polyurethane formulation using protein-based material |
US11884701B2 (en) | 2008-09-02 | 2024-01-30 | Merck Millipore Ltd. | Chromatography membranes, devices containing them, and methods of use thereof |
US10981949B2 (en) | 2008-09-02 | 2021-04-20 | Merck Millipore Ltd. | Chromatography membranes, devices containing them, and methods of use thereof |
US10800808B2 (en) | 2008-09-02 | 2020-10-13 | Merck Millipore Ltd. | Chromatography membranes, devices containing them, and methods of use thereof |
WO2011058439A1 (en) * | 2009-11-13 | 2011-05-19 | Natrix Separations, Inc. | Hydrophobic interaction chromatography membranes, and methods of use thereof |
US20110117626A1 (en) * | 2009-11-13 | 2011-05-19 | Komkova Elena N | Hydrophobic Interaction Chromatography Membranes, and Methods of Use Thereof |
WO2012037101A2 (en) * | 2010-09-14 | 2012-03-22 | Natrix Separations Inc. | Chromatography membranes for the purification of chiral compounds |
WO2012037101A3 (en) * | 2010-09-14 | 2012-07-05 | Natrix Separations Inc. | Chromatography membranes for the purification of chiral compounds |
JP2013537316A (en) * | 2010-09-14 | 2013-09-30 | ナトリックス セパレイションズ インコーポレーテッド | Chromatography membrane for purification of chiral compounds |
US10315133B2 (en) * | 2010-09-28 | 2019-06-11 | Sartorius Stedim Biotech Gmbh | Method for separating viruses from a contaminant-containing liquid |
JP2018075568A (en) * | 2011-05-17 | 2018-05-17 | ナトリックス セパレイションズ インコーポレーテッド | Laminar and tubular membrane for chromatography and method for using the same |
US9873088B2 (en) | 2011-05-17 | 2018-01-23 | Natrix Separations Inc. | Layered tubular membranes for chromatography, and methods of use thereof |
JP2014518765A (en) * | 2011-05-17 | 2014-08-07 | ナトリックス セパレイションズ インコーポレーテッド | Layered tubular membrane for chromatography and method of use thereof |
US10195567B2 (en) | 2011-05-17 | 2019-02-05 | Natrix Separations Inc. | Layered tubular membranes for chromatography, and methods of use thereof |
US10874990B2 (en) | 2011-05-17 | 2020-12-29 | Merck Millipore Ltd. | Layered tubular membranes for chromatography, and methods of use thereof |
JP2020006371A (en) * | 2011-05-17 | 2020-01-16 | ナトリックス セパレイションズ インコーポレーテッド | Layered tubular membranes for chromatography, and methods of use thereof |
US9575059B2 (en) | 2012-06-05 | 2017-02-21 | 3M Innovative Properties Company | Lanthanum-based concentration agents for microorganisms |
US9410007B2 (en) | 2012-09-27 | 2016-08-09 | Rhodia Operations | Process for making silver nanostructures and copolymer useful in such process |
US10845277B2 (en) * | 2012-10-18 | 2020-11-24 | Innovaprep, Llc | Liquid to liquid biological particle fractionation and concentration |
US20140231256A1 (en) * | 2012-10-18 | 2014-08-21 | Innovaprep Llc | Liquid to Liquid Biological Particle Fractionation and Concentration |
CN104884933A (en) * | 2012-10-18 | 2015-09-02 | 伊诺瓦普瑞普有限公司 | Liquid to liquid biological particle fractionation and concentration |
WO2014063125A1 (en) * | 2012-10-18 | 2014-04-24 | Innovaprep Llc | Liquid to liquid biological particle fractionation and concentration |
WO2014134147A1 (en) * | 2013-02-26 | 2014-09-04 | Natrix Separations Inc. | Mixed-mode chromatography membranes |
US11554361B2 (en) | 2013-02-26 | 2023-01-17 | Merck Millipore Ltd. | Mixed-mode chromatography membranes |
US20210069648A1 (en) * | 2019-09-06 | 2021-03-11 | Repligen Corporation | Scale-down tangential flow depth filtration systems and methods of filtration using same |
CN114502248A (en) * | 2019-09-06 | 2022-05-13 | 瑞普利金公司 | Scaled-down tangential flow depth filtration system and filtration method using same |
AU2020343312B2 (en) * | 2019-09-06 | 2023-07-13 | Repligen Corporation | Scale-down tangential flow depth filtration systems and methods of filtration using same |
EP4299156A1 (en) * | 2022-06-29 | 2024-01-03 | Sartorius Stedim Biotech GmbH | Tangential flow filtration/chromatography systems, use thereof, and methods of separation |
WO2024003141A1 (en) * | 2022-06-29 | 2024-01-04 | Sartorius Stedim Biotech Gmbh | Tangential flow filtration/chromatography systems, use thereof, and methods of separation |
Also Published As
Publication number | Publication date |
---|---|
EP2334413A2 (en) | 2011-06-22 |
US10981949B2 (en) | 2021-04-20 |
CA2736814C (en) | 2017-02-28 |
KR20110066157A (en) | 2011-06-16 |
KR20180083970A (en) | 2018-07-23 |
AU2009288234A1 (en) | 2010-03-11 |
KR101694426B1 (en) | 2017-01-09 |
WO2010027955A2 (en) | 2010-03-11 |
KR102178191B1 (en) | 2020-11-13 |
EP2334413A4 (en) | 2013-09-18 |
JP5767584B2 (en) | 2015-08-19 |
US20170145053A1 (en) | 2017-05-25 |
KR20170005184A (en) | 2017-01-11 |
JP2012501245A (en) | 2012-01-19 |
WO2010027955A3 (en) | 2010-06-10 |
AU2009288234B2 (en) | 2014-08-21 |
US11884701B2 (en) | 2024-01-30 |
KR102028628B1 (en) | 2019-10-04 |
US10800808B2 (en) | 2020-10-13 |
KR20190112858A (en) | 2019-10-07 |
US20210206801A1 (en) | 2021-07-08 |
US20190040099A1 (en) | 2019-02-07 |
CA2736814A1 (en) | 2010-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11884701B2 (en) | Chromatography membranes, devices containing them, and methods of use thereof | |
AU2019204359B2 (en) | Layered tubular membranes for chromatography, and methods of use thereof | |
ES2764441T3 (en) | Protein purification with prefiltering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NATRIX SEPARATIONS INC.,CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRELLISFORD, DAMIAN;CROSSLEY, DONNA LISA;MCINTOSH, GREG;AND OTHERS;SIGNING DATES FROM 20090911 TO 20091103;REEL/FRAME:023528/0619 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |